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Aquaporins (AQPs) are membrane channel proteins which facilitate rapid water 
transport across cell membranes. It is believed these channels are involved in many 
physiological processes including renal water conservation, neuro-homeostasis, 
digestion, regulation of body temperature and reproduction. At least 11 mammalian 
AQPs (AQPO - AQP10) have been identified to date, making them potential 
therapeutic targets for drug intervention. 
Initial studies have shown that Hg 2+  irreversibly blocks water transport in AQP-1 by 
the formation of a mercaptide covalent bond with cysteine residue 189 deep within 
the pore. AQP-1 function can also be modified by tetraethylammonium chloride 5 
(TEA) (lOOj.tM), which reversibly blocks water permeability in Xenopus laevis 
oocytes injected with AQP-1 and AQP-2 by 44 ± 11 % and 49 ± 18 % respectively. 
However, a specific reversible AQP inhibitor has so far not been reported. 
A 2.2 A high resolution crystal structure of Escherichia coli glycerol facilitator 
(G1pF) was employed as a model for water transport through AQP-1. A number of 
compound libraries, based on the lead compounds of glycerol 7 and TEA 5, have 
been synthesised using a range of automated techniques. Several of these 
compounds have been screened as putative aquaplugs on Xenopus laevis oocytes 
injected with AQP-1, 2, 3, 4 and 5. 
IV 
Abstract 
Initial results suggest that it is possible to selectively block water throughput in 
AQP-1, using dimethyl ethyl hexadecanyl ammonium bromide 152 (100 jtM), by 
80 ± 7 % and AQP-2, using triethyl decanyl ammonium bromide 122 (100 tiM), by 





These results have provided the basis to develop more focussed lead compound 
optimisation which in turn should establish further qualitative structure-activity-
relationship data to aid in our understanding of the mechanisms associated with 
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This thesis concerns the design and synthesis of inhibitors to water permeability 
through physiologically important water channels called aquaporins (AQPs). By 
way of introduction, important aspects of the drug discovery process and structure-
based ligand design have been discussed, together with an overview of the literature 
describing the structure and function of these recently discovered cell membrane 
proteins. Furthermore, detailed aspects of the synthetic routes employed towards the 
generation of novel, putative 'aquaplug' compounds have been described. 
1.1 DRUG DISCOVERY 
1.1.1 CLASSICAL LEAD DIscoVERY 
Historically, natural products were the most important source of new drugs. In 
particular the isolation and purification of active leads from plants and their 
derivatives formed the basis of early drug discovery practices. Once isolated, these 
structurally complex molecules were systematically modified using standard 
medicinal chemistry and tested in whole animals to determine their efficacy and 
toxicity. This approach has permitted the discovery of numerous compounds 
including important therapeutic examples like the anti-bacterial drug, penicillin' 1 
and the anti-inflammatory compound, piroxicam 2 2 (Figure 1.1). 
1 







Figure 1.1 	General structure of pencillin 1 and the structure of piroxicam 2. 
Pharmaceutical leads based on natural products are often highly functionalised, 
polycyclic molecules bearing multiple stereocentres. At the time, limited synthetic 
methodologies along with inefficient spectroscopic tools to assist with compound 
characterisation and purification made the design and synthesis of potential drug-like 
compounds difficult and time consuming. Cycles of synthesis and screening for 
biological activity were done one at a time, with the goal of obtaining analogues with 
improved activity, selectivity, bioavailability and ADMET (absorption, distribution, 
metabolism, excretion and toxicity) properties. In addition, lead compounds based 
on natural products were often developed with unknown targets and unspecified 
mechanisms of action. 
These difficulties have contributed towards dramatic changes in the drug discovery 
process over the last two decades. The advent of numerous technological advances 
complemented by the development of robust chemical syntheses, protein engineering 
and computational techniques have shaped the course of drug discovery for the 
future. 
'-I 
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1.1.2 DRUG DISCOVERY PROCESS AND TARGET VALIDATION 
The drug discovery process begins with the identification of a medical need, 
including a decision on whether adequate therapies already exist. Together with 
current knowledge about the disease target it is possible to hypothesise on how to 
improve/advance the method of drug treatment for patients with the target disease. 
Inventing and developing new medicines is a long, complex, costly and highly risky 
process. Research and development for most medicines today requires 12-24 years 
for a single new medicine, starting from the initial idea through to the launch of the 
drug product. It is estimated that the average overall process cost is around $1.4 
billion for a single new medicine. 2 Even though considerable time and money is 
spent in the research phase of the drug discovery programme, very few lead 
compounds are actually selected as potential drug candidates for further 
development. 
Historically, approximately 1 out of 15-25 drug candidates survive the detailed safety 
and efficacy testing in animals and man, required for it to become a marketable 
product. In addition, drug candidates that successfully reach the market will not 
necessarily recover the cost of development in the competitive marketplace. It is 
estimated that only 1 in 3 new drugs will become major commercial successes. 
Figure 1.2 outlines the main stages in the modern drug discovery process. 
3 
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Preclinical Studies 
Chemicals tested for efficacy 
Research team formed 	 _______ Novel chemicals___________ and safety in test tubes 	Formulation, scale-up synthesis, 
and objectives set synthesized 	 and animals, 	 chronic safety in animals 
Results determine choice of 
drug candidate. 
Clinical Studies 
DRUG 	 Phase 3: large clinical trials a 	Phase 2: studies in patients 	 Phase 1 studies in healthy humans 
	
(in many patients) 	 (efficacy) 	 (toleration) 
Figure 1.2 	Stages in the drug discovery process. 
FDA - Food and Drug Administration 
As a consequence, most pharmaceutical companies have heavily invested in new cost 
effective technologies which speed up the drug discovery process. Furthermore, the 
advent of molecular biology and advancements in genomic sciences has increased 
our understanding of disease processes at the molecular level and has provided 
opportunities to identify optimal molecular targets for drug intervention. 3 These 
developments have enabled drug companies to streamline R&D processes and have 
dramatically increased the number of potential therapeutic targets, such as enzymes, 
receptors and transporters available for clinical validation. 
1.1.3 COMBINATORIAL CHEMISTRY AND HIGH THROUGHPUT SCREENING (HTS) 
Once a target has been validated, the next step is to identify a potential lead 
compound. In the last decade, high throughput, automated techniques have been 
employed to screen hundreds of thousands of individual compounds for biological 
activity against specific drug targets. As a result, the pharmaceutical industry has 





structurally distinct molecules in a time and cost effective way. For this reason 
combinatorial chemistry (combichem) has emerged as a powerful tool in the drug 
discovery cycle. 4 
The key feature of this method is that compound synthesis is designed so that a range 
of analogues can be prepared simultaneously using similar reaction conditions. The 
reactions can either be done in the same reaction vessel or individually, in parallel, 
using semi-automated synthesis. For example, reacting monomer A with monomer 
B gives the product A-B, however, combinatorially, reacting nA with nB can 
generate numerous product combinations (Figure 1.3). 
A1 \ 	/ B1 
B3 
A2 	 B2 
____ 	 V ____ 
A + B 	 AB 	
B4 	
A1B10 
A4 A  
orthodox methodology 	 combinatorial methodology 
Figure 1.3 	Comparison between orthodox and combinatorial methodologies. 
Initially developed and optimised for peptides and oligonucleotides, 5 Merrifield's 
solid phase synthesis approaches presented in 1963 are the conceptual basis for all 
synthetic combinatorial strategies. 6 By attaching the desired compound to a 





be achieved by rinsing away unreacted components from the support bound material. 
Also, the optimisation of reaction yields can be facilitated by driving the reactions to 
completion by using reagents in excess. Efficiency and economic viability are two 
other advantages associated with this synthetic strategy. 
Furthermore, the development of parallel and split-mix technologies  has enabled the 
generation of structurally diverse compound collections, in which drug-like 
compounds with various rings and functional groups can be assembled in rapid 
sequence. The ability to generate large numbers of compounds by combinatorial 
methods was predicted to provide millions of potential drug-like pharmacaphores. 
By 2000, more than 1250 combinatorial libraries had been described from both 
academic and industrial laboratories. 8 The solid phase synthesis of 1,4 
benzodiazepine derivatives by Eliman and co-workers is a classical example of how 
a combinatorial approach can be successfully employed to incorporate structural 











Building block 1 	Building block 2 	Building block 3 
	
Benzodiazepine derivatives 
Scheme 1.1 Combinatorial library generation of 1,4 benzodiazepine derivatives 
showing locations of four variable R groups. 
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High throughput screening is the method usually chosen to screen large libraries of 
compounds and allows the simultaneous biological screening of each library 
member. This approach enables the inhibition of the chosen target to be measured in 
a time efficient manner and can result in identification of structure-activity -
realtionships (SARs) between the compound and the target of interest. 10 
However, several limitations to the combichemlHTS approach have been realised, in 
particular, difficulties in separating pure potential leads from the deconvolution of 
biologically active mixtures has proved a major challenge. In addition, overcoming 
complications in handling the large amounts of biological data generated through 
HTS approaches has also been problematic. Unfortunately, the expected dramatic 
increase in potential drug-like compounds has not materialised using this strategy 
and the overall number of new viable, quality lead compounds has not significantly 
improved. As a consequence, most modern pharmaceutical research concentrates 
more on automated parallel synthesis of focused small libraries of spatially addressed 
single compounds. By using this approach it is possible to prepare high purity 
compound libraries geared towards a single therapeutic target or a family of related 
7 
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1.1.4 PROTEIN ENGINEERING 
Rapid and revolutionary developments in genome sciences, informatics and 
structural biology have had a major impact on the drug discovery process. Genome 
sequencing research has provided many potential new targets for disease therapy and 
an increase in demand for new 3D protein structures. However, advances in 
proteomics and structural genomics' 2 have already provided the basis for a 
substantial increase in the number of known 3D protein structures in recent years. 13 
Furthermore, due to improvements in structure elucidation methods, 14  important bio-
physical techniques are emerging as particularly useful tools in the drug discovery 
process. For example, NMR spectroscopy, 15  X-ray crystallography 16,17  and 
computational methodologies' 8 have greatly facilitated protein structure 
determination have become critical components of many drug discovery 
programmes. 
Advances in protein isolation and purification by cloning and expression in bacterial 
or cell culture have meant that potentially important proteins are now available in 
sufficient quantities to be used in biological assays. In addition, recombinant DNA 
methods and site directed mutagenesis studies are routinely used to determine if 
structural modifications to the protein or enzyme will have an effect on its biological 
function. By adopting the strategy of mutating specific residues located within the 
protein or enzyme it is possible to postulate binding sites within the structure which, 
in turn, can reveal invaluable information about potential interactions of the drug 
with the biological target. 
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It can be expected that with ongoing improvements in gene technology and structure 
elucidation techniques many new potential targets for disease therapy will emerge. 
For the past ten years, combinatorial chemistry and diversity based HTS have been 
the strategies of choice for lead identification of potential drug compounds. In 
contrast, computational methods have been predominantly employed in lead 
optimisation activities. More recently, due to the integrated application of biology, 
medicinal chemistry, X-ray crystallography and protein biochemistry, technological 
advances in computational tools have meant that computational methodologies have 
become a crucial component for lead discovery as well as for lead optimisation. 
1.1.5 STRUCTURE-BASED DESIGN 
Structure-based drug design 19 is based on a firm understanding of molecular 
recognition between protein active site groups and interacting molecules and has 
become an integral part of modem drug discovery. If the 3D structure of a given 
protein is known, this information can be used as a blueprint for the drug design of a 
lead compound. The compound can then be modelled to fit into the active site of the 
target, considering both steric aspects (i.e. geometric shape) and functional group 
interactions, such as hydrogen bonding and hydrophobic interactions. 
Computational approaches that 'dock' small molecules to protein binding sites can 
be used to predict possible ligand conformations and orientations within a desired 
target. This information can then be used to generate new ideas about ways of 




experimental confirmation, the proposed lead ligand can then be optimised to exhibit 
higher affinity and better selectivity, after which, the next cycle of ligand design 
begins. 
This iterative structure-based design process has been successfully applied in a 
number of drug discovery programmes. There are a range of commercially available 
drugs on the market that have originated from this approach. 19 For example, the 
human immunodeficiency virus (HIV) drugs, such as amprenavir 3 (Agenerase®) 
and nelfinavir 4 (Viracept®) have been developed from existing lead structures in 
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Figure 1.4 	Structure of amprenavir 3 and nelfinavir 4. 
There are a number of well established docking programmes which can be used to 
predict interactions between a ligand and a target such as DOCK 4. 0, 2' FlexX, 2 ' and 
LIDAEUS. 22 Although specific ligand-protein interactions can only be 
quantitatively identified by an X-ray crystal structure of the inhibitor-target complex, 





possible trends in structure-activity-relationships. In early stages of lead discovery, 
this technique can be employed to screen virtual libraries of compounds in silico. By 
using docking algorithms,' 8 compounds can be ranked (scored) by estimating the 
approximate fit of a ligand into the active site. For the pharmaceutical industry, this 
process, termed 'virtual screening', is a time reducing and cost effective alternative 
to the combinatorial synthesis of large numbers of compounds and allows chemists 
to reduce a huge virtual library to a more manageable size. 23 
However, due to the complicated nature of most protein structures the quantitative 
prediction of binding affinities based on protein-ligand interactions is difficult to 
achieve. Several important factors need to be considered before validating a 
potential lead compound for optimisation: 
. Proteins are flexible, dynamic structures that may have several low-energy 
conformations within the active site. This can affect the prediction of ligand 
positions and reduce the ranking of the compound. 
. When binding occurs, a corresponding loss in entropy due to loss of internal 
degrees of freedom is observed. As a result, flexible molecules tend to score 
lower than conformationally constrained ligands. 
• Displacement of water molecules occurs upon a ligand binding to a protein. 
Enhanced binding can be achieved if the ligand has stronger interactions with 
the protein than the water molecules that are released. 
11 
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. Precise modelling and scoring can only be approximated due to other factors 
which may influence binding, such as van der Waals, electrostatic, entropy 
and solvation processes. 
Further computational methods involving molecular dynamics simulations are also 
popular techniques currently used in the drug discovery process. In this way, it is 
possible to simulate different parts of a protein-ligand system at different 
temperatures. 24  Based on Newton's equation of motion, F = m X  a, where F is force, 
m is mass and a is acceleration, atomic forces and masses of atoms can be calculated 
from changes in potential energy between current and new positions. This 
information provides a trajectory of changes in atomic position over time. As a 
relevant example, molecular dynamics simulation studies have been performed on 
AQPs to predict possible mechanisms of water permeability through cell 
membranes. 25 
1.1.6 CoNcLusioN 
It is expected that in the future, the challenges of designing molecules based on 
protein-ligand interactions will increase along with the growing number of potential 
therapeutic targets that become available. However, the iterative process of 
computer design, synthesis, biological testing, structure elucidation and data analysis 
will undoubtedly aid in the development of potential inhibitors. 
12 
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It is hoped that the continual improvement and development of docking techniques 
employed towards lead identification will increase our understanding of the 
molecular features which determine ligand affinity and selectivity. The 
quantification of differences in hydrophobic, electrostatic, hydrogen bonding and 
charge distributions between a series of library members would provide the rationale 
to determine how ligand modification can be optimised. In this way, it may be 
possible to predict why small changes in a lead ligand structure often result in 
variable and unpredictable biological effects. 
In the past, information on important aspects of the pharmacokinetics of drug-like 
compounds, such as solubility, absorption and bioavailability were only considered 
in the later stages of the drug development process. 26  Furthermore, the shift towards 
in vitro screening of lead compounds to determine SARs early on in a drug discovery 
program has meant that the risk of observing poor pharmacokinetics and oral 
bioavailability using in vivo models later on is increased. For these reasons, it is 
important that the pharmacokinetic properties of a potential drug candidate are 
considered at an early stage of development. 
Although traditional drug discovery, involving natural product synthesis and 
systematic modification of natural leads will remain important in the drug discovery 
process, the cycles of structure-based drug design and lead optimisation will 
probably become an increasingly important tool in the selection of lead compounds. 
As the amount of structural information on biological targets increases and the 





emerging new techniques and traditional methods are likely to significantly increase 





1.2 AQUAPORIN WATER CHANNELS 
1.2.1 WATER PERMEABILITY ACROSS BIOLOGICAL MEMBRANES 
The movement of water across cell membranes is fundamental to life. Water 
constitutes about 70% of the mass of most living organisms. Large volumes of water 
pass across membranes in plants and animals, amounting to hundreds of litres per 
day in adult humans. As a consequence the regulation of water distribution is critical 
in maintaining fluid balance within different parts of the human body. 
The water permeability of biological membranes has been a long standing problem in 
physiology. Until the discovery of ion channels in the 1950's, 27 an explanation for 
how cells maintained their optimal intracellular environment when bathed in an 
extracellular fluid of lower/higher pH or containing toxic concentrations of Ca 2+  or 
other solutes was difficult to justify. For years it had been suggested that transport of 
water was due to diffusion through the lipid bilayer, however, experimental 
observations in different high water permeability membranes had elucidated that 
diffusion was not the only pathway for water transport across the cell membrane. 28 
Although simple lipid bilayers exhibit limited water permeability, the membranes of 
red cells, cells in renal proximal tubules and certain other cell tissues, such as 
amphibian bladder, are extremely permeable to water. While various explanations 
for water transport were proposed, it was generally accepted that diffusion was not 
sufficiently rapid to allow many physiological processes to occur. 
15 
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It was not until the serendipitous discovery of a water specific transport protein in 
1992 that it was established that diffusion and channel mediated water transport both 
exist. 29 
1.2.2 DIFFERENCES BETWEEN DIFFUSION AND CHANNEL MEDIATED WATER 
TRANSPORT 
The major difference between these modes of water permeation is the rate at which 
water passes through the cell membrane. Whereas diffusion occurs at relatively low 
velocity, water channel proteins, termed aquaporins (AQPs), have been shown to 
have a 10 to 100 fold higher capacity for water permeation. 30  In addition, members 
of the AQP family are highly selective for permeation of specific small molecules, 
with absolute exclusion of ions and other charged solutes. The selectivity of AQPs is 
so high that even protons (1-130) are excluded from entering these channels. 
This distinction is emphasised by the normal function of mammalian renal tubules in 
the kidneys which reabsorb 99% of the water from the primary filtrate to prevent 
dehydration. 31  If our kidneys reabsorbed both water and acid we would develop 
systematic acidosis. Furthermore, it is generally assumed that diffusion processes are 
bi-directional, as water enters and is released from cells, whereas AQP mediated 
water transport permits water molecules to rapidly pass through the cell membrane 
bi-directionally by osmotic gradients. Another important difference between 
diffusion and channel mediated water throughput is that chemical inhibitors of 





mercurial compounds inhibit water transport in red blood cells, although water 
permeability can be restored by treatment with reducing agents. 32  These 
observations led to the prediction that AQPs must be proteins containing sulfanyl 
groups that have a low Arrhenius activation energy (Ea) (< 5 kcal mor) compared to 
the high Ea associatedwith the diffusion process (10-20 kcal moi'). 
1.2.3 CHANNEL MEDIATED WATER TRANSPORT 
AQPs are a family of small membrane spanning proteins that facilitate the rapid 
transport of water across cell membranes. These water channels are believed to be 
involved in several physiological processes that include renal water conservation, 
digestion, body temperature regulation and reproduction. Since their discovery, 
members of the water channel superfamily have been found in a range of cell types 
from mammals to bacteria. To date, at least 11 mammalian AQPs have been 
identified, referred to as AQP-0 - AQP-10, and more than 200 other members of the 
AQP family have been found in plants, invertebrates and vertebrates. The 
mammalian homologues AQP-0 to AQP-10 can be divided into two major 
groups: 33,34 
• AQP-0 to AQP-2, AQP-4 to AQP-6 and AQP-8 are permeable to water but 
not to small organic and inorganic molecules 35 
• AQP-3, AQP-7, AQP-9 and AQP-l0 are permeable to glycerol and urea 36  as 
well as water (referred to aquaglyceroporins) 
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Figure 1.5 Phylogenetic tree of mammalian aquapons and E. coli homologues. 37 n  
Illustration of the human AQP gene family. Also shown are E. coil homologues (AqpZ 38 and 
G1pF). The scale bar represents genetic distance between homologues. Two mammalian 
homologues (AQP-3 and AQP.- 7) are evolutionarily closer to GIpF. 
1.2.4 STRUCTURE ELUCIDATION OF AQP-1 
The discovery of a 28 kDa integral membrane protein in red cells and renal tubules 39 
ended the controversies about the possible existence of molecular water channels. 
The protein now known as AQP-1 was first purified from red cell membranes and 
found to exist as a 269 amino acid polypeptide with intracellular N- and C-
termini,402 an organisation similar to several ion channel proteins. 43 
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The first insight into the structure and function of AQP-1 came from sequence 
analyses and expression studies in Xenopus laevis oocytes. These studies suggested 
that AQP-1 is a six-transmembrane domain integral protein, 44  and the N- and 
C- terminal halves of the protein are related sequences comprised of three bilayer 
spanning domains and two connecting loops, B and B, which each contain 
Asn-Pro-Ala (NPA) motifs that enter the membrane from opposite surfaces and are 
juxtaposed in the centre (Figure 1.6, Top). 
Subsequent studies by Preston et al. focused on identifying the binding site for 
mercury inhibition. 45  Mercuric compounds form strong covalent bonds with sulfanyl 
groups in cysteine. Four cysteine residues are found in AQP- 1, however only the 
residue in loop E (Cys 189 proximal to the second NPA motif) is inhibited by 
mercuric compounds. Site directed mutagenesis experiments revealed that mutation 
of Cys 189 to serine resulted in full water permeability without evidence of mercury 
inhibition. Replacement of the corresponding position in loop B with a cysteine 
residue (Ala 73 Cys) established the protein exhibited water permeability that was 
sensitive to the presence of mercury. 45 Further residue substitutions elsewhere in 
AQP-1 failed to produce this behaviour, leading to the proposal that AQP-1 subunits 
each contain an internal aqueous pore formed as a result of loops B and E folding 














Figure 1.6 	Hourglass model for AQP-1 membrane topology 46 
Top - A schematic representation of the folding of loop B (intracellular) and loop E 
(extracellular); the loops overlap within the lipid bilayer to form a single aqueous pathway. 
Bottom - NPA motifs form a single aqueous channel spanning the bilayer flanked by the 
mercury sensitive Cys 189 residue. (Reproduced from Jung et al., J.Biol. Chem, 1994, 269, 
14648). 
1.2.4.1 	Studies Towards a High Resolution Membrane Protein Structure 
The atomic model of AQP-1 derived from a 3.8 A resolution potential map obtained 
by electron crystallography gave the first indication into water specificity and proton 
blockage.47 This was the first atomic structure of a human membrane protein to be 
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solved and a significant breakthrough in determining the structure and function of 
AQP-1 using a variety of crystallographic techniques including atomic force 
microscopy (AFM)48 and cryo-electron microscopy (EM) . 49 
A series of studies were performed by a number of research groups to determine how 
reconstitution of the purified protein at high concentrations into synthetic lipid 
bilayers would effect AQP-1 function. 50-52  Each study came to the same general 
conclusion: that water permeability function in AQP-1 was entirely preserved. 
Water permeability measurements also confirmed AQP-1 function was retained, 
implying that the proposed protein architecture gave an accurate representation of the 
physiological state of the protein. 53 
Interestingly, further investigations into AQP-1 structure revealed that, unlike ion 
channels, in which four subunits surround a central pore, AQP- 1 exists as a tetramer, 
with each subunit containing its own aqueous pore (Figure 1.7). In addition, it was 
observed that each pore narrows to approximately 3 A in diameter midway between 
the extracellular and intracellular sides of the lipid bilayer, forming a constricted 
region. This observation further supported the 'hourglass' model predicted by Jung 





Figure 1.7 	AQP-1 tetramer viewed from above. 54 
The functional unit of AQP-1 is a tetramer with each monomer providing an independent 
water pore. Two of the monomers also contain a space filling model to outline the pore 
entrance. The central pore is not believed to be involved in water transport. (Reproduced 
from Sui et al., Nature, 2001, 414, 872). 
Although the crystallographic information gave a good insight into the AQP-1 
membrane protein structure, the question of how the pore allows rapid transit of 
water without the passage of protons remained unanswered. To answer this, further 
refinement of the resolution of the AQP-1 structure was required. 
1.2.4.2 	Refinement of AQP-1 structure 
Fortunately, around this time, Stroud and colleagues 55 reported the atomic structure 
of the glycerol facilitator (G1pF), a closely related homologue to AQP-1, by X-ray 
analysis of 3D protein crystals to 2.2 A resolution. 
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This work provided detailed insight into the specificity of the GIpF channel for 
glycerol and linear carbohydrates and served as a basis for understanding substrate 
permeation through the transmembrane bilayer. The GIpF structure was the first 
high resolution structure of a cell membrane channel that conducts organic molecules 
and excludes ions. Shortly after, using GIpF as a model, workers at the Lawerence 
Berkeley Laboratory solved the atomic structure for AQP-1 from bovine red cells at 
2.2 A resolution. 54 
The high resolution structure of bovine AQP- 1 established by X-ray crystallography 
highlighted the positions of the side chains that determine the properties of the 
channel pathway. Together with the structure of GlpF it provides the molecular 
information required to understand the mechanisms regarding water regulation and 
other solute selectivity within the AQP superfamily. In addition, further refinement 
of the structure of human AQP-1 was achieved by molecular dynamics simulations 
performed by Bert de Groot and Helmut GrubmUller 25 at the University of Gottingen 
and Klaus Schulten at the University of Illinois. 
56  These simulations provided 
detailed structural comparisons between different members of the AQP family 
resolved by cryo-EM and X-ray crystallography and have shown that bovine AQP-1 
and human AQP- 1 share a high degree of structural similarity (90.6% for amino acid 
residues 9-232). 57 
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1.2.4.3 	Structural Oerview of AQP-1 
As mentioned previously, each monomer contains SIX transmembrane helices and 
two pore forming loops with short non-membrane-spanning a-helices entering the 
membrane from the extracellular and intracellular surfaces respectively (Figure 1.8). 
Figure 1.8 	Combined ribbon diagram and space filling model of AQP- 1 
monomer viewed parallel to the membrane. 54 





The residues comprising the six transmembrane and the two membrane inserted non 
hi laver spanning helices (Ml -M8) are illustrated in Figure 1.9. 
Ml 
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ls..ap1 - - AVQDNVKVLFG L S IATLQ GHI3.HLNI A TLGLLLSCQICIRIMi 
PGVLPGLTVLTM.PVGRI gGupnETIQLw3GkPPrEvva'! 




oAQP1 IIkQC'JGIVT.xLsGI gLprNgL.GL .LAPG --------- -;NQGLG--- 
isi xIoc'.aAIv..T.ILsGxTgLTG$LGRurLACG ---------;'N3Q3LG--- 14 C  
ftq 	 - - - - - - - - - GTGEHgPQTg 
443 TLQ GFLG.GIVPOLY 	IW 	DNQLPVG---PNTAGIPATYPSGLt 
G4F 
M5 	 M'3 
bNP1 ------ IEIIQTLQ VLC LA'rw- -RRR&ELGGG LA OFS ALG. -LLA ITT 
asom ItIIGTLQLVLCVL.ATTE- -L RDLGGgAPIJIGLgVALORLLXtY7 
AZ ML$ALVVCLVL 
)4zIavpDQpIcTAsLx vcvIAIvDPuwPv PRO- LApTvGLvvLvxGTsMGF 
CApp VVQAVAVMVITAIU4GLIL.ALTD- DaNGvP*GpLAPLLIGLLIAvIGASMOPI. ' 
M 
cpi 	Pi 	F- --------- - - VIT- -FQRWIPWVGFFIGALAVLIYTF 
cci GC C IPiRG - - - - - - - - - - - LAVIT - - 1IF CHI WIPWVGPIGGALA'JLIYDV - 
NTVPkRST -----------VAIFQGGWAtEQLWFPWVVPIVGGIIGGLITRT s 
YVNPARrPPELFTALGWGS';VTTG- -Q WVPIVLSIG'JF7YQL 
GP4NPkRtFQPV PAWL GWGNVFTGGREI 1PLvPLPGI IVG..IVGFkTK 53 
DAQVI ILAP SCLT VKWTSGQVTI3LtALtI)JSRVEMKPK 21 
n,pi ILAP gC.LTDVKVWTSGQVKYt,LE.ACCINPVEMKPK 	., 
s 	MIGCULKQPPP 	-------- £KIVILARVUK2QI - - - 
QpF LIQRELP-CDI V-------- VEgZ2TTTPg2QXASL-- - 
Figure 1.9 	Amino acid sequence alignment of bovine AQP-1, human AQP-1, 
E.coli AqpZ, human AQP-3 and E.coli G1pF54 
Membrane embedded helices are colour coded as shown in Figure 1.8 and labelled M1-M8. 
M3 and M7 are membrane inserted non-membrane-spanning helices. (Reproduced from Sui 
et al., Nature, 2001, 414, 872). 
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The N- terminus of the polypeptide is located on the cytoplasmic side of the cell 
membrane and leads into the first of two transmembrane helices. 43 These two helices 
(Ml and M2) are followed by a membrane inserted loop that contains the NPA 
signature motif and leads into the non-membrane-spanning helix, M3. The loop 
exiting this very short helix enters the cytoplasm and turns back into the membrane 
to connect to transmembrane helix, M4. This ends the N- terminal half of the 
structure on the extracellular side of the cell membrane. The second half of the 
structure is an inverted repeat of the topology of the first half resulting in the location 
of C- terminus at the cytoplasmic face (Figure 1.6). 
1.2.4.4 	Structure of the AQP-1 Pore 
The hourglass structure of AQP-1 consists of three elements; an extracellular 
vestibule, an extended narrow pore/selectivity filter containing the constriction 
region and a cytoplasmic vestibule (Figure 1.10). Helices M4 and M8 do not 
contribute residues to the pore. The channel wall along the selectivity filter can be 
considered half hydrophobic and half hydrophilic. It is understood that the 
hydrophilic face provides the residues that are essential for displacing waters of 
hydration and establishes a pathway for coordinating water transport. The 
extracellular vestibule is conical in shape and has a mouth diameter of about 15 A.56 
Over a distance of about 20 A the extracellular vestibule tapers down to the 
narrowest point in the channel, —2.8 A in diameter, forming the constriction region 
and the beginning of the —20 A long selectivity filter. Over the next —15 A, the pore 
gradually opens up towards the cytoplasmic end of the selectivity filter where it 
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expands to create a conical shaped cytoplasmic vestibule with a mouth of 15 A in 
diameter. In addition, the hydrophilicity of the channel significantly increases at this 
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Figure 1.10 Side view of bovine AQP-1. 54 
The backbone of bovine AQP- I is represented by ribbon format, residues depicted in ball 
and stick representation. Residues lining the pore are in solid colours. The pore profile is 
highlighted by an array of blue dots. The constriction region is visible as the narrowest area 











1.2.4.5 	Constriction Region in AQP-1 
At a distance of about 8 A above the channel centre, the constriction region is 
believed to play a critical role in controlling the transport of water molecules through 
the pore. The residues defining this region determine the selectivity of the channel 
by using a combination of steric restriction and electrostatic repulsion (Figure 1.11). 
T' 
Figure 1.11 Residues defining the constricted region in bovine AQP-
Residues defining the constricted region in bovine AQP-I (H182, R197, F58 and C191) 
(solid colours) and G1pF (G1 91, R206, W48 and F200) (transparent colours). (Reproduced 
from Sui et al., Nature, 2001, 414, 872). 
It can be observed that residues H182, R197 and the carbonyl oxygen of residue 
Cl 91 provide the hydrophilic contacts required for water permeation. The imidazole 
ring of H182 protrudes into the centre of the pore while the bulk of arginine residue 
197 points upwards in line with the pore axis. R197 also provides a functionally 
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important positive charge at the narrowest point in the channel. Hi 82 is uncharged 
at neutral pH, but becomes protonated at lower pH providing an additional charge. 
The resultant positive dipole is thought to provide repelling charges against the 
passage of protons during water permeation. It is proposed that the hydrophobic F58 
side chain sitting opposite the hydrophilic face orientates the water molecules in such 
a way that strong hydrogen bonds are formed to R197 and H182. R197, H182 and 
F58 are conserved across all water specific AQPs. 58 
The 2.8 A diameter of the constriction region is similar in size to the van der Waals 
diameter of a single water molecule. Steric limitations alone provide a plausible 
explanation for how water-specific AQPs can block the passage of larger solutes at 
this site while allowing the passage of water. Furthermore, interesting differences 
between the residues lining this region occur between AQP-i and GIpF as shown in 
Figure 1.11. 
1.2.4.6 	Glycerol versus Water 
In the bacterial aquaglyceroporin GIpF, H182 of AQP- 1 is replaced by a smaller 
glycine residue, significantly increasing the size of the constriction region by 
approximately 1 A in diameter. In addition, C191 is replaced by a phenylalanine 
residue which increases the hydrophobicity of the pore. These changes mean that 
GIpF is optimised for the rapid transport of glycerol and has a much lower 
conductivity for water than water-specific AQP channels. 59  Stroud and co-workers 
postulated that altering the polar nature of this area improves channel interactions 
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between the hydrophobic backbone of glycerol, promoting the energetically 
favourable passage of polyols and linear carbohydrates. 55  In contrast, the 
conductivity of water is thought to be impaired by the increased hydrophobicity of 
the pore. 
It is expected that aquaglyceroporins, such as AQP-3 or AQP-7, have a constriction 
region similar in size to G1pF but possess more hydrophilic residues along the pore 
wall that permit both water and glycerol transport at moderate rates. 60 
1.2.5 MECHANISM OF SUBSTRATE SELECTIVITY IN AQP-1 
The pathway for water permeation is thought to involve a series of solvent accessible 
carbonyl oxygens leading from the extracellular vestibule through the constricted 
regions of AQP-1 and GIpF. Using bovine AQP-1 as an example, the proposed 
water pathway is provided by residues G190, C19l, G192 and 1193 of the connecting 
loop leading into non-transmembrane helix M7. Past the constriction region, 
subsequent carbonyl oxygens provided by residues L77, 1176, A75 and G74 line the 
pore wall before the start of the long selectivity filter extending away from the NPA 
motifs towards the cytoplasmic vestibule. An illustration of the proposed water 
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Figure 1.12 Side view of the AQP-1 channel showing water molecules located 
within the channel and residues forming the hydrophilic face of the 
pore. 54 
Side chains shown are thought to be critical in establishing a hydrophilic path through the 
selectivity filter. Four water molecules (shown as green spheres) are located within the 
selectivity filter. The two middle water molecules are close enough to form a water-water 
hydrogen bond. The constriction region is indicated by a light blue arrow. (Reproduced 
from Sui et al., Nature, 2001, 414, 872). 
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The rate of water transport through AQP- 1 (approximately 3 x  109 water molecules 
per subunit per second) 6 ' is considerably faster than other described channels. For 
example, potassium ions permeate at a rate of 1 x 10 8  ions per second through the 
KcsA channel, which is reported to be the fastest ion channel. 62 
Extensive MD simulations by co-workers de Groot and GrubmUller 25 have 
determined that rapid transport of water molecules is, in part, a consequence of the 
properties of water in bulk solution. Hydrogen bonding interactions exist in bulk 
solution, which means that in order for a single water molecule to diffuse through the 
constriction region of the pore it needs to shed waters of hydration. To make this an 
energetically favourable process, hydrogen-bonding hydrophilic residues lining the 
channel replace hydration shell waters so that single water molecules can readily 
move through the constriction region. 
MD simulations in human AQP-1 also revealed that hydrogen bonded water chains 
are interrupted adjacent to the positively charged Arg 195 residue, known to repel 
protonated water (H 30). Furthermore, re-orientation of the water dipole occurs at 
this point as a result of hydrogen bonding interactions with the two asparagine 
residues in the NPA motifs (N194 and N78). 3 ' It has been predicted that as the water 
molecule enters from the extracellular side of the pore the oxygen atom faces down. 
Interactions with both the asparagine residues results in the water molecule flipping 
i.e. the oxygen atom facing upwards before it moves further down the channel. It is 
postulated that the same molecular events will occur in reverse, as water is released 
from the cell through the AQP (Figure 1.13). 
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Figure 1.13 Diagram illustrating reorientation of water molecule through human 
AQP-1 
Highlighted hydrogen bonding interactions between the extended amido groups of Asn 76 
and/or Asn 192 into the constricted region of the pore. (Reproduced from Murata et al., 
Nature, 2000, 407, 599). 
In addition, the NPA motif region of the cell membrane is thought to have another 
important role in AQP function by preventing proton passage. This is a consequence 
of a strong positive dipole occurring from the close proximity of the two partially 
positive terminal ends of the short non-membrane-spanning a-helices in the centre of 
the membrane (Figure 1.14). In addition to the charged arginine residue, this 
structural feature serves to repel positively charged protons and other charged ions 
from entering the cell. 
Finally, as the water molecule passes through the constricted region it enters the long 
hydrophobic selectivity filter. There are relatively few sites where water can interact 





contributing to the rapid speed at which water moves through the channel. This 
proposed mechanism of water transport permits the single file passage of water 
molecules but prevents the formation of hydrogen bonds between them. 
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Figure 1.14 Schematic representation proposing the mechanism for blocking 
proton permeation through AQP- 1. 47 
Partial charges from the helix dipoles restrict the orientation of the water molecules passing 
through the constriction region of the pore. (Reproduced from Murata et al., Nature, 2000, 
407, 599). 
1.2.6 AQUAPORINS AS THERAPEUTIC TARGETS 
Recent advances in our understanding of the movement of water through cell 
membranes have stimulated significant interest in assigning AQP function in a 
number of different organs. As mentioned previously, eleven different mammalian 
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AQPs have been identified so far, each believed to have been derived from the 
diverse water requirements exhibited by different cells and organs in the body for the 
regulation of water balance. 
Since the discovery of AQP-1 in the renal proximal tubules in the kidney the 
predominant distribution of the other known mammalian aquaporin homologues have 
been described (Table 1. 1).3063  The genetic manipulation of rodents and the 
identification of humans with altered AQP genes have provided considerable insight 
into AQP related physiology. It is now widely believed that the AQP family have 
fundamental roles in the regulation and physiology of several organs in the human 
body. 
The growing wealth of structural and physiological information associated with 
AQPs makes them attractive targets for the development of novel drug therapies for 
disorders that are now known to involve water movement. For example, in humans, 
the kidney is primarily responsible for filtering and eliminating toxic substances from 
the blood. This function is achieved by the filtration of blood in specialised units 
called nephrons, which are particularly important in the reabsorption of water. 
AQPs are expressed in high levels in the collecting duct of the nephron, known to be 
important in maintaining the pH balance of blood. 36 In particular, the importance of 
AQP- 1 in water reabsorption has been demonstrated in transgenic mice. With a 
targeted knockout of this AQP, 64 these studies have shown that the mice exhibit 
increased urine output and the inability to concentrate urine. 
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Aquaporin 	 Permeability 	 Tissue Distribution 
AQP-O Water (low) 
AQP-1 Water (high) 
AQP-2 Water (high) 
Water (high) Glycercol 
AQP-3 (high) 
Urea (moderate) 
AQP-4 Water (high) 
Lens (eye) 
Red blood cell, kidney, lung, vascular 
endothelium, brain, eye 
Kidney, vas deferens 
Kidney, skin, lung, eye, colon 
Brain, muscle, kidney, lung, stomach, 
small intestine 
Salivary gland, lacrimal gland, sweat 
AQP-5 Water (high) 
gland, lung, cornea 
Water (low) 
AQP-6 Kidney 
Anions (NO3 , Cl) 
Water (high) 
Glycerol (high) 
AQP-7 Adipose tissue, kidney, testis 
Urea (high) 
Arsenite 
Testis, kidney, liver, pancreas, small 








AQP-10 Glycerol (High) Small intestine 
Urea (High) 
* AQP-8 might be permeated by water and urea. 
Table 1.1 Predominant distribution of mammalian AQP homologues in the body. 
In humans lacking functional AQP- 1, normal renal function and urine output is 
observed, except under stress conditions. When deprived of water, individuals 
lacking AQP- 1 exhibit a 50% reduction in their ability to concentrate urine. 65 
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Also predominant in the kidney, AQP-2 has been associated with the autosomal form 
of the hereditary genetic disorder, nephrogenic diabetes insipidus (NDI). Individuals 
who exhibit loss of function of AQP-2 experience a profound increase in the 
production of dilute urine (up to 20 litres per day). 66 In contrast, significant increases 
in AQP-2 expression have been observed in clinical conditions associated with 
retention of water, such as pregnancy, congestive heart failure and cirrhosis of the 
liver. 36  Several further examples of clinical conditions associated with known or 
proposed alterations in AQP function or expression are reported in the literature. 67 
1.2.7 KNOWN BLOCKERS TO WATER PERMEATION 
As previously stated, it has long been understood that water transport in many cells is 
sensitive to inhibition by mercury containing compounds. However, due to its 
known toxicity and other pharmacological actions, mercury is hardly an ideal 
therapeutic inhibitor to AQP function. In addition to mercury, a number of other 
metal ions exhibit inhibitory effects on water permeability. For example, salts 
containing copper, nickel, silver and gold have all shown to be potent inhibitors of 
several members of the AQP family. 68  It is proposed that the mechanism of 
inhibition involves the ability of the metal ion to interact with the nucleophilic SH 
group of cysteine residue located at the 2.8 A constriction region of the pore. 
Interesting comparisons between the ionic diameter of the Hg 2+  ion (2.2 A), the Ag 
ion (2.5 A) and the Au ion (2.7 A) can be made, revealing why the combination 
of reactivity and size constitutes the basis for potent, irreversible, non-selective AQP 
inhibition. 
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Very few examples of non-metal based inhibitors of AQPs have been reported in the 
literature. Brooks et al. 69 recently reported that tetraethyl ammonium chloride (TEA) 
5, which is widely used as a blocker of potassium channels, inhibits water 
permeability through AQP-l. Furthermore, phloretin 6 has also been reported 70 as a 
relatively potent inhibitor of several AQPs, including the aquaglyceroporin AQP-9 
(Figure 1.15). 
OH 0 
HO H OH 
Figure 1.15 Structure of TEA 5 and phloretin 6. 
However, phloretin lacks specificity, as it exhibits inhibitory activity against solute 
transporters as well as ion channels. 7 ' Further developments on using TEA 5 as an 
inhibitor to water transport through its action on AQPs are discussed in Chapter 3. 
1.2.8 CONCLUSION 
The absence of good pharmacological modulators for AQP function has presented a 
challenge in defining the function of AQPs in many physiological processes. 
Furthermore, the discovery of new potential lead compounds also presents a 
challenge as the screening strategies frequently employed to study ion channels, 
G-protein-coupled receptors and enzymes are generally not applicable to water 





function could pave the way for treatments of life threatening disorders, such as, 
stroke, traumatic injury and tumour-induced brain swelling, as well as other 
conditions, such as, glaucoma and cystic fibrosis, which currently lack adequate 
medical treatment. 
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2 	RESULTS AND DISCUSSION I - GLYCEROL-BASED ANALOGUES 
2.1 PROJECT OBJECTIVES 
The overall aim of this project was to use a parallel (combinatorial) chemical 
methodology to generate libraries of new compounds with the ultimate goal of 
creating potential inhibitors (aquaplugs) of AQP water channels. By adopting a 
structure-based design approach, the main emphasis of this research has focused on 
the development of robust chemistry which can be adapted towards automated 
library construction. 
Initial studies concentrated on the development of glycerol chemistry to provide the 
basis for rational library design. There are several advantages for using glycerol 7 as 
a lead structure for the design of putative aquaplug libraries. Firstly, glycerol 7 is 
commercially available and inexpensive and secondly, the symmetrical nature of the 
molecule makes it a good scaffold for further reaction (Figure 2.1). In addition, 
routes towards glycerol-based libraries can be developed using a wide range of 
commercially available building blocks. It was envisaged that it would be possible 
to generate structurally diverse libraries using a glycerol core. 
OH 
HO 
Figure 2.1 	Structure of glycerol 7. 
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As discussed in Chapter 1, members of the AQP family are composed of functionally 
distinct subgroups that include water conducting channels (aquaporins) and glycerol 
conducting channels (aquaglyceroporins), including the Escherichia coli glycerol 
facilitator (GlpF). Since the natural ligand for G1pF is glycerol 7, it was predicted 
that it may be possible to locate the glycerol 7 analogue within the pore by 
mimicking some of the hydrogen bonding interactions along the channel pathway. 
By exchanging or modifying hydroxyl functionality with larger hydrophobic/charged 
groups within the glycerol structure it seemed reasonable to postulate that 
compounds of this type could interact with important glycerol binding residues and 
act as a 'plug' within the pore. Opportunities for further ligand modification could 
also be envisaged by using glycerol as a lead structure. In addition, it is known that 
the amphipathic nature of aquaporins/aquaglyceroporins coincides well with the 
hydrophobic backbone and hydrophilic functional groups of glycerol molecules 
(Figure 
replacement with charged/hydrophobic groups 
eg HNRR", R = Me, Et, Pr etc 
OH 	 extracellular 
OH
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Our initial objectives were: 
To develop efficient and reproducible chemistry suitable for discrete library 
synthesis. 
. To use this chemistry to prepare a number of glycerol-based ligands. 
. To determine if these compounds exhibit inhibitory effects in AQPs. 
To further develop leads for specific AQP blockers in order to understand 
their mechanism of action. 
. To generate a list of compounds (including commercially available 
compounds) which have inhibitory effects on AQP function. 
With library generation in mind, we hoped to generate novel compounds that block 
specific AQPs and as a result improve our understanding of the structural 
determinants of transport, specificity and regulation of these physiologically 
important cell membrane proteins. 
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2.2 DEVELOPMENT OF GLYCEROL-BASED ANALOGUES 
2.2.1 CLICK CHEMISTRY OF EPDXIDES 
As stated previously, an objective of the project was to establish reaction conditions 
which could be adapted to develop a range of glycerol-based analogues. It was 
proposed that a robust and efficient route towards these compounds could be 
developed by the nucleophilic ring opening of glycidol 8 (Figure 2.3). 
C0 	 OH 
OH 	 Nu 	 OH 
Nu _._Y 3 2 	- 2 
1 	 3 	1 
8 
Figure 2.3 	Regioselective nucleophilic attack of glycidol 8. 
Nucleophilic attack of glycidol 8 appears to be a good starting point towards the 
synthesis of glycerol analogues. There are several advantages which make this route 
a viable option for reaction optimisation and future library design. Firstly, racemic 
glycidol 8 is inexpensive and commercially available. Both (R) and (S) forms are 
commercially available, however it was decided that the enantiomeric purity of the 
glycidol was not important at this point in the project. Secondly, epoxides are 
versatile intermediates in organic synthesis. The inherent polarity and strain of the 
three membered ring makes them susceptible to reaction with a large number of 
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and some oxidising agents. Epoxides can be ring opened by a large variety of 
nucleophiles; some examples include water, alcohols, phenols, nitrogen containing 
compounds and sulphur containing compounds, making them potentially suitable 
building blocks for library design. Thirdly, ring opening can occur in either neutral, 
basic or acidic conditions, however, in general the presence of an acid accelerates 
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HO R 






Scheme 2.1 Epoxide ring opening under different conditions. 
In neutral and basic media, the reaction proceeds via nucleophilic attack on the 
neutral epoxide .72 In acidic media, protonation of the epoxide precedes nucleophilic 
attack. It has been proposed the reaction follows an SN2  mechanism resulting in 
inversion of the carbon centre of the epoxide. 73 
Finally, investigations into the literature concerning reactions with glycidol 8 
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different chemistry. 74  Several reported examples of simple nucleophilic additions to 
glycidol 8 are outlined in Table 2.1. 
OH 
0 	 nucleophilic addition 
OH 
8 	 9-13 
Entry Compound Reagent X Yield (%) 	Ref 
1 9 EtMgBr/Li2CuC14/THF Et 71 
75 
2 10 R2NH/base R2N 90 	
76 
3 11 ROH/Ti(OR)4 RO 69 	
77 
4 12 RCO2WTi(O'Pr)4IEt2O RCO2 40 	
78 
5 13 PhSHINaOH/dioxane PhS 88 	
79 
Table 2.1 	Simple nucleophilic additions to glycidol 8. 
Epoxides have been described by Sharpless et al. 80 as being part of an expanding set 
of powerful, selective and modular building blocks that work reliably in both small 
and large scale applications. The advantage of SN2  ring-opening of epoxides is that 
the competing elimination processes are stereoelectronically disfavoured 8 ' resulting 
in high yielding reactions and easy product isolation. As a result, epoxide ring 





Results and Discussion I 
2.2.1.1 Click Chemistry 
Click chemistry 80  is a relatively new approach to synthesis which was introduced to 
aid the process of lead discovery and optimisation to generate collections of test 
compounds for screening. Consequently, its applications are increasingly found in 
all aspects of drug discovery, ranging from lead identification through to 
combinatorial chemistry, proteomics and DNA research . 82 There are several 
guidelines which define a click chemistry reaction: 
. The reaction must have wide scope and be reliable under different reaction 
conditions. 
. The reaction should give consistently high yields with a variety of starting 
materials. 
. The reaction must be easy to perform, be inert to oxygen or water and use 
only readily available building blocks. 
. Reaction work-up and product isolation must be simple. 
Several reliable processes for the synthesis of building blocks and compound 
libraries have been reported in the literature. 80 Some examples include: 
• Cycloaddition reactions, particularly Diels-Alder 1,3-dipolar additions. 
• Nucleophilic ring opening reactions, especially strained heterocyclic 
electrophiles such as epoxides, aziridines and cyclic sulfates etc. 
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Carbonyl chemistry reactions which involve imine-forming condensation 
reactions to give oximes, hydrazones and aromatic heterocycles etc. 
. Addition to carbon-carbon multiple bonds such as oxidation and Michael 
addition reactions. 
Click chemistry has already proven to be a powerful tool in biomedical research 82 
and it is predicted that it will help accelerate both lead identification and lead 
optimisation of future drug compounds based on reliable and high yielding reactions. 
For these reasons, we hoped that reactions of glycidol 8 would be applicable for the 
focused library design of glycerol-based analogues using a variety of reaction 
conditions and reagents. 
2.2.2 NUCLEOPHILIC ADDITION TO GLYCIDOL 8 
In general, with unsymmetrical epoxides, the position of nucleophilic attack is 
governed by both the structure of the epoxide and the reaction conditions. With 
monosubstituted epoxides, attack can occur at either the less or more substituted end 
of the epoxide to afford a mixture of products. If the substituent is considerably 
bulky or has electron withdrawing properties, preference for attack normally occurs 
at the sterically less hindered site. Importantly, nucleophilic addition to glycidol 8 
occurs almost exclusively at the C 3 position (Figure 
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Investigations into epoxide opening were instigated by Dr David Rice at the 
University of Edinburgh. Using modified conditions reported by Banzatti et al. ,83 
ring opening of glycidol 8 was attempted by nucleophilic attack with potassium 
pthalimide 14 under basic conditions to generate diol 15 shown in Scheme 2.2. 
LOH 	+ 	
DMF, 1000C, 6h 	 OH 
DCM, 4% NaOH 	 N OH 
(26%) 
0 
8 	 14 	 15 
Scheme 2.2 Initial attempt at ring opening glycidol 8 using potassium pthalimide 14. 
After work-up, the crude material 15 was obtained in a disappointing 26% yield. 
This reaction was repeated a number of times however the overall yield was always 
poor. It was thought that the diol functionality, formed in the product, increased the 
solubility in the aqueous phase resulting in a loss of product during the work-up step. 
To tackle this problem, a number of protecting groups were chosen to protect the 
primary alcohol of glycidol 8. These are outlined in Scheme 2.3. By incorporating 
more hydrophobic functionality into the molecule it was hoped to decrease the 
solubility of the crude product in the aqueous phase and, in turn, improve the overall 
yield of the reaction. 
A silyl protecting group was selected, as this had the additional advantage that it 
could be employed at a later stage to attach glycidol 8 to a solid support via a silyl 
linker. 84  The THP protecting group (Ellman linker) 85 was also chosen for this 
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reason. In addition, it was considered that subsequent deprotection steps could be 

















Scheme 2.3 Proposed routes towards glycidol 8 protection. 
Both the tert-butyldimethylsilyl ether 16 and the triethylsilyl ether 17 of glycidol 8 
were successfully obtained in 56% and 40% yields, respectively. The synthesis of 
glycidyl tetra-hydro-2-pyranyl ether 18 proved to be more difficult to achieve. 
Purification was attempted by both column chromatography and Kugelrohr bulb to 
bulb distillation however the desired product was not obtained. It was therefore 
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2.2.3 ATTEMPTED RING OPENING OF TBDMS-PROTECTED GLYCIDOL 16 
Initial investigations into ring opening reactions of protected glycidol were also 
performed by Dr David Rice at the University of Edinburgh. It was decided that the 
use of heterogeneous alumina surfaces would be an advantageous route towards the 
development of these compounds. Reactions at alumina surfaces are generally very 
mild, highly selective and product isolation is simplified as it usually only involves 
filtration and solvent evaporation. A number of ring opening reactions were 
attempted on both TBDMS-protected glycidol 16 and glycidol 8 using modified 
conditions reported by Posner et al. 86 as summarised in Table 2.2. 
Entry Epoxide Catalyst Nucleophile Solvent Product 
Isolated 
Yield 
1 16 A1203 Et2NH Et20 Yes (16a) 12% 
2 16 A1203 MeOH Et20 No N/A 
3 16 A1203 H20 Et20 No N/A 
4 8 A1203 Et2NH Et20 No N/A 
*Reactions were performed at room temperature and monitored by TLC 
Table 2.2 Summary of attempted nucleophilic epoxide ring opening. 
After varying the reaction conditions and employing a range of nucleophiles, it was 
decided that these reactions were not compatible with the silyl ether protecting 
group. Problems arose during the purification steps and made recovery of the 
desired product difficult. It was envisaged that incorporation of a protecting group 
which was more stable to ring opening conditions would be a more successful 
alternative. For this purpose, commercially available benzyl glycidyl ether 21 was 
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selected. It was anticipated that de-O-benzylation could be achieved using PdJC 
catalysed hydrogenolysis at a later stage. It was also postulated that the use of a 
different catalyst to activate the epoxide, might improve the success of these 
reactions. 
2.2.4 AMINOLYSIS OF BENZYL GLYCIDYL ETHER 21 
Ring opening addition reactions of epoxides with various nucleophiles are widely 
used in the formation of 3-amino alcohols. 87  A literature search revealed that metal 
salts have been frequently employed for mild and efficient aminolysis of epoxides. 
Crotti et al. 88  reported conditions for the use of several readily available metal salts 
that effectively promote high yielding aminolysis of 1 ,2-epoxides with a variety of 
amines. This was achieved by mixing equimolar amounts of epoxide and amine in 
the presence of catalytic salt in acetonitrile solution for a few hours at room 
temperature. The ring opening of 1,2-epoxy-3-phenoxypropane 19, using a variety of 
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0 metal salt 
Ph 	 HN(R)2 , MeCN, RT 
19 	 (90-98%) 















Scheme 2.4 Proposed conditions for metal salt catalysed ring opening of epoxides. 
These conditions were used as a starting point to attempt ring opening of benzyl 
glycidyl ether 21 with diethylamine 22 (Scheme 2.5). Zinc chloride was chosen as 
the activating metal catalyst due to its solubility in acetonitrile. The activated 
epoxide was formed by addition of neat benzyl glycidyl ether 21 to a 1.0 M solution 
of zinc chloride in acetonitrile. This reaction was highly exothermic and was cooled 
over ice before addition of the nucleophile. The reaction was monitored by TLC 
which showed that after an hour starting material was still present. The reaction was 
continued for a further 24 hours. However, column chromatography of the reaction 
mixture on silica gel resulted in the recovery of mainly starting material 21 (70%) 
and a small amount of product 23 was afforded in 12% yield. 
NH 
22 
0 	 1.0 M ZnCl2 in MeCN 	 OH 
0 P 	
MeCN, RT, 24 h 	
N OPh 
21 	 (12%) 	 23 
Scheme 2.5 Initial conditions used to ring open benzyl glycidyl ether 21. 
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The poor yield can be attributed to a number of factors. During the course of the 
reaction, an insoluble precipitate formed which required filtration. This probably 
results from exchange of the chloride ions in the metal salt with hydroxide ions 
present in the reaction solution (possibly from water) to form Zn(OH)2. It was 
postulated that the use of anhydrous zinc chloride and acetonitrile would reduce the 
likelihood of such unwanted by-products forming. It was decided to use freshly 
distilled diethylamine 22 and increase the number of equivalents used. After further 
investigation it was also decided to reduce the number of equivalents of the Lewis 
acid employed. The reaction was repeated using the modified conditions and after 
24 hours, the presence of product 23 only was indicated by ES-MS. Further 
evidence of epoxide opening was provided by the IR spectrum, which showed a 
broad peak at 3430 cm' indicating the presence of the hydroxyl group. 'H NMR 
confirmed the presence of the characteristic ethyl functionality in the desired 
product. In addition, formation of the unwanted Lewis acid by-product was 
significantly reduced. After purification the desired product 23 was isolated as a 
colourless oil in 90% yield. 
2.2.5 RING OPENING OF BENZYL GLYCIDYL ETHER 21 WITH DIFFERENT AMINES 
Our next step was to determine if these modified conditions could be used to 
generate similar compounds using other amines. If successful, this route could be 
adapted towards automated parallel library synthesis, the details of which are 
described later in this chapter. With the goal of increasing the steric bulk of the 
attacking nucleophile; pyrrolidine 24, piperidine 25 and benzylamine 26 were chosen 
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as potential candidates to open the epoxide. Test reactions were performed on the 
scale required for library synthesis using the optimised conditions as outlined before. 
The results are summarised in Table 2.3. 
Entry Epoxide 	Nucleophile 	 Product 	 Yield(%) 
OH 
1 	21 	 62 
24 	 27 
N 	 OH 
2 	21 	 ii) 	 CNII'LOBn 	92 
25 	 28 
OH 
3 	21 	IfjLNH2 	iIIIIL)L,I...OBn 	70 
26 	 29 
Table 2.3 	Altering the nucleophile using optimised ring opening conditions. 
It was observed that increasing the size of the incoming nucleophile does not appear 
to hinder the ring opening reaction of the epoxide and the desired products 27-29 
were obtained in good yields. Further reaction with another molecule of benzyl 
glycidyl ether 21 could occur through the secondary amine formed in 0-amino 
alcohol product 29 to yield the unwanted dimer product. However, formation of the 
dimer was not observed under these conditions. On the basis of these results it was 
decided to repeat the optimised reactions using robotic equipment for parallel 
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possible to generate small numbers of structurally diverse compounds in a time and 
cost effective manner. 
2.3 SOLUTION PHASE PARALLEL SYNTHESIS OF GLYCEROL-BASED 
ANALOGUES 
2.3.1 EQUIPMENT 
The aim of this parallel approach was to prepare a small library of glycerol 
derivatives in order to become familiar with the operation of the equipment and to 
investigate the potential to generate larger numbers of compounds in this manner. 
Figure 2.4 outlines the robotic equipment available for library synthesis and 
purification. 
Bohdan Neptune 
XY Robot - solution preparation Myriad Allex Christ 	-RVC 
- dispensing 
2 phase liquid-liquid 
extraction 
solvent evaporation 
MiniBlock Synthesiser- vortex 
- healing/cooling Reaction 
Solvent 
Removal 
- filtration Work-up 
Reagent Preparation + Synthesis 
Waters ZMD 4000 
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2.3.2 SELECTION OF AMINES FOR AUTOMATED LIBRARY SYNTHESIS 
In order to broaden the range of structural diversity, a number of different amines, 
22, 26, 30-37, were selected to be incorporated into the library as shown in Figure 
2.5. Selection criteria included steric size, aromatic ity, commercial availability and 
cost. 
H 	 H 
N N 
NH 
NH2 C NH2 O  
H 
	
22 	 26 	 30 	 31 	 32 
"'T NH 	 NH2 N 	NH2 
33 	 34 	 35 	 36 
	
37 
Figure 2.5 	Commercially available amines to be included in library synthesis. 
2.3.3 REAGENT PREPARATION AND SYNTHESIS 
In the automated synthesis of an array of compounds it is beneficial to be able to 
dispense all of the required reagents as solutions in an appropriate solvent, in order to 
minimise manual effort and time. The reagents were dispensed using the Bodhan 
Neptune TM-MB Automated Workstation into a MiniBlock (the MiniBlock Tm  
consisted of 12 fitted glass reaction vessels (RVs) (20 mL), each reversibly sealed at 
the narrow tube end by a pinching mechanism, and encased in an insulated block 
which may be heated or cooled). The reactions were carried out on a 5 mmol scale 
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in 10 mL total volume of solution. After reagent dispension, the MiniBlock was 
placed on the MiniBlockTM  High Capacity Shaking and Washing Station for 24 
hours. The experimental procedure for this step is outlined in Section 5.2.3.2. 
After this time, it was observed that the precipitate which had previously formed 
during the early reaction optimisation steps was once again present in a number of 
the reaction vessels. Each reaction mixture was filtered under vacuum into 20 mL 
reagent vials. This step proved problematic in some cases as the white precipitate 
blocked the porous fits in several of the reaction vessels. However, each filtrate was 
eventually collected and the solvent was removed by vacuum centrifugation to leave 
an oily residue ready for reaction work-up. 
2.3.4 PARALLEL AQUEOUS WORK-UP 
It was anticipated that the Myriad® Allex liquid-liquid extraction system could be 
used for purification of the crude reaction mixtures. The Myriad® Allex is capable 
of separating a two phase system (aqueous and organic layers) by sensing the change 
in dielectric constant at the meniscus. It can then transfer either the top or bottom 
phase to a different reaction vessel, with separation just above or just below the 
meniscus depending on the layer required. In addition, two phase systems can also 
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Each product was dissolved in EtOAc (2 mL) and placed back in the MiniBlockTM. 
Aqueous sodium bicarbonate (2 mL) was added and the filtrate was collected into a 
deep well microtitre plate (24 x  10 mL). After work-up, the organic phases were 
combined, dried over anhydrous MgSO4, filtered and concentrated using the vacuum 
centrifuge to afford the desired crude oil. The next step was to redissolve each 
product (50 mg) in a solution of MeCN:H20 (50:50) with 0.1% AcOH prior to mass 
directed purification on the Waters® ZMD mass spectrometer. 
2.3.5 MASS DIRECTED PURIFICATION (ZMD) 
As a consequence of developments in mass spectrometry and split flow technologies, 
it is possible to purify libraries of compounds using a mass spectrometer as the 
detector, which triggers the fraction collector based on the presence of a desired 
molecular weight. LC-MS based purification enables the user to selectively collect 
specified masses only. A schematic diagram showing the Waters® FractionLynxTM 
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Figure 2.6 Waters® FractionLynxTM Flow Scheme. 
A predetermined volume of crude sample is dissolved in the desired solvent mixture 
(typically MeCN:H20 (50:50) with 0.1% AcOH). After injection the sample is run 
through a preparative HPLC column. The eluent flows into a splitter which splits the 
flow between the mass spectrometer and the fraction collector. A pump dilutes and 
carries a very small part of the sample from the splitter to the mass spectrometer 
where the elution is monitored by API (atmospheric pressure ionisation) mass 
spectrometry. The majority of the sample is carried to the fraction collector. 
FractionLynxTM software allows fraction tracking using OpenLynx TM browser which 
displays the target ion, ionisation mode, fraction collector tube location and the 
number of tubes the compound is in. In this way, products 23, 29 and 38-45, were 
purified using ZMD conditions outlined in Section 5.2.3.2. The results from the 
library synthesis are summarised in Table 2.4. 
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Entry 	Product Number 	Product Obtained 	
mlz LMH1 ion 	isolated 
observed Yield 
1 	 23 	 238 	 85% 
2 	 29 	 1L.L1OBO 	272 	 70% 
O'i 	OH 
3 	 38 	 252 	 51% 
4 	 39 	
HN 	OH 
L,_N...IOBfl 	251 	 11% 0 
5 	 40 	 _....J......OBn 	222 	 53% 
6 	 41 	 y OH1OBn 	252 	 66% 
7 	 42 236 	 74% 
8 	
OBn 	
259 	 19% 
Nr 
9 	 44 	 >1__N__&.__OBn 	238 	 52% 
10 	 45 	 286 	 92% 
Table 2.4 	Glycerol analogues generated using parallel solution phase approach. 
The isolated yields after ZMD purification were generally good. However, it can be 
observed that compounds 39 and 43 were isolated in poor yield. A possible 
explanation for this result is that piperazine 31 and 2-amino pyridine 35 are solids at 
room temperature. As a consequence, these compounds were manually dispensed 
during library synthesis and it was noted that they were not readily soluble in the 
reaction mixture. 
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Overall, the parallel approach worked well for the synthesis of the majority of these 
compounds but there were a few problems associated with this route that needed to 
be considered. Firstly, the generation of unwanted by-products during the library 
synthesis step made filtration of the desired product difficult. It was necessary to 
transfer the reaction solution to different reaction vessels a number of times in order 
to unblock the frits of the MiniBlock Tm tubes. Secondly, the set-up of the robotic 
protocols took considerable time to configure. After this was done, it was hoped that 
the parallel aqueous work-up procedure would speed up the purification of this 
library. However, problems arose during separation of the aqueous and organic 
phases due to difficulties in the sensor detecting the meniscus between the two 
layers. Finally, although the mass directed purification worked well in the end, 
significant amounts of product were lost to waste and a considerable amount of time 
was spent optimising the chromatographic conditions required for good product 
isolation. 
It was for these reasons that we decided to investigate the possibility of employing a 
solid support strategy towards the synthesis of glycerol-based compounds. This 
route offers two important advantages over solution phase synthesis. Firstly, it 
allows for the removal of reactants and non-bound by-products by simple filtration 
and secondly, it enables the use of excess reagents to afford high yields with minimal 
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2.4 SOLID PHASE SYNTHESIS 
As discussed in Chapter 1, solid phase organic synthesis has emerged as a powerful 
technique to rapidly generate combinatorial libraries of small molecules for 
medicinal purposes  .4  In addition to peptide and oligonucleotide synthesis, the 
advantages of solid phase strategies are reflected by the increasing amount of 
examples in the literature that use this technique for a whole range of 
applications. 89,90 
We proposed to transfer the epoxide chemistry onto a solid support based on a 
synthetic route adapted from work described by Rosse and co-workers. 9 ' They 
developed a strategy involving the formation of 3,4-epoxypiperidine Wang resin 46 
and subsequent ring opening with primary and secondary amines to generate the 
corresponding polymer-bound fl-amino substituted piperidinol products 47a and 47b 
(Scheme 2.7). 
OH 
iNKEyNTIX E~E  
LiClO in MeCN 	 ' 	 47a 
I 	LO 	 + 
HNR 1 R2 
24-48 hours 
85°C 	 I 
46 
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It was proposed to modify these conditions by using commercially available 2-
chlorotrityl chloride polystyrene resin 48 as the solid support. It was thought this 
would be a good choice of resin due to its high reactivity 92 towards a number of 
functional groups e.g. acids, amines, thiols and alcohols. It was anticipated that 
cleavage from the resin could be easily achieved using mild acidic conditions. 
2.4.1 RING OPENING OF GLYCIDOL 8 ATTACHED TO 2-CHL0RO TRITYL RESIN 48 
Work began by synthesising the epoxide resin in a one step reaction starting from 2-
chloro trityl polystyrene resin 48 and glycidol 8. The hydroxyl functionality in 
glycidol 8 offered a convenient site of attachment onto a polymeric support (Scheme 






IJCI04 in MeCN (1 .OM) 
MeCN, 85°C, 24h 
48 
OH 	 011 
I - 	HOINEt2 	
5%TFNDCM 
RT, 3h 
51 	 50 
Scheme 2.7 Proposed solid phase route towards diol 51. 
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In the first step, the epoxide functionalised resin was prepared by the addition of 
glycidol 7 to 2-chloro trityl resin 48 in the presence of pyridine in anhydrous THE 
This afforded epoxide resin 49. The epoxide was ring opened using freshly distilled 
diethylamine as the nucleophile and a 1 .OM solution of lithium perchlorate in MeCN 
as the activating catalyst. 94  Using this approach the epoxide resin was reacted with 2 
equivalents of lithium perchlorate and 4 equivalents of diethylamine in acetonitrile at 
85°C for 24 hours to generate the solid supported p3-amino alcohol 50. Cleavage 
from the resin was achieved using 5% TFA in DCM to afford a yellowish oil (10 mg, 
8%). ES-MS confirmed the presence of the desired product. The 'Hand ' 3C NMR 
spectra were consistent with the data reported in the literature. 
This approach provided an effective route towards the synthesis of 3-amino alcohol 
51. It provided a number of advantages over the solution phase route as previously 
described. Primarily, the generation of unwanted by-products was not observed and 
the isolation of the desired product was achieved without purification. However, 
there were a number of limiting factors that had to be considered before attempting 
this synthesis for a broader range of amines. Firstly, the overall reaction time was 
considerably longer than in solution. Previous investigations by Rosse and co-
workers showed that the nucleophilic addition of primary amines to a solid supported 
epoxide required even longer reaction times (up to 48 hours). 9 ' Secondly, the 
amount of product recovered after cleavage was low and it was felt the scope for 
scale-up of this synthesis would be restricted on solid phase. Development of this 
chemistry was not pursued. 
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2.5 MICROWAVE ASSISTED SYNTHESIS OF GLYCEROL-BASED 
ANALOGUES 
2.5.1 MICROWAVE SYNTHESIS 
At this point in the project a CEM Discover® Microwave Synthesizer was made 
available. Microwave technology has been used in inorganic chemistry since the late 
1970's however it has only been used in synthetic organic chemistry since the mid 
1980's. Compared to other technological advances in organic chemistry, for 
example, combinatorial and computational chemistry, microwave assisted organic 
synthesis has been slow to develop. However, the last decade has seen a significant 
increase in its use for a variety of reasons. This is mainly due to the increased 
availability of commercial microwave equipment and the development of solvent 
free techniques. In addition, improved safety aspects and shorter reaction times, 
along with expanded reaction ranges have also contributed to the growing 
importance of this technique in organic synthesis. 
Traditionally, organic reactions are heated using conventional oil baths which rely on 
transferring heat to the reaction vessel prior to heating the reaction mixture. In 
contrast, microwave radiation passes through the walls of the reaction vessel and 
directly heats only the reactants and solvent. Several papers cited by Lidstrom et al. 
highlight the advantages of using single mode microwave irradiation at 2.45 GHz to 
heat and speed up reactions. 95 
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2.5.1.1 Microwave Dielectric Heating 
Dielectric heating occurs as a result of two mechanisms: dipolar polarisation and 
conduction. In the dipolar polarisation mechanism, a substance must have a dipole 
moment in order to align itself with the oscillating electric field of microwave 
radiation (Figure 2.7). However, under high frequency microwave irradiation the 
molecules do not have enough time to align with the field. The difference between 
the orientation of the field and the dipole results in energy loss from the dipole by 
molecular friction and collisions. The conduction mechanism occurs when ions 
move within a solution under the influence of an electric field. This results in an 
increased collision rate, converting the kinetic energy to heat. This mechanism is a 
more efficient method of heat generation than dipolar polarisation. 
V" 
Figure 2.7 	Dipolar molecules attempting to align themselves with an oscillating 
electric field. 
M. 
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2.5.1.2 Solvent Choice 
The solvent choice for microwave irradiation is very important. The solvent must 
have good interactions with microwaves and have a high boiling point to avoid high 
pressure reactions. When a solvent is heated, the dielectric constant decreases as the 
temperature increases. Polar solvents such as ethanol and water effectively couple 
with microwave irradiation. Non-polar solvents such as DCM are not heated under 
microwave irradiation. However, the addition of small amounts of polar solvent or 
ionic liquid can increase the absorbing capacity of the non-polar solvent very 
efficiently. Organic microwave chemistry has been particularly useful in the 
synthesis of compounds that require polar reaction solvents and have long reaction 
times. It was thought that this microwave approach could be advantageous in the 
synthesis of glycerol analogues. 
A comprehensive review of microwave assisted organic chemistry is available in the 
literature. 95 A number of papers were found which focused on the microwave 
chemistry of epoxides. Saidi et al. 96  describe the ring opening of a range of epoxides 
with primary and secondary amines within 1 minute under solvent free conditions 
using a domestic conventional microwave oven (900 W), in the presence of 
montmorillonite K10 clay (Scheme 2.8). Montmorillonite KlO is acidic and has 
been used as a catalyst in several other organic reactions. 
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Scheme 2.8 Epoxide opening under microwave conditions. 
When epoxide 21 (1 mmol) was treated with 1 equivalent of morpholine 30 in the 
presence of activated Montmorillonite Kl 0 clay under microwave irradiation, 
without any solvent there was complete conversion led to n-amino alcohol 38. This 
reaction proved to be highly regioselective with only one product in excellent yield. 
In addition, Gupta and co-workers have reported the opening of epoxides using 
microwave irradiation with various N-nucleophiles in neutral, basic and acidic 
conditions, using ethanol as the energy transfer medium. 97  After mixing 1,2-epoxy-
3-phenoxypropane 19 (10 mmol) with 1.5 equivalents of amine in ethanol, the 
reaction mixture was subjected to microwave irradiation for 2.5 mins at 210 W 
(neutral conditions). Basic and acidic reaction conditions were achieved by the 
addition of one pellet of NaOH or 2-3 drops of conc. HC1 to each reaction mixture 
respectively. Enhanced reaction rates over classical methods and dramatic 
reductions of reaction times were observed along with better yields for each. This 
route has the added advantage of not requiring a filtration step to remove the 
montmorillonite Ki 0 clay catalyst. It was decided to try and adopt these reaction 
conditions using the GEM Discover® Microwave Synthesizer. Reaction conditions 
were monitored using a black body radiation sensor to measure temperature, and a 
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pressure probe inserted through the septum of the reaction tube. A variety of 
conditions were used to establish optimised ring opening of benzyl glycidyl ether 21 
with diethylamine 22 as shown in Table 2.5. 
Reaction 	Microwave 	 TLC analysis/Comments 
Conditions Conditions 
Neutral 	140°C (80 W) 3 mins 	TLC showed starting material still present 
140°C (80 W) 4 mins 	 Product spot only 
140°C (80 W) 5 mins 	Product spot only, possible solvent evaporation 
Acidic 
140°C (80 W) 3 mins 	 Product spot only 
(HCl) 
140°C (80 W) 4 mins 	 Product spot only 
140°C (80 W) 5 mins 	Product spot only, possible solvent evaporation 
Basic 
140°C (80 W) 3 mins 	 Starting material present 
(NaOH) 
140°C (80 W) 4 mins 	Starting material and product present 
140°C (80 W) 5 mins 	Product spot, possible solvent evaporation 
Table 2.5 	Optimisation of microwave conditions. 
It was found that neutral conditions were optimal for ring opening. The reaction 
proceeded cleanly and the desired product spot was seen by TLC after 4 mins. ES-
MS of the reaction mixture indicated the presence of the molecular ion peak at 238 
m/z. A broad peak at 3435 cm' was observed in the IR spectrum corresponding to 
the secondary alcohol functionality present in the product. 'H NMR of the crude 
mixture showed no traces of starting material however residual solvent peaks for 
ethanol were also observed. This was removed using a high vacuum. 
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2.5.2 C'o\I1'.-RIso' OF Soit TIO\ PIi-\SF \FRt S\IICRO\\A\F IRRADI iio 
I decided to investigate if compounds 23, 29 and 38-45, generated using the parallel 
solution phase approach, could be synthesised using the microwave conditions 
outlined in Scheme 2.9. 






co, EtOH, 4 mins, 1400C 
21 	 80W 	 23, 29, 38-45 
(81-96%) 	 (refer to Table 2.4) 
Scheme 2.9 Library generation using microwave irradiation. 
It was observed that in each case the overall reaction yield of the microwave route 
was increased compared to results from the parallel solution phase approach. These 
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Compound 
Parallel Synthesis • Microwave Synthesis 
Graph 2.1 	Comparison of product yields obtained by parallel and microwave 
synthesis. 
Of 
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In particular, significant improvements in the yields of compounds 39 and 43 can be 
seen. This could be a result of the increased solubility of the amine starting material 
in the reaction mixture compared to the parallel approach. Uniform heating of the 
reaction mixture may have also helped drive the reaction to completion. Product 
isolation was achieved by simple evaporation of the reaction solvent. If necessary, 
purification was performed using Kugelrohr bulb to bulb distillation. 
I have shown that ring opening benzyl glycidyl ether 21 by microwave irradiation is 
a convenient, highly efficient and high yielding approach towards the synthesis of f3-
amino alcohols. In addition, this route can be used to incorporate a range of amines 
into the glycerol 7 structure, avoiding problems like product isolation and unwanted 
by-product formation associated with the parallel solution phase chemistry. 
Although the microwave reactions were done in series, the reaction times were 
considerably shorter and the potential to generate larger libraries of compounds has 
been increased. Also, this method offers more flexibility for scaling-up reactions 
over a solution phase parallel approach. 
2.5.3 RING OPENING OF EPICHLOROHYDRIN 52 USING MICROWAVE 
IRRADIATION 
At this point I was interested in investigating the possibility of using microwave 
irradiation to ring open alternative epoxides, opening the door towards further 
glycerol modification. Research by Saidi et al. have also shown that it is possible to 
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react epichiorohydrin 52 with morpholine 30, using solvent free conditions 96  to form 
1-chloro-3-morpholino-propan-2-ol 53a in 54% yield as shown in Scheme 2.10. 
+ C°) 
Montmodllonite K10 clay O 	 OH 
	
(0) 
+ HO Cl 
w, I mm 
H major product (54%) 
52 	 30 	 53a 	 53b 
Scheme 2.10 Reaction of epichlorohydrin 52 with morpholine 30 under 
microwave conditions. 
The regioselectivity of this reaction was lower than the case of benzyl glycidyl ether 
21 with a ratio of 1.7 of 53a to 53b observed. To determine if the conditions used to 
generate the first microwave library would be applicable to this synthesis 
epichlorohydrin 52 (1 mmol) was reacted with diethylamine 22 (1.5 mmol) in 
absolute ethanol (2.5 mL) for 4 mins under microwave irradiation. After solvent 
evaporation, the crude product was obtained as a clear colourless oil. No trace of the 
starting material was observed by TLC. Several peaks were observed by ES-MS, 
none of which corresponded to the desired molecular ion mass of 166 mlz. Also, the 
expected chlorine isotope peak at 168 mlz was not observed. However, an intense 
molecular ion peak at 203 mlz (100%) and a smaller peak at 130 m/z (50%) were 
evident and a further peak at 332 m/z was also observed. The microwave conditions 
used for this reaction could have promoted further reaction of unwanted side 











1 21  
HO 
0 OH  
54 
56 55 
(332 m/z) (203 mlz) 
Scheme 2.11 Proposed route towards dimer 55. 
Dimer 55 was purified by column chromatography and characterised by 'H and ' 3C 
NMR confirming that this had formed in 75% yield. A broad peak in the IR 
spectrum of the dimer at 3365 cm' indicated the presence of the hydroxyl group. It 
is proposed that the amine initially displaces the chloride prior to epoxide opening 
under these conditions. To try and avoid this problem, activated Kl 0 clay was added 
to the reaction mixture to see if this would increase the reactivity of the epoxide over 
chloride displacement. This was unsuccessful and formation of the dimer and other 
side products was observed once again. 
It was apparent that development of these reaction conditions was required. Firstly, 
the number of amine equivalents was reduced to equimolar amounts compared to the 
epoxide. The reaction was repeated using the same conditions as before however the 
desired product peak was still not observed in the ES-MS. 
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Since TLC analysis showed that dimer 55 had formed after 1 minute in the 
microwave a series of reactions were then performed to determine if reducing the 
reaction temperature would promote desired product formation. The results are 
summarized in Table 2.6. 
Entry 	Solvent 	Time 	Temp (°C) 	[MH]' seen (mlz) 
Ethanol 	1 min 	140 	130, 203, 332 
	
2 	Ethanol 	I min 	90 	 130, 203, 332 
3 	Ethanol 	I min 	70 	 130,203 
4 	Ethanol 	I min 	50 	130,166 (168), 203 
5 	Ethanol 	1 min 	30 	130,166 (168), 203 
6 	Ethanol 	1 min 	20 	 166 (168) 
* Masses highlighted in bold show mass of desired product 
Table 2.6 	Microwave optimisation of ring opening of epichlorohydrin 52. 
Reducing the number of equivalents of diethylamine 22 to 0.9 equiv. and the 
reaction temperature to 20°C it was possible to prevent dimerisation and further 
unwanted epoxide ring opening reactions. Using these modified conditions, the ring 
opening of epichlorohydrin 52 using the range of amines that were previously 
incorporated into both the parallel and microwave libraries was carried out (Figure 
2.4). The results from this library synthesis are summarized in Table 2.7. 
74 












164 [166] yes 65 
59 178 [180] yes 72 
4 60 
OH 
180 [182] yes 70 
5 61 
H 	 OH 
N 179 [181] yes 61 
6 62 
N.lCt 
180 [182] yes 12 
7 63 
i 	OH 
L1ci 214 [216] yes 76 
8 64 
OH 
H 150 [152] yes 55 
9 65 L..IY.1CI 164 [166] no N/A 
10 66 H 200 [202] no N/A 
OH 
11 67 186 [188] no N/A 
H 
12 68 166 [168] no N/A 
*Masses in square brackets indicate that the 'Cl molecular ion was observed 
Table 2.7 	Glycerol analogues generated using microwave irradiation. 
It can be observed that the modified conditions worked well for ring opening of 
epichlorohydrin 52 with the secondary amines shown in entries 1-7, furnishing the 
desired products 57-63 in good yields. Purification was achieved by removing the 
solvent under reduced pressure at low temperature. With the exception of the 
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allylamine product 64 (entry 8), the desired products 65-68 were not obtained using 
any of the other primary amines chosen under these conditions (entries 9-12). In 
each of these cases, ES-MS indicated that dimerisation and further side-product 
formation had occurred. A further attempt to ring open epichiorohydrin 52 with 
benzylamine 26 was made carrying out the reaction at 0°C. After 3 hours, TLC 
analysis indicated a mixture of products had formed and these could not be separated 
2.6 SUMMARY AND FURTHER WORK 
In summary I have shown that it is possible to generate focused libraries of glycerol 
analogues using parallel solution phase and microwave assisted chemistry. After 
optimising conditions, 21 novel compounds were made using these approaches. In 
particular, microwave assisted ring opening of benzyl glycidyl ether 21 by a variety 
of amines proved to be an efficient and high yielding route towards synthesising 
these types of compounds. We have also shown it is possible to use this route with 
the goal of increasing library diversity. This presents the opportunity to incorporate 
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Scheme 2.12 Possible routes towards increasing library diversity. 
At this stage several potential biological assays were being developed by a number of 
different groups involved in the project to screen potential AQP inhibitors. To begin 
with, development of these systems proved problematic and as a result the testing of 
these compounds was delayed. Consequently, since investing further time and effort 
into the development of this chemistry would be futile until preliminary biological 
evaluation could be carried out, further development of this chemistry was 
postponed. 
At this point in the project a number of other potential lead compounds had been 
shown to have potential inhibitory effects on AQP function. These are discussed in 
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3 	RESULTS AND DISCUSSION II— TEA-BASED ANALOGUES 
3.1 IDENTIFICATION OF POTENTIAL AQUAPLUGS 
As stated in Chapter 2, One of the project objectives was to compile a list of 
compounds which have inhibitory effects on AQP function. Previously, the 
development of the glycerol analogue libraries was made using a rational structure-
based design approach based on the E. coli GIpF facilitator model, a homologue to 
AQP- 1. However, we were also keen to explore the development of other potential 
inhibitors that effect water permeability in AQP water channels. 
3.1.1 BASIS FOR FURTHER DEVELOPMENT 
As previously described in the introduction, the only known blockers of water 
transport through AQP-1 water channels were mercurial reagents such as HgC12 and 
more recently silver and gold reagents such as AgNO3, silver sulfadiazine 69 and 
HAuC14 (Figure 3.1). 
Ad 
	NH  
N 	N111 S 
69 
Figure 3.1 	Silver sulfadiazine 69 is a potent inhibitor to AQP-l. 
78 
Chapter 3 	 Results and Discussion II 
For AQP-1, formation of a covalent mercaptide bond with the cysteine residue 189, 
situated in the constricted region of the pore, inhibits water permeation by up to 
55% 98  However, Niemetz and co-workers recently reported silver to be the most 
potent inhibitor of AQPs described so far. 68  This work suggested that silver 
inhibition of water permeability was about 200 times more potent than that of 
mercury compounds. However, this form of inhibition is not reversible without 
treatment with reducing reagents such as dithiothreitol 70 (DT-17) and 3- 
mercaptoethanol 71 (Figure 3 .2).9929 
'OH 
SH 
HS 	 ,,-,'OH 
 
OH 
70 	 71 
Figure 3.2 	Structures of DTT 70 and 3-mercaptoethanol 71. 
Common structural features between AQPs and potassium channels have been 
reported by a number of groups. 100,4'  Furthermore, it has been reported that 
tetraethylammonium chloride (TEA) 5 and other quaternary ammonium compounds 
cause inactivation of potassium ion channels.' ° ' On this basis Brooks et al. 69 
suggested that known ion channel blockers may be potential candidates for novel 
inhibitors of AQP-1 water permeability. As a result different quaternary ammonium 
compounds, including TEA 5, were screened using swelling assays in AQP-1 
expressing oocytes. These studies demonstrated that TEA 5 reversibly blocks the 
water permeability of AQP-1 in a dose-dependent manner. Further research by Yool 
and co-workers 102  has shown that TEA 5 reduces water permeability of AQP-1 
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channels in kidney and kidney-derived cells, demonstrating this effect is not limited 
to the oocyte expression system. 
3.1.2 PREDICTED INTERACTIONS BETWEEN TEA 5 AND AQP-1 
Site-directed mutagenesis studies 69 have also revealed that water permeability is 
influenced by TEA 5 in the loop E region of AQP-1. As discussed in Chapter 1, this 
part of the pore is known to contain the fingerprint asparagine-proline-alanine (NPA) 
motif which is conserved throughout the AQP family. Structural analysis of AQP-1 
has shown that this sequence is involved in forming part of the aqueous pore that is 
important in determining water selectivity through the channel. 25 
On this basis, Tyr 186 in AQP-1, close to the mercury binding Cys 189, was mutated 
using PCR to phenylalanine (Y1861 7) and expressed in oocytes. 69 Osmotically 
induced swelling assays demonstrated that water permeability was comparable to 
that observed in wild type AQP-1. Further mutations of AQP-1 Tyr 186 to alanine 
and asparagine, created channels which were impermeable to water, providing 
further evidence that this residue is important for water transport. The effect of 100 
jiM TEA 5 was then evaluated on Y18617-expressing oocytes. This experiment 
showed a rapid increase in relative cell volume, similar to that seen for wild type 
AQP- 1, with no evidence of TEA 5 inhibition. Increasing the concentration to 10 
mM TEA 5 also showed a comparable increase in relative cell volume to wild type 
AQP-1. Furthermore, it has also been reported that substitution of Cys 189 with 
methionine, tryptophan and tyrosine in AQP-1 loop E reduces water permeability by 
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up to 95%•45  In contrast, substitution of Cys 189 with alanine or serine did not affect 
water permeability in AQP-1 but removed inhibition by HgCl2. 
The results of these studies demonstrated that AQP- 1 function expressed in ooctyes 
can be significantly altered by compounds other than mercurial or other heavy metal 
reagents. Inhibition is reversible and appears to be influenced by the Tyr 186 residue 
in the amino acid sequence of loop E in AQP- 1. If indeed this is the preferred 
binding site of TEA 5, then it could be speculated that quaternary ammonium 
compounds analogous to TEA 5 might reduce water permeability in other AQP 
family members which contain this conserved sequence of amino acid residues. 
3.1.3 OOCYTE SWELLING ASSAY 
Xenopus laevis ooctyes were chosen as the assay system for a number of reasons. 
Firstly, they are very large cells which normally have a diameter measuring between 
600-1300 rim. This makes manipulation of the cell relatively easy. Secondly, they 
possess high RNA translation capacity enabling exogenous mRNA to be injected into 
the cell in order to study the expression of heterologous proteins. Expression of 
mRNAs in Xenopus laevis oocytes has led to the identification of aquaporins in red 
blood cells, 29 kidney tubules' 03"04 and plants. 105  Thirdly, the low water permeability 
of the plasma membrane makes oocytes a suitable model to study the activity of 
water channel proteins. 
The common procedure to assay for AQP activity is to shift ooctyes, 2-3 days after 
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influx of water after the shift, it is possible to determine the changes in cell volume. 
The presence of AQP water channels in the plasma membrane increases the osmotic 
water permeability, Pf (cm s'). Several biophysical parameters which provide 
insight into the geometric nature of the water-transporting pathway have been 
characterised. 106,107  Osmotic water permeability is defined as the net flow of volume 
across a membrane in response to a hydrostatic or osmotic driving force. 
The mathematical formula is represented as follows: 
Pf J,/ {SVW [(P1-P2) / RT + a1  (fl21 -flu)]) 
Equation 3.1 Formula to calculate osmotic water permeability in oocytes. 
• J, = volume flow (cm 3 s') 
• S = membrane surface area (cm 2) 
• 	= partial molar volume of water (18 cm  moi') 
• P = hydrostatic pressure (atmospheres) 
• 	= reflection coefficient of the ith solute 
• f1i = osmolality of the ith solute (mosM) 
• R = universal gas constant 
• T = absolute temperature (K) 
The assay for Pf is based on the rate of swelling of defolliculated ooctyes in response 
to dilution of the extracellular solution. The increase in oocyte volume is 
quantitatively measured using a transmission light microscope in which the ooctye 
diameter is viewed simultaneously along two orthogonal axes using a video monitor. 
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Fluorescence quenching' 08  and stop-flow light-scattering experiments 6 ' have enabled 
quanti tcation of osmotic water permeability in oocytes. These techniques have 
permitted the calculation of the unit permeation, Pf 3 x  109 water molecules per 
subunit per second, highlighting the huge capacity for water transport in AQPs. This 
influx of water causes the oocytes to increase in volume by around 50% and to 
rupture within 2 to 6 minutes of hypotonic exposure, compared to non-injected 
oocytes which burst after 45 to 60 minutes. An example of an ooctye bursting is 
shown in Figure 3.3. 
Figure 3.3 	The functional expression of AQP-1 water channel in Xenopus laevis 
oocytes. 3° 
Incubation of hypotonic buffer fails to cause swelling of a control oocyte (left). However, an 
oocyte injected with A QP- I cRNA (right) exhibits high water permeability and has exploded. 
3.1.4 EFFECTS OF QUATERNARY AMMONIUM AQUAPLUGS ON AQP FUNCTION 
To determine if quaternary ammonium ions had significant effects on water 
permeability in AQPs, TEA 5 and closely related analogues were tested on Xenopus 
laevis oocytes expressing AQP-1, 2 and 3 in a swelling assay. Initially, five 
commercially available quaternary ammonium salts; 5 and 72-75, were selected for 
testing. The structures of these compounds are shown in Figure 3.4. 
*1 
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CI 	 CI 	 CI 
N 	 N N 	 N 
72 	 5 	 73 	 74 	 75 
TMA 	 TEA 	 TPrA 	 TBA 	 TPeA 
Figure 3.4 	Structures of the quaternary ammonium salts tested. 
It was hoped that a positive result from this biological screen would provide a 
potential lead for further compound development. The screening work that is 
reported throughout this thesis was performed by Dr Frank Detmers from the Dept. 
of Cell Physiology, Nijmegen Centre of Molecular Life Sciences, UMC St. Radboud, 
Nijmegen, The Netherlands. The results from this initial biological screen are 










No 	TMA 	TEA 	TPrA 	TEA 	TPeA 
inhibitor 
• AQP-1 u AQP-2 o AQP-3 
Graph 3.1 	Effect on water permeability on AQP-1, 2 and 3 by symmetrically 
increasing the alkyl chain length in quaternary ammonium salts. 
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The results show that symmetrically increasing the alkyl chain length around the 
quaternary nitrogen centre from methyl > ethyl > propyl > butyl > pentyl does not 
significantly improve inhibition over TEA 5. For every compound or control, at least 
10 oocytes were measured to give the average water permeability with an associated 
standard deviation. An unpaired student t-test was used to compare the Pf values of 
a series of ooctyes to determine if one measurement was significantly different from 
another. It can be observed that 100 jiM TEA 5 significantly reduces water 
permeability of oocytes expressing AQP-1 and 2 by 44 ± 11% and 49 ± 18% 
respectively. There was no significant effect on ooctyes expressing AQP-3. TPrA 
73 reduces water permeability in AQP-1 by 32 ± 15%, however no effect was 
observed for AQP-2 and 3. This data further suggests that TEA 5 is not selective for 
a particular AQP, however it is interesting to note that TPrA 73 selectively reduces 
water permeability in AQP- 1 only. These results are in good accordance with similar 
water permeability measurements reported in the literature. 69 
In view of this trend we postulated that steric factors, coupled with increased 
hydrophobicity of the alkyl functionality, could be important in determining how 
these compounds interact with the channel. There appears to be an optimal 
symmetrical alkyl chain length associated with water inhibition. Surprisingly, TMA 
72 does not show a reduction in water permeability in any of the AQPs that were 
expressed in ooctyes. A combination of decreased hydrophobic shielding around the 
positive nitrogen centre together with reduced flexibility of the smaller methyl 
groups (compared to ethyl) could affect possible protein interactions with the 
constriction region. In contrast, symmetrically increasing the alkyl chain length to 
C4 (TBA 74) and C5 (TPeA 75) had no effect on water permeability. In these cases, 
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it is possible that steric bulk alone may prevent these quaternary ammonium ions 
from making contact with possible binding residues within the water channel. 
TEA 5 is also a known substrate for the organic cation transporter (OCT) found in rat 
kidney. Furthermore, it is reported in the literature that quinine 76 is a non-
transported inhibitor of OCT. 109 It was postulated that this compound could 
potentially have an affinity for AQPs. For this reason quinine 76 was tested to 
determine if it inhibits water transport using the oocyte expression system. The 
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Graph 3.2 Effect of 100 .tM quinine 76 on oocytes injected with AQP-1, 2 and 3. 
It was observed that 100 jtM quinine 76 inhibits water permeability in oocytes 
injected with AQP-1, 2 and 3 by 34 ± 14%, 31 ± 18% and 31 ± 16% respectively. 
After testing, the oocyte was rinsed several times with saline solution and allowed to 
recover to normal volume over a short period of time, indicating that the inhibitory 
effect was reversible. This result provided the basis for further investigation into 
quinine 76 as a potential AQP blocker. 
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3.1.5 DATABASE MINING AND STRUCTURE SIMILARITY SEARCHES 
At this point, we had identified three potential structures with which to develop 









Figure 3.5 	Lead ligands for further development 
We decided to perform a commercial availability search based on these lead 
structures. Using MDL® Isis Base software we were able to search the Available 
Chemicals Directory (ACD) database which contains over 247 000 compounds from 
various sources including Fluka, Sigma-Aldrich and Maybridge catalogues. 
Selection criteria were based on cost, molecular weight, steric factors, availability 
and chemical intuition. The results from this search are shown in Tables 3.1, 3.2 and 
3.3 together with the biological evaluation of those analogues which were tested 
using the oocytes assay system. 
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Entry 	Compound 	 Structure 	
Inhibition of water permeability (100 pM) 
AQP1 	AQP2 	AQP-3 
1 	 7 	 HOjOH 	 No effect*  No effect* 	ND 
2 	 51 	
OH 
N._LOH 	
No effect 	No effect 	No effect 
3 	77 	 NI OH 
	
No effect 	No effect 	No effect 
/- 	OH 
4 	 78 	 cL.OH 	 No effect 	ND 	ND 
79 	
OH 	
No effect 	ND 	ND 
OH (NH 
6 	 80 	 No effect 	ND 	ND 
OH (o 
7 	 81 	 O'NJ 	No effect 	ND 	ND 
8 	 82 	 A 	ND 	ND 
9 	 83 A 	ND 	ND 
10 	84 	 A 	ND 	ND 
11 	85 	 A 	ND 	ND 
0 	 0 
12 	86 	 L- 0 L- 	 A 	ND 	ND 
*Gl ycerol was tested at 15mM concentration; ND - not determined; AW - awaiting testing 
Table 3.1 	Biological results of commercially available compounds based on 
glycerol 7 template. 
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Inhibition on water permeability (100pM) 
Entry 	Compound 	Structure 
AQP-1 AQP-2 	AQP-3 	AQP-4 	AQP-5 
1\_jCI 	44± 	39± 	No 	55± 	No 
11% 	18% 	effect 	15% 	effect 
H 
2 	87 	 ND 	ND 	ND 	ND 	ND 
3 	88 	
- 	No 	No 	No 	No 	No 
effecteffect 	effect 	effect 	effect 
\ 	CI 
4 	89 
43± 	No 	No 	No 	No 
i'\ 18% 	effect 	effect 	effect 	effect 
5 	90 	 ND 	ND 	ND 	ND 	ND 
56± 	No 	No 	No 	No 
6 	91 	 () 	
13% 	effect 	effect 	effect 	effect Br 
p 
\ 	II 
7 	92 	 AW 	AW AW 	AW 	AW 
\ 	ci 
8 	93 	 AW 	AW AW 	AW 	AW 
ND - not determined; AW - awaiting testing 
Table 3.2 	Biological results of commercially available compounds based on 
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Inhibition on water permeability (100pM) 
Entry 	Compound 	 Structure  
AQP-1 AQP-2 AQP-3 AQP-4 AQP-5 
1 	76 	
HO 	 34± 31± 31± ND 	
No-'rbH 	 14° /o 	18% 	16% 	 effect 
No No Not No 
ND 
effect effect effect effect 
No No No No 
ND 
effect effect effect effect 
No 	No 	No 	 No 
ND 
effect 	effect 	effect 	 effect 






effect effect effect effect 
No No No No 
6 98 ND 
effect effect effect effect 
0 
OI N 	N"N  
No No No 
ND ND 
effect effect effect 
No No No 
8 100 N ND ND 
effect effect effect 
ND- not determined 
Table 3.3 	Biological results of commercially available compounds based on 
quinine 76 template. 
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3.1.6 SCREENING RESULTS OF COMMERCIALLY AVAILABLE COMPOUNDS 
3.1.6.1 Glycerol 7 Derivatives 51 and 77-86 
Unfortunately, the results from the screening of commercially available glycerol 
analogues (Table 3. 1, entries 1-12) did not show any effects on water permeability on 
AQP- 1, 2 and 3. Testing on AQP-4 and 5 was not possible due to the lack of 
availability of the mRNA's for these proteins. 
There are potentially a number of reasons why no inhibition was observed for the 
glycerol analogues. Firstly, the rational ligand design was initially based on a 2.2 A 
high resolution crystal structure of G1pF, as a high resolution structure of AQP- 1 was 
not available at the time. Secondly, water has favourable steric accessibility through 
both AQP-1 and GIpF channels, however there is an important difference in glycerol 
7 accessibility between these pores; the constriction region in G1pF is about 1 A 
wider than AQP-1 There are a number of amino acid differences in this region 
that explain this observation. 
In AQP-1, histidine residue 182 is thought to be critical in supporting rapid water 
throughput whilst hindering the passage of other solutes. In G1pF, this residue is 
replaced by glycine which significantly increases the size of the pore, allowing 
glycerol 7 transport. Another residue change, at cysteine 191 to phenylalanine, 
increases the hydrophobicity of this region which in turn improves channel 
interactions with the hydrophobic backbone of glycerol 7 and reduces water 
91 
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permeability through the pore. A representation of the critical residues defining the 
constricted region is shown in Chapter 1 (Figure 1.11). 
In AQP-3 it is speculated that the constriction region is similar in size to G1pF, with 
the main difference being the substitution of Phe 200 with a slightly more polar 
tyrosine residue. This change could provide an additional location for hydrogen 
bonding and may explain why AQP-3 conducts both water and glycerol 7. However, 
problems with the quality of the batch of oocytes harvested at this time, meant that 
only a small number of commercially available glycerol analogues could be tested. 
Unfortunately, none of those selected inhibited water permeability of AQP-3 
expressed in oocytes. It is proposed that glycerol analogues; 23, 29 and 38-45 as 
described in Chapter 2, would be tested when the reproducibility of the biological 
results from the oocytes assay could be improved. 
3.1.6.2 TEA 5 Derivatives 87-93 
The screening results shown in Table 3.2 (entries 1-8) indicate that l00pM TEA 5 
shows significant water inhibition of AQP-1, 2 and 4 but not AQP-3 or 5. These 
results were interesting as they suggested that TEA 5 could have a binding affinity 
for other AQPs which exhibit the conserved tyrosine residue in the E loop of AQP-l. 
Water permeability through AQP-1 (but not AQP-2 to 5) is also affected by triethyl 
methyl ammonium chloride 89 and triethyl hexyl ammonium bromide 91. A 
significant increase in water inhibition compared to TEA 5 was not observed for 
compound 89, however compound 91 inhibited water permeability in AQP-1 by up 
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to 56 ± 13%. These results gave the first indication that it may be possible to 
selectively block different AQPs by altering the headgroup size and adjusting the 
length of one of the alkyl side chains. 
3.1.6.3 Quinine 76 Derivatives 94-100 
The biological results obtained from this set of compounds, shown in Table 3.3 
(entries 1-8) were disappointing. As mentioned earlier, quinine 76 inhibits AQP- 1, 2 
and 3 but further investigation revealed that it has no effect on water permeability 
through AQP-4 or 5 expressed in oocytes. None of the other quinine-related 
compounds, 94-100, showed inhibition of water permeability on AQP-1 or any of the 
other AQPs tested. Specificity differences between TEA 5 and quinine 76 could be a 
result of different ligand interactions within the water pore. It is hard to envisage 
that the same mode of water inhibition can be applied to quinine 76 as for TEA 5. It 
could be speculated that steric bulk alone would make penetration of quinine 76 into 
the water pore particularly difficult. 
3.1.7 LIGAND DOCKING AND MOLECULAR DYNAMIC (MD) SIMULATIONS 
At this stage I was interested in determining how these types of compounds might 
orientate themselves within the pore of AQP- 1. It could be anticipated that it would 
be possible to maximise the geometric and physicochemical interactions between the 
protein and the ligand by using molecular docking techniques. In particular, I hoped 
to be able to fit small molecules, such as TEA 5 and glycerol 7, into a model of 
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pore. A 2.2 A resolution 1H61 model of bovine AQP-1 was used for a series of 
docking experiments. Unless otherwise stated, these docking pictures were produced 
by Andre\\ Hinton from the Dept. of Structural Biology at the University of 
Edinburgh using IJDAEUS and DOCK 4.0 modelling packages. 
Figure 3.6 	Possible orientation and binding site oF TEA 5 in bovine AQP-l. 
(Produced by Dr Matthias Muller from the Dept. of Biophysical Chemistry 
at the Max Planck Institute, Gottingen, Germany.) 
Figure 3.6 represents TEA 5 docked into the extracellular side of the monomer AQP-
I pore, looking from above. Highlighted are channel residues surrounding the 
constriction region of the pore which may be involved in ligand binding. The 
residues shown in red are negatively charged whereas the Arg 126 residue shown in 
blue is positively charged. In particular, Tyr 186 is believed to be involved in TEA 
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Figure 3.7 	Possible orientation and binding site of TPrA 73 in bovine AQP-1 
(Produced by Dr Matthias Muller from the Dept. of Biophysical Chemistry at the Max 
Planck Institute, Gottingen, Germany.) 
Viewed from the extracellular side of the AQP-1 pore, TPrA 73 is modelled into the 
same location as the proposed binding site for TEA 5 in the loop E region of AQP-1. 
It is postulated that the pore interactions highlighted in Figure 3.6 are similar for 
TPrA 73. The loop E region of AQP- 1 is highlighted in yellow. This docking 
picture was used to determine if the bulkier hydrophobic propyl groups surrounding 
the quaternary nitrogen centre would prevent docking of TPrA 73 close the 
constriction region due to steric limitations. The docking results indicated that this 
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Figure 3.8 	Grasp representation of surface electrostatics of the 2.2A resolution 
crystal structure of bovine AQP1. 
Figure 3.8 shows the extracellular vestibule region viewed from above with TEA 5 
docked into the loop E region making close associations with Y188. The negative 
electrostatic charge of D50, Dl 87, Y 188 and D21 0 are clearly identified in red with 
the blue positive charge of pore residue R197. In this model, it can be clearly seen 
that TEA 5 has been docked some distance away from the central pore indicating that 
several binding sites could exist for this compound. 
C hapicr $ 
	







Surface representation of the 2.2A resolution crystal structure of 
bovine AQP1. 
In Figure 3.9 the extracellular vestibule region is viewed from above and is shown 
with compound 91 sandwiched between aspartic acids, D50 & D187, shown with a 3 
A field of effect. The hexyl side chain lies close to backbone atoms of Q49 and N5 1. 
Molecular docking models like this suggest that the hexyl side chain can make 
energetically favourable van der Waals contacts with the hydrophobic residues lining 
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Figure 3.10 Connelly Surface representation of the 2.2 A resolution crystal 
structure of bovine AQPI. 
Figure 3.10 illustrates the extracellular vestibule region of AQP- 1 viewed from 
above with compound 87 sandwiched between aspartic acids, D50 and D187, shown 
with a 3 A field of effect. The hydroxyl group could form a hydrogen bond with the 
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Figure 3.11 A cartoon representation of the constriction region of bovine AQP1. 
Shown in Figure 3.11 are the pore constriction residues R197, F58, H182 & C191. 
Glycerol 7 is seen modelled into the upper vestibule region making possible 
hydrogen bonding contacts with Gln 47, with the glycerol 7 backbond stabilised by 
Val 52 and Ile 184 using site points from the LIDAEUS docking package. The 
hydrophobic alkyl backbone of glycerol 7 makes energetically favourable van der 
Waals contacts with the hydrophobic half of the channel wall. 
rd 
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Figure 3.12 A cartoon representation of the constriction region 0fAQPI viewed 
vertically along the length of the pore. 
Shown in Figure 3.12 are the pore constriction residues R197, F58, H182 & C191. 
Glycerol analogue 23 is seen modelled into the upper vestibule region using site 
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Figure 3.13 A cartoon representation of the constriction region of AQPI viewed 
vertically along the length of the pore. 
Shown in Figure 3.13 are the pore constriction residues R197, F58, H182 & C191. 
Glycerol analogue 41 is seen modelled into the upper vestibule region using site 
points from the LIDAEUS docking package. The bulky aromatic benzyl protecting 
group could be involved in a 11-stacking arrangement with the hydrophobic aromatic 
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3.2 DEVELOPMENT OF QUATERNARY AMMONIUM SALT ANALOGUES 
3.2.1 LEAD STRUCTURE DESIGN 
In light of the biological results of the commercially available quaternary ammonium 
ions that were screened using the oocytes assay, we decided to investigate the 
potential for generating compound libraries of quaternary ammonium analogues 
based on TEA 5. So far, other than TEA 5, three quaternary ammonium compounds 
had shown significant reversible water inhibition of AQP-1 (Figure 3.14). 
\— C. 	--\— .cI_ 	 CI- 	 - Br-CI \ 	+ 
N 	
I 
N— 	 N—\ 
73 89 	 91 
AQP-1, 2 and 4 	AQP-1 	 AQP-1 	 AQP-1 
Figure 3.14 Commercially available quaternary ammonium salts which inhibit 
water permeability in AQP water channels expressed in oocytes. 
These screening results indicated that AQP-1 might be tolerant to further 
modification of the core TEA structure. In particular, it appeared that introducing a 
longer alkyl chain moiety did not have a detrimental effect on water inhibition. As a 
consequence, it was decided to investigate the effect on AQP function by modifying 
one of the alkyl chains attached to the quaternary nitrogen centre whilst retaining the 
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related to triethyl hexyl ammonium bromide 91, however, I was also keen to 
introduce functionality within the alkyl tail which could be used as a handle for 
further modification at a later stage. With these objectives in mind, we proposed to 
implement an efficient and mild route towards the photochemical synthesis of a 
number of functionalised quaternary ammonium analogues and determine their 
inhibitory activity in different AQPs. 
3.2.2 UV ACTIVATED ADDITION OF THIOLS TO TRIETHYL ALLYL AMMONIUM 
BROMIDE 88 
This strategy employed UV irradiation to initiate the reaction between a number of 
commercially available thiol compounds 101-107 and triethyl allyl ammonium 
bromide 88 as outlined in Scheme 3.1. The use of free radical additions of thiols to 
C-C double bonds has been the subject of many reviews. 110 It is well understood 
that, under radical conditions, addition to an unsymmetrical unsaturated C-C double 
bond undergoes anti-Markovnikov regioselectivity. 
B Br 	 r 
N 	
UV irradiation (254 nm) 
+ HS—R  
88 	 101-107 	
MeOH,8h 	
108-114 




-CH2CH(OH)CH(OH)CH 2SH 105 
-(CH2 )3SH 106 
-CH2CH20H 107 
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3.2.2.1 Proposed Mechanism of Thiol Addition 
In general, the free radical addition of a thiol to an unsaturated double bond requires 
initiation by exposure to UV irradiation or by addition of chemical initiators. Thiols 
are good candidates for these types of reactions due to their inherent weak S-H bond 
(364 kJ moi') which can be heterolytically cleaved under mild photochemical 
conditions. It is believed that the alkyl thiyl radicals generated during irradiation, 
subsequently add to the unsaturated substrate to form a C radical. The C radical then 
reacts with another thiol molecule generating the final product and a new thiyl 
radical, thus propagating the radical chain. Each of these steps are exothermic, so 
once this process has started it continues until radicals are lost to termination events 
(Scheme 3.2). 
Initiation 	R—SH 	 R—S. + H. 





RS\ RS\ H 
	







Scheme 3.2 Proposed radical chain reaction.' 
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The regioselectivity of this reaction can be explained by the preferred formation of 
the more stable intermediate secondary radical. Accordingly, the addition of thiyl 
radicals to simple olefins takes place preferentially at the less substituted end of the 
unsaturated system to give the more highly substituted and therefore more stable 
alkyl radical. On this basis, it should be possible to generate a number of novel 
quaternary ammonium thioether analogues without encountering potential problems 
such as undesired side-product formation. 
3.2.3 SYNTHESIS OF QUATERNARY AMMONIUM THIOETHERS 
Following conditions reported by Klaffke et al. 112  a test reaction between triethyl 
allyl ammonium bromide 88 and 1-hexanethiol 101 (5 equiv.) which had been 
dissolved in degassed methanol and transferred to a water-cooled photochemical 
reactor was carried out. The mixture was stirred at room temperature, under 
nitrogen, and irradiated by UV light (254 mn) for 8 hours. Upon completion, the 
reaction mixture was concentrated in vacuo to yield a viscous yellow oil. ES-MS of 
the crude product indicated that the molecular ion peak [M] for the desired product 
was present at 260 mlz. Other potential quaternary ammonium adducts which could 
have potentially formed during the reaction were not observed. 
3.2.3.1 ZMD purification 
Purification of the desired product was achieved using the Waters® FractionLynxTM 
LC-MS system as described in Section 2.3.5. A reverse phase gradient solvent 
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the chromatographic trace and corresponding mass spectrum that was obtained is 
shown in Figure 3.15. After purification the fractions containing the desired product 
were collected, concentrated in vacuo and freeze-dried overnight to remove any 
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3.2.3.2 Increasing the Structural Diversity of Thioether Analogues 
With the goal of increasing structural diversity, thioether analogues 109-114, were 
synthesised using the experiemental conditions as described in Section 3.2.3. The 
results are outlined in Table 3.4. 
Entry 	Compound 	Thiol 	 Expected Product 	
mlz [M) 	Isolated 
Ion seen Yield 
Br yes 
1 109 101 
219 
15% 








4 112 104 52% 
296 
Br 




r \ ( yes 6 114 106 
2 20 
N/A  
Table 3.4 	Synthesis of functionalised quaternary ammonium salts 
The results show that products 109-113 were successfully obtained and isolated 
using this photochemical approach. The molecular ion peak for crude product 114 
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was observed by ES-MS however, ZMD purification of this compound proved 
unsuccessful. The mass spectrum of the purified sample indicated the presence of a 
peak at 142 mlz (100%) corresponding to starting material 88, however the desired 
product 114 was not obtained. 
In addition, it can also be observed that in general, the reactions were not particularly 
high yielding. There are a number of possibilities why this might be the case; firstly, 
during UV irradiation in the photochemical reactor, a thin film of material could be 
observed building up on the outside glass wall of the mercury lamp. Over time, this 
could reduce the exposure of the reactants to the UV light and in turn decrease the 
efficiency of the reaction. Secondly, problems with the ZMD purification step were 
encountered if unreacted triethyl allyl ammonium bromide 88 was present in the 
crude sample. In particular, purification of thioether 114 was not achieved under the 
chromatographic conditions employed due to co-elution difficulties encountered with 
starting material 88. 
3.2.3.3 Optimisation of ZMID Chromatographic Conditions 
Co-elution of the product 114 and unreacted starting material 88 resulted in a number 
of fractions containing both of these compounds. Further HPLC method 
development was carried out to resolve this problem by exchanging the Phenomenex 
Luna C18 65 x  21.2 mm column, with an X-Terra® Prep MS C18 19 x  50 mm, 5 11 
microns column, capable of withstanding basic mobile phase conditions upto pH 12. 
The use of high pH mobile phases in conjunction with typical silica gel C18 columns 
can result in complete dissolution of silica and greatly reduce the column lifetime. 
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The X-Terra® Prep column reduces the rate of surface dissolution by incorporating 
bonded methyl groups on the surface sites which in turn improves separation of basic 
compounds and aids in prolonging the column life expectancy. Altering the run time 
and adjusting the pH of the gradient solvent system to pH 10 (H 20:MeCN (95:5) 
with 0.1% 10 mM (NH4)2CO3) enhanced the separation of product 114 from starting 
material 88. This alteration increased the retention time of the desired product peak 
and greatly reduced contamination of the collected fractions with unreacted triethyl 
allyl ammonium bromide 88. However, further problems were encountered after 
purification as the hygroscopic nature of this compound made product isolation 
difficult after lypholisation, resulting in a white paste rather than a crystalline solid. 
This made compound handling awkward and increased the likelihood of loss of 
product yield. As a result product 114 was not successfully isolated using this 
approach. 
Overall, this is a mild and effective route towards the synthesis of these types of 
functionalised quaternary ammonium analogues. In addition, the formation of 
unwanted side-products during the radical addition step was not observed. It was 
envisaged that this one-step reaction could provide the basis for further modification 
of potential lead aquaplugs if inhibitory effects were established in AQP function. 
This synthetic route also provides functionality at the terminal end of the alkyl tail, 
such as a thiol moiety, which could be used as a site of attachment for further ligand 
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3.2.4 BIOLOGICAL EVALUATION OF QUATERNARY AMMONIUM THIOETHERS 
At this stage we were keen to establish whether these compounds affected water 
transport in AQPs 1-5 expressed in oocytes. The results of the biological assay are 
shown in Table 3.5. 
Entry 	Compound 	 Structure 	
Inhibition on water permeability (100 pM) 
AQP-1 AQP-2 AQP-3 AQP-4 AQP-5 
(r No No No No 




ND ND 	ND ND ND 
\_ (r 
No No No No 
N 	 S 	.— 
effect 
ND 
effect effect effect 
[Br 	 OH No No No No 
effect 
ND 
effect effect effect 
OH 
Br 	 No 	No 	No 	No 
6 	113 	 SH 	 ND 
effect effect 	effect effect 
ND - not determined 








No 58± 	 No 	No 
ND 
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It was observed from the screening results that compounds 109, 111-113 did not 
inhibit water permeability in AQP- 1, 2, 4 or 5. Surprisingly however, thioether 108 
significantly inhibited water permeability in AQP-2 expressed in ooctyes by up to 58 
± 16%. This contrasts to the effect of the structurally related triethyl hexyl 
ammonium bromide 91 which reduced water permeability in AQP-1 only. 
This result raised a number of questions: 
. Is the quaternary ammonium headgroup involved in determining selectivity? 
If so, would altering the headgroup have an effect on inhibition? 
Is increasing/decreasing the alkyl tail length of one of the substituents 
important? If so, is there an optimum tail length requirement? 
Is the thioether moiety required for possible protein interactions within the 
pore? Does the carbon analogue of product 108 show significant water 
inhibition? 
. How is water permeability affected in the mutant AQP- 1 channel compared 
to wild-type AQP-l? 
3.2.5 BIOLOGICAL EVALUATION OF THI0ETHER 108 
At this point, the dimethylethyl ammonium analogue of thioether 108 was 
synthesised to determine whether altering the quaternary ammonium headgroup 
would have an effect on water permeability in AQP-2. The synthetic route is shown 









115 	 116 	
(86%) 
Br 	H S 
101 
UV light (254 nm) 
117 	 MeOH, RI, 8hrs 
- 	 (65%) 
Br 
118 
Scheme 3.3 	Synthetic route towards thioether 118. 
Allylation of tertiary amine 115 with allyl bromide 116 proved facile and the desired 
precursor 117 to the radical addition step was isolated in 86% yield. Subsequent 
photochemical coupling with thiol 101, followed by ZMD purification, furnished the 
desired product 118 as an off-white solid in 65% yield. Thioether 118 was then 
screened for biological activity against AQP-2 along with commercially available 
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These observations demonstrated that replacement of two of the ethyl substituents 
with methyl groups reduced water permeability in AQP-2 by 25 ± 12%. This result 
was not an improvement over thioether 108 but it did reinforce the previous 
observation that altering the length of the alkyl substituents around the quaternary 
headgroup appears to have a significant effect on water permeability through the 
pore. In addition, the biological screen also revealed that triethyl allyl ammonium 
bromide 88 did not show significant water inhibition in AQP-2. This was an 
interesting comparison to make with TEA 5, suggesting that by replacing one ethyl 
substituent with an allyl group, water permeability through AQP-2 expressed in 
oocytes is not effected. 
3.2.6 SYNTHESIS AND BIOLOGICAL EVALUATION OF ClO TAIL ANALOGUES 
To determine whether the thioether linkage was important in reducing water 
transport in AQP-2 we decided to synthesise a number of related carbon analogues. 
To achieve this we proposed to alter the size of quaternary ammonium headgroup 
whilst maintaining the number of carbon atoms in the extended alkyl tail. 
The preparation of these compounds was easily accomplished by direct alkylation of 
the corresponding commercially available tertiary amines 115, 119 and 120 with an 
excess of 1-bromodecane 121 in anhydrous DCM at room temperature (Scheme 3.4). 
Compounds 122-124 were made in parallel using the MiniBlockTM High Capacity 
Shaking and Washing Station as described in Section 2.3.3. 
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N-  (CH 2)9CH3  (75%) 
122 
119 








Scheme 3.4 Alkylation of tertiary amines with 1 -bromodecane 121. 
Initially, purification was attempted using the ZMD chromatographic conditions 
employed for thioether analogues 108-113. Co-elution problems similar to those 
experienced for thioether 114 were also observed for the carbon analogues making 
isolation of the desired products difficult. This was a particular problem in the case 
of triethyl decanyl ammonium bromide 122, which resulted in a substantial decrease 
in product yield at this step. An alternative purification method involving 
crystallisation of the crude product from diethyl ether resulted in a more time 
consuming but easier isolation of the desired salt. Compounds 122-124 were then 
tested against AQP-2 to determine whether they exhibited similar water inhibition 
properties compared to the thioether analogues. The results from the biological 
screen are shown in Graph 3.4. 
114 
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Graph 3.4 	Effect on water permeability through AQP-2 with respect to altering 
headgroup size whilst maintaining a C 1 alkyl tail (100 jiM). 
It was observed that carbon analogue 122 inhibits water permeability in AQP-2 by 63 
± 17%, which is comparable to previous measurements observed for thioether 108. 
In contrast, replacement of one of the ethyl substituents with a methyl group 
(compound 123) did not significantly affect water transport in AQP-2. Interestingly 
however, replacement of two ethyl substituents with methyl groups gave the 
dimethyl ethyl analogue 124 which selectively inhibits water transport in AQP-2 by 
48 ± 16%. A control experiment using 100 jiM TEA 5, showed a reduction in water 
transport in AQP-2 by 35 ± 20%. None of these compounds exhibited water 
inhibition in AQP-.l expressed in oocytes. 
The biological evaluation of these compounds provided more evidence to suggest 
that it is possible to effect water permeability by altering the size of the quaternary 
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be particularly important in determining water transport in AQP-2 as the equivalent 
carbon analogue 122 (C 10 tail) shows comparable water inhibition to thioether 108. 
3.2.7 PARALLEL SYNTHESIS OF TRIETHYL/DIETHYLMETHYL/DIMETHYLETHYL 
ANALOGUES 
The next goal was to determine whether modifications to the C10 alkyl tail would 
have significant effects on AQP function. Incorporation of functionality at the 
terminal end of the alkyl chain may have an effect on water inhibition and give an 
indication of how the hydrophobic tail interacts with the channel. Parallel synthesis 
of a small library of compounds using the MiniBlocklM  apparatus as previously 
described in Section 2.3.3, was carried out using the functionalised alkyl bromides, 
125, 126 and 127 and the tertiary amines 115, 120 and 128 (Scheme 3.5). 
DMF 	 11 Br 
I 	+ 	Br—(CH,),—FG 	 R2—N—(CH2 )9 —FG 
R3 RT,24h 	 I R3 
Ri =R2= Me, R3=Et 115 FG(CH 2 )20H 125 	 129-137 
R1 Me, R2R3Et 120 	=CH=CH2 126 
Ri = R2 = R3 = Me 	128 = COOH 	127 
Scheme 3.5 Proposed format of parallel library synthesis. 
Each amine (2 mmol) was dissolved in DMF and transferred to the respective 
reaction vessels (RVs) in the apparatus. The MiniBlockTM  was then transferred to the 
High Capacity Shaking and Washing Station for 20 mins to ensure complete 
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alkyl bromide was carefully added to each RV and the MiniBlockTM  was shaken for 
24 hours at room temperature. The contents of each RV was then transferred to a 10 
mL reagent vial and placed in a Christ 3-RVC vacuum centrifuge and concentrated in 
vacuo overnight. Prior to purification, the crude solids obtained from the reaction 
were examined by ES-MS to determine if the desired molecular ion was present. 
Initially, each crude sample (50 mg) was subjected to ZMD purification, using the 
modified basic chromatographic conditions, however, poor product recovery was 
observed for a number of the library members. In those instances, crystallisation of 
the crude sample from diethyl ether was carried out to afford the desired salt. The 
results of the library synthesis are outlined in Table 3.6. 
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m!z 
Entry 	Compound 	 Expected Product 	 (M-Br] 	Yield Comments 
Ion seen 









I 	Br yes ZMD 
3 131 30%  
230 purified 
L 	Br yes ZMD 
4 132 72% 





Br yes ZMD 
6 134 46% 
212 purified 
Br 
NOH yes ZMD 
7 135 34% 
258 purified 
\—N 
(r yes ZMD 








9 61% R 
244 
R - crystallised from diethyl ether 
Table 3.6 	Results of parallel library synthesis. 
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3.2.7.1 Biological Evaluation of Functionalised Analogues 129-137 
These quaternary ammonium compounds were screened against AQP-1, 2 and 4 
expressed in oocytes. Unfortunately, none of them showed significant inhibition of 
water permeability in any of the AQP water channels. This was a surprising result, 
suggesting that small functional group changes to the terminal end of the extended 
alkyl tail remove inhibitory effects in AQP water transport. In particular, compounds 
132 and 133, closely related analogues to dimethyl ethyl decanyl ammonium 
bromide 124 and triethyl decanyl ammonium bromide 122 respectively, which were 
shown previously to inhibit water transport in AQP-2, did not alter AQP function. 
At this stage it is unclear why small modifications abolished the effect on water 
transport in these cell membrane proteins. 
3.2.8 FURTHER PARALLEL LIBRARY SYNTHESIS OF CARBON ANALOGUES 
As the introduction of terminal functionality to the alkyl chain appeared to have no 
effect on water transport through AQPs, we decided to explore the effect on water 
permeability in AQPs by extending/shortening one of the alkyl tails attached to the 
quaternary nitrogen headgroup as shown in Scheme 3.6. Nine commercially 
available alkyl bromides were selected for inclusion in the library synthesis, ranging 
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R2 	R1 	 0CM 	 P Br 
+ 	Br—(CH2)CH3 	 10 R2N(CH2) —CH3 
R3 	 RT,24h 	 R3 
R1=R2=Me,R3=Et 115 	
n=3to21 
R1=R2=R3=Et 	119 138-146 	 147-164 
Ri =R2= Et, R3=Me 120 
Scheme 3.6 Proposed parallel library synthesis route towards extending / 
shortening the alkyl tail length. 
The MiniBlock set-up, implemented for previous parallel compound generation, 
was employed in the same manner for this proposed library synthesis. Each amine (5 
mmol) was placed in the appropriate RV, dissolved in anhydrous DCM (5 mL) and 
placed on the High Capacity Shaking and Washing Station for 20 mins to ensure 
complete dissolution of the starting reagents. An excess of alkyl bromide was 
dispensed manually to each RV in the MiniBlockTM  prior to shaking for 24 hours at 
room temperature. Compound purification was achieved by crystallisation of the 
crude material from diethyl ether. A total of 19 compounds were synthesised in this 
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3.2.8.1 	Biological Screening Results of Library Compounds 124, 147-155 
against AQP-1 expressed in oocytes (100 pM) 
These compounds were tested against AQP-1 expressed in ooctyes to determine if 
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Graph 3.5 	Effect on water permeability 	in AQP- 1 by altering the alkyl tail length 
whilst retaining the dimethylethyl headgroup. 
It was observed that increasing the alkyl tail length whilst retaining the dimethyl 
ethyl ammonium headgroup had significant inhibitory effects on water permeability 
through AQP-1. The results showed that by increasing the alkyl tail length to C16 
(hexadecanyl) it is possible to reversibly block water transport in AQP-1 by 80± 7%. 
This observed inhibition is a dramatic improvement over TEA 5 and triethyl hexyl 
ammonium bromide 91, both known to reversibly inhibit AQP-1. It can also be seen 
that the inhibitory effect appears to tail off as the number of methylene groups in the 
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(octadecanyl) to C20 154 (eicosanyl) and C22 155 (docosanyl) water permeability in 
AQP-1 is reduced by 45 ± 9%, 22 ± 8% and 14 ± 12% respectively. 
These observations suggest water function in AQP-1 can not only be affected by the 
size of the alkyl substituents surrounding the quaternary ammonium headgroup but 
also by the tail length of the extended alkyl chain. This trend was validated by the 
biological evaluation of two further analogues, 165 and 166, which were synthesised 
based around the dimethyl ethyl ammonium headgroup and incorporate a Cl 5 (from 
1-bromopentadecane 167) and C17 (from 1-bromoheptadecane 168) extended alkyl 









Figure 3.17 C15 165 and C17 166 alkyl tail analogues. 
The screening results revealed that compounds 165 and 166 both reduce water 
permeability in AQP-1 by 60 ± 8% and 55 ± 15% respectively. These observations 
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H- AQP 1] 
Graph 3.6 	Changes in water permeability inhibition against increasing alkyl tail 
length in AQP-1. 
Graph 3.6 clearly shows that by decreasing the alkyl tail length below fifteen carbon 
atoms whilst retaining the dimethyl ethyl quaternary ammonium headgroup, water 
permeability through AQP-1 expressed in oocytes is not effected. These 
observations give the first indication that AQP function can be modified by small 
incremental structural changes to the extended alkyl tail. 
3.2.8.2 	Biological Screening Results of Library Analogues 147-152 
against AQP-2 expressed in oocytes (100 tM) 
Previous biological results had already established that dimethyl ethyl decanyl 
ammonium bromide 124 inhibited water transport through AQP-2 expressed in 
ooctyes by up to 48 ± 16%. This result led us to consider how extending/shortening 
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the alkyl tail would affect water permeability through this channel. The results from 
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Graph 3.7 	Effect on water permeability in AQP-2 by altering the alkyl tail length 
whilst retaining the dimethylethyl headgroup (100 .tM). 
It was observed that altering the length of the alkyl tail did not improve water 
inhibition through AQP-2 over dimethyl ethyl decanyl ammonium bromide 124, 
however, significant water inhibition by up to 22 ± 12% was observed by extending 
the alkyl tail length to C12 (analogue 150). In contrast to the results with AQP-1, 
dimethyl ethyl hexadecanyl ammonium bromide 152 did not significantly effect 
water transport through AQP-2. Shortening the alkyl tail below C 1 did not seem to 
have an effect on water transport through AQP-2. Further biological testing of 
compounds 153-155 revealed that by extending the alkyl tail above C12, water 
permeability through AQP-2 was not affected. The results from the biological screen 
of compounds 156-166 still have to be determined as problems with the 
reproducibility of the initial screen, due to the poor quality of the ooctyes available 
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for compound evaluation, gave inconclusive biological results. These data suggest 
that AQP-2 function can be modified in a similar manner to AQP-1, however small 
incremental differences in tail length do not seem to follow the same trend. In 
contrast to AQP- 1, it could be speculated that AQP-2 water channels may not be able 
to accommodate alkyl tail lengths over Cl 2. Overall these screening results strongly 
suggest that correlations between quaternary ammonium headgroup size and alkyl 
tail length are very important in determining water permeability and AQP selectivity. 
3.2.9 LEAD COMPOUND DEVELOPMENT BASED ON ANALOGUE 152 
So far, our research had shown that it was possible to selectively inhibit AQP- 1 
function by dimethyl ethyl hexadecanyl ammonium bromide 152. This compound 
did not show any inhibitory effects with AQP-2 or 4. Although initial results 
suggested that a C16 tail length was optimum for inhibition, I was also interested to 
determine what the effect on water permeability in AQP- 1 would be by altering the 
quaternary ammonium headgroup. To do this previously synthesised compounds 
159 and 164 and two commercially available analogues, 169 and 170, closely related 
to dimethyl ethyl hexadecanyl ammonium bromide 152 (which is also commercially 
available), were selected for testing against AQP-1 expressed in oocytes (Figure 
3.18). 
r. 	r. 	I 	 + N(CH2) 15CH3  —N(cH 2 )15cH 3 	—(cH2)15cH3 	
CN(CH2)l5CH3 
159 	 164 	 169 	 170 
Figure 3.18 Altering the quaternary ammonium headgroup whilst retaining the 
C 1 alkyl tail. 
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The results from this screen (Graph 3.8) showed that improved water inhibition of 
AQP-1 over lead compound 152 was not observed. Pyridinium hexadecanyl 
ammonium bromide 170 inhibited water transport by 39± 12%, which is comparable 
to TEA 5, however, altering the dimethyl ethyl headgroup for diethyl methyl 
analogue 164, trimethyl analogue 169 and triethyl analogue 159 did not effect water 
transport through AQP-1 expressed in oocytes. These results provide further 
evidence to suggest that the size of the quaternary ammonium headgroup may have a 
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Graph 3.8 	Effect on water permeability in AQP-1 after altering the quaternary 
ammonium headgroup and retaining the C16 alkyl tail. 
Although at this stage we had established that dimethyl ethyl hexadecanyl 
ammonium bromide 152 was the best selective reversible inhibitor for AQP- 1 so far, 
we had no information regarding how this compound may interact within the channel 
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Possible binding, sites for TEA 5, would be difficult to achieve in this case due to the 
flexibility and floppiness of the extended alkyl tail. However, an attempt to model 
compound 152 into bovine AQP-1 was made and the result is shown in Figure 3.19. 
Surf flue Pote,tinf 	-10.000 	-5.000 	 0,000 	 >- 
  
( 
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. 4 
POSE  c- • fpo  I 
Figure 3.19 Grasp representation of surface electrostatics of the 2.2 A resolution 
crystal structure of bovine AQP-1. 
The extracellular vestibule region viewed from above is shown with compound 152 docked 
(FlexX) into two alternative binding poses. Negatively charged regions are shown in red. 
Positively charged regions are shown in blue. POSE 1: The positive head quaternary 
ammonium headgroup is associated with the negatively charged region of D187 and Y188 
with the long alkyl chain extending into the pore region. POSE 2: The positive head group 
of compound 152 is modelled making electrostatic interactions with the negatively charged 
D210 residue. The extended a/kyl chain is making hydrophobic interactions with G134, 
S137, G138, L141, 1.143 & W212. 
128 
Chapter 3 	 Results and Discussion II 
These modelling studies only highlight possible interactions with the channel pore 
however, at this stage, it is not known how compound 152 inhibits water 
permeability in AQP-l. Current investigations are focusing on resolving the high 
resolution crystal structure of AQP-1 complexed with compound 152, along with 
several of the other quaternary ammonium compounds that have significantly 
reduced water transport in AQP- 1. In this way, it is hoped that it will be possible to 
precisely locate important protein-ligand interactions and improve modelling studies 
to provide a clearer understanding of the mechanism of water inhibition through this 
channel. 
3.2.10 INHIBITORY EFFECTS OF LEAD COMPOUND 152 ON MUTANT AQP-1 
FUNCTION 
It was hoped to determine if dimethylethyl hexadecanyl ammonium bromide 152 
interacts with the channel residues in the same manner as TEA 5 by screening it 
against the Y  86F human AQP mutant. As described earlier, AQP-1 function can be 
altered by site directed mutagenesis in the loop E region of AQP- 1, the proposed 
binding site for TEA 5. I was keen to establish if Y1 86F hAQP-1 removed evidence 
of dimethyl ethyl hexadecanyl ammonium bromide 152 inhibition as observed in the 
case of TEA 5. The results from this experiment are outlined in Graph 3.9. 
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No inhibitor 	 5 	 152 
• AQP-1 WT • AQP-1 YF 
Graph 3.9 	Effect on water permeability through wild type AQP-1 and Y186F 
AQP-1 expressed in oocytes by dimethylethyl hexadecanyl 
ammonium bromide 152. 
The results show that in wild type AQP-1, TEA 5 and compound 152 reversibly 
reduce water transport by 32 ± 14% and 70 ± 7% respectively. These results are 
comparable to those previously determined. Screening results against mutant AQP- 1 
revealed no evidence of TEA 5 induced water inhibition. However, interestingly, 
inhibition of water transport by 59 ± 5% for dimethyl ethyl hexadecanyl ammonium 
bromide 152 was observed. This screening data elucidates that dimethyl ethyl 
hexadecanyl ammonium bromide 152 may have an alternative binding site other than 
the proposed binding pocket for TEA 5 in the loop E region of AQP-1. This result 
could also indicate why this compound is selective for AQP- 1 only. 
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3.3 FURTHER LEAD COMPOUND DEVELOPMENT AND FUTURE 
DIRECTIONS 
3.3.1 FURTHER LEAD COMPOUND DEVELOPMENT BASED ON ANALOGUE 152 
At this time, further biological evaluation of these compounds was temporarily 
suspended. However, we were still interested in generating compounds which would 
potentially help us establish possible interactions between the aqueous pore and the 
hydrophobic tail of the extended alkyl chain. With this goal in mind, we proposed to 
develop synthetic routes towards a number of quaternary ammonium analogues, 
based around dimethyl ethyl hexadecanyl ammonium bromide 152, which could be 
screened at a later stage. 
As mentioned earlier, the flexibility of the extended alkyl tail of compound 152 
makes precise modelling of this structure into the pore difficult to achieve. As a 
consequence, it is hard to predict how this hydrophobic side chain will interact in an 
aqueous environment. If the binding affinity of compound 152 is mainly influenced 
by protein-ligand interactions between the positively charged headgroup of the 
ligand and a negatively charged pore residue lining the channel wall then it could be 
anticipated that the alkyl chain length would not effect water inhibition. However, 
our screening data suggests that this is not the case and important hydrophobic 
interactions are likely to exist between the alkyl tail and the protein residues involved 
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3.3.2 MODIFICATION OF THE EXTENDED ALKYL TAIL 
We postulated that the introduction of branching along the extended alkyl chain may 
restrict the flexibility of the ligand within the pore and provide further hydrophobic 
contacts with the pore wall. As one half of the channel wall in AQP-1 is lined with 
hydrophobic residues it is feasible that interactions between a branched alkyl chain 
and the protein could exist if the alkyl tail orientates itself in such a way as to 
maximise favourable hydrophobic contacts. The synthesis of two compounds which 
could provide further SAR data based on possible hydrophobic interactions between 
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Following conditions adapted from work described by Lin and co-workers" 3 
analogue 172 was prepared by bromination of phytol 171 by dropwise addition of 
phosphorous tribromide at 0°C. The reaction was warmed to room temperature over 
2 hours, after which time the reaction temperature was increased to 100°C and gently 
refluxed for 1.5 hours. Following work-up, purification of bromide 172 was 
achieved by Kugelrohr bulb-to-bulb to isolate the desired yellow oil in 54% yield. 
Displacement of bromide 172 with tertiary amine 115 furnished the desired yellow 
solid, after crystallisation, in 70% yield. 
3.3.2.2 Double Bond Incorporation 
174 	 0 
amine 175 
borohydride resin 176 
24h, DCM, RT 
anhydride resin 177 












Scheme 3.8 Synthetic route towards double bond functionalisation 
The reductive amination of commercially available cis- 11 -hexadecanal 174 with 
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presence of solid-supported borohydride resin 176. After stirring for 24 hours, 
anhydride resin 177 was added to the reaction mixture which was left to stir for a 
further 48 hours. After this time, the crude mixture was filtered and concentrated in 
vacuo to yield a light green oil (78%) which was then purified by Kugelrohr bulb-to-
bulb distillation to yield desired product 178 as a colourless oil in 72% yield. 
Subsequent reaction of product 178 with excess iodomethane at 0°C afforded 
analogue 179 after 4 hours, as confirmed by ES-MS. Following solvent removal, 
crystallisation of the solid product from cold, anhydrous diethyl ether gave desired 
product 179 in 71% isolated yield. 
Analogues 173 and 179 may provide more information on how the extended alkyl 
tail affects water permeability through AQP- 1. By incorporating more 
hydrophobicity/steric bulk and reducing the flexibility, it may be possible to more 
accurately predict the features of the alkyl chain which are important in inhibiting 
water transport. 
134 
Chapter 3 	 Results and Discussion II 
3.3.3 SUMMARY AND FUTURE WORK 
I have employed a structure-based design approach towards the synthesis of a range 
of novel inhibitors of AQP water channels based on TEA 5. This research has 
shown that it is possible to selectively reversibly inhibit water transport through 
AQP-1 by up to 80 ± 7% using dimethyl ethyl hexadecanyl ammonium bromide 152 
(100 tM). Furthermore, it has been established that selective reversible inhibition of 
AQP-2 can be achieved by up to 63 ± 12% using triethyl decanyl ammonium 
bromide 122 (100 j.tM). To the best of my knowledge these compounds, are the first 
known selective, reversible inhibitors of AQP water channels. 
This research has shown that AQP water inhibition is closely related to the size of the 
quaternary ammonium headgroup and the length of an extended alkyl tail. The 
results suggest that a C16 tail is optimal for water inhibition in AQP- 1, whereas in 
AQP-2, maximum inhibition is observed when a ClO tail is incorporated into the 
quaternary ammonium salt structure. In both cases, subtle differences between the 
alkyl substituents surrounding the quaternary nitrogen appear to be critical in 
providing the necessary binding contacts required to give optimum water inhibition. 
In AQP-1, optimal inhibition is observed when a dimethyl ethyl headgroup is 
incorporated into the quaternary ammonium structure whereas in AQP-2, it appears 
that a triethyl headgroup is important for water inhibition. Modelling studies suggest 
that important electrostatic interactions may exist between the positively charged 
nitrogen atom and negatively charged Dl 87 and Yl 88 amino acid residues lining the 
pore wall. It could be postulated that these contacts have an important role in 
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determining the binding affinity of TEA 5 based analogues. Further investigations 
into the importance of this interaction could be determined by replacement of the 
quaternary nitrogen centre with alternative positively charged functional groups. 
In addition, it can be envisaged that if the biological evaluation of analogues 173 and 
179 show a reduction of water permeability through AQP-1 then further synthetic 
alterations of the alkyl tail could be performed to maximise ligand-protein 
interactions. For example, selective introduction of double bond moieties into the 
extended alkyl tail would not only restrict the flexibility of the chain but also provide 
an accessible synthetic starting point to develop a range of functionalised alkyl tail 
derivatives. This topic is discussed in more detail in Chapter 4. 
The complex nature of AQPs has meant that a high resolution crystal structure of 
AQP- 1 complexed with compound 152 is not available to date. However, research to 
establish the exact binding mode of these types of quaternary ammonium compounds 
is currently being undertaken by a number of groups. Although the oocyte 
expression system is widely used to biologically evaluate AQP function there are 
problems with the reproducibility of assay results. It is believed that these problems 
are directly associated with the quality of the batches of oocytes used. Factors which 
effect oocyte quality include the origin and age of the frog, the time of year the eggs 
are harvested and the size of the eggs that are available. Furthermore, the nature of 
the assay has meant that compound testing has been relatively low-throughput. 
Initially, it was hoped that several libraries of compounds could be tested in parallel, 
however, reproducibility problems have delayed the development of higher-
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have yet to be tested. However, progress is being made and it is hoped that, in the 
near future, it will be possible to screen these compounds in parallel using a 96 well 
plate format. In addition, once the oocyte assay reproducibility problems have been 
rectified it should be possible to calculate IC 50 values for those compounds which 
inhibit AQP function. 
As mentioned earlier, a range of thioether analogues were synthesised which 
provided terminal functionality at the end of the alkyl tail. This functionality could 
be used as a handle to introduce further diversity into the structure. For example by 
incorporating a fluorophore into the analogue structure it may be possible to use 
fluorescence to detect a compound within the channel pore. A proposed route 
towards the synthesis of a fluorescently labelled analogue is shown in Scheme 3.9. 
Ri 	 Ri Fluorescent Probe (FP) 
I 	 NH4(CO3 )2 	I 
R3 H20 R3 
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It is expected that addition to thiol reactive fluorescein-5-maleimide 180 would 
proceed readily under aqueous conditions due to the excellent water solubility of 
both starting materials. These dyes have been used in the preparation of low 
molecular weight modification of thiol derivatives. 114  As the steric limitations of 
water transport through AQPs are high it could be predicted that a fluorescently 
labelled analogue of this type would not pass through the constricted region of the 
channel. However, by using this approach, it may be possible to establish if ligand 
binding occurs in the extracellular vestibule of the pore. 
Future lead compound generation will rely on ongoing MD simulations and more 
precise molecular modelling experiments. Once the ligand binding site(s) has been 
identified, it should be possible to improve water inhibition for selective AQPs by 
optimising the structures of known aquaplugs. 
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4 
	
	RESULTS AND DIscussIoN III— SYNTHETIC ROUTES TowAlus 
LED COMPOUND DEVELOPMENT 
4.1 PROPOSED LEAD OPTIMISATION 
The successful development of selective aquaplugs based on TEA 5, was achieved 
by employing a solution phase parallel approach to the synthesis of closely related 
quaternary ammonium analogues. This has established that AQP function can be 
altered by incremental changes to the extended alkyl tail and alkyl substituents 
surrounding the quaternary ammonium nitrogen. Although quaternary ammonium 
analogues 153 and 125 selectively inhibit AQP-1 and AQP-2 respectively, the exact 
binding mode of these compounds remains unknown. At this stage it is difficult to 
predict how further structural modification of these analogues could further decrease 
water permeability through selective AQPs, as the high resolution crystal structure of 
the protein-ligand complex is unavailable. 
At first glance, dimethyl ethyl hexadecanyl ammonium bromide 152 provides little 
scope for obvious lead compound optimisation. However, the generation of more 
derivatives based on these types of compounds is necessary to improve our 
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To achieve this I proposed the development of a synthetic methodology which would 
permit the incorporation of both hydrophobic and hydrophilic functionalities along 
the extended alkyl chain. This approach would provide an accessible starting point 
for the generation of a number of functionalised alkyl tail derivatives which could be 
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Figure 4.1 	Possible functional group modificationsto a common building block. 
Possible synthetic modifications which could be carried out to increase structural diversity 
along the alkyl tail. Starting from a common building block it may be possible to (a) 
selectively increase the length of the alkyl tail, (b) introduce polar hydroxyl groups along the 
chain, (c) introduce double bonds into the tail and (d) selectively alkylate the nitrogen centre 
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Using this strategy, it would be possible to include a number of H-bond donors along 
the extended alkyl tail with the aim of improving hydrophilic ligand interactions with 
potentially important polar amino acid residues which line the pore wall. It would 
also be feasible to selectively incorporate hydrophobic alkyl groups along the tail 
which could potentially improve ligand affinity with the hydrophobic half of the 
channel. Furthermore, it may also be possible to reduce the flexibility of the alkyl 
chain by selectively introducing a double bond into the tail. This structural 
modification would reduce the degrees of freedom in the alkyl chain and provide a 
more substantial basis to accurately predict important ligand-protein interactions 
using molecular modelling techniques. 
4.1.1 PROPOSED SYNTHETIC STRATEGY 
Initial studies focused on developing a synthetic route towards a suitable building 
block for further lead compound generation. Scheme 4.1 outlines the synthetic 
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H 	 amide bond formation 
+ 	 OH 
181 	 182 183 




185 	 0 I 	 184 
Proposed building block 
Scheme 4.1 Proposed synthetic route towards suitable building block generation. 
In planning the synthesis it was predicted that secondary amine 181 would react 
readily with 4-pentenoic acid 182 to afford diene 183, a linear precursor to the lactam 
formation step. Ring closing metathesis (RCM) might be an effective tool for the 
construction of the seven-membered cyclic olefin 184. Following ring closure, 
hydrolysis of cyclic intermediate 184 should give alkene 185. 
Subject to time constraints, the goal was to establish an efficient synthetic route 
towards the formation of product 185 which could then be employed as a building 
block for further compound development. This compound would provide the basis 
to incorporate further structural diversity in the alkyl tail backbone. This could be 
achieved, for example, via dihydroxylation of the double bond to introduce the 
desired diol functionality. In addition, the acid moiety at the terminal end of the tail 
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Quatemarisation of the nitrogen centre could be readily achieved with treatment of 
an appropriate alkylating agent. For these reasons compound 185 would provide an 
excellent basis for further structural modification. 
4.2 AMIDE BOND FORMATION 
4.2.1 PREPARATION OF N-ETHYL ALLYLAMINE 181 
Prior to commencing the synthesis an attempt was made to prepare N-ethyl 
allylamine 181 via the direct N-alkylation of ethylamine hydrochloride 185 with allyl 




NH2 	 N 	 + 	 N 
Cs2CO3 	 H 
185 	 DMF, RT, 5h 	 181 	 186 
Scheme 4.2 Attempted synthesis of N-ethyl allylamine 181. 
To begin with, equimolar amounts of cesium carbonate and ethylamine 
hydrochloride 185 were added to a flask containing anhydrous DMF. After stirring 
for 30 minutes allyl bromide 116 was added dropwise and the resultant orange 
solution left to stir for a further 5 hours. Following work-up, the organic layers were 
dried and the crude product was filtered and concentrated in vacuo to yield a 
yellow/orange oil (0.67 g). The desired product (86 mlz) was not observed by ES- 
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MS. However, the molecular ion peak at 126 mlz confirmed the presence of the 
over-allylated tertiary amine side-product 186. This reaction was repeated several 
times, with stoichiometric reductions in the number of equivalents of allyl bromide 
116 used, however, in each instance, formation of the unwanted tertiary amine 186 
was observed. As a result, it was decided to adopt an alternative strategy towards the 
synthesis of N-ethyl allylamine 181 using conditions reported by Surzur et al. 
(Scheme 4.3). 116 





32 	 187 	 181 
Scheme 4.3 Synthesis of N-ethyl allyl amine 181. 
This route involved the dropwise addition of bromoethane 187 (1 equiv.) to neat 
allylamine 32 (5.5 equiv.) with stirring. The reaction mixture was then gently 
refluxed for 48 hours. Subsequently, excess allylamine 32 was removed by bulb to 
bulb distillation. The remaining orange residue was treated with KOH (5 M) and the 
crude product extracted with ether and dried over anhydrous MgSO4. Following 
flash chromatography the desired product (0.95 g) was isolated in 37% yield. 'H 
NMR and ES-MS confirmed the presence of the desired product. In this case, only 
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4.2.2 PREPARATION OF ACID CHLORIDE/FLUORIDE, DERIVATIVES 
The next step was to convert commercially available 4-pentenoic acid 182 into the 





OH 	 188 	 Cl 
o 	 0CM 
182 	 O'C -> RI, 3 hours 	 189 
catalytic DMF 
67% 
Scheme 4.4 Formation of acid chloride derivative 189. 
This was achieved by dropwise addition of oxalyl chloride 188 to 4-pentenoic acid 
182 in anhydrous DCM which had been cooled over ice under an inert nitrogen 
atmosphere. Following solvent evaporation, a crude yellow oil (2.93 g) was 
obtained. Kugelrohr bulb to bulb distillation was performed to remove unreacted 
starting material 182. A distinct sharp peak in the IR spectrum at 1799 cm 
corresponding to the carbonyl stretch of the acid chloride 189 confirmed that the 
residual pale yellow oil left over after distillation was the desired product 189 (1.95 
g, 67%). In this case, isolation of acid chloride 189 was difficult to achieve due to 
similar boiling point values compared to 4-pentenoic acid 182. As a result, a trace 
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Adopting conditions reported by Babu et al., an attempt to synthesise the acid 





DCM, RI, 2.5 hours 
55% 
191 
Scheme 4.5 Formation of acid fluoride derivative 191. 
Acid 182 was dissolved in anhydrous DCM and DAST 190 (1.2 equiv.) was 
carefully added. Following reaction completion, the resultant crude acid fluoride 191 
was purified by Kugelrohr bulb to bulb distillation to afford a pale yellow oil in 55% 
isolated yield. A sharp peak at 1843 cm -1 in the JR spectrum corresponding to the 
carbonyl stretch in acid fluoride 191 confirmed the presence of the desired product. 
No evidence of unreacted acid 182 was observed by FT-JR. 
4.3.2 	REACTION OF N-ETHYL ALLYLAMINE 181 AND ACID CHLORIDE 189 
The next goal was the attempted amide coupling reaction between N-ethyl allylamine 
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Na2CO3 
H 	 CA~~ + 
	
0CM, 00C>  RT, 2 hours 	 0 
181 	 189 	 78% 	 183 
Scheme 4.6 Amide bond formation. 
Amine 181 (1 equiv.) was dissolved in anhydrous DCM to which Na 2CO3 (2 equiv.) 
was added. After stirring for 5 mins, the solution was added dropwise to an ice 
cooled solution of acid chloride 189 (1.2 equiv.) at 0°C. After this time, crude 
product 183 was concentrated in yacuo and purified by bulb to bulb distillation to 
yield a yellow oil (380 mg, 78%). ES-MS confirmed the presence of the molecular 
ion peak at 168 mlz for diene 183. The 'H NMR and JR spectra of compound 183 
showed no traces of starting material. 
At this point, the precursor for the RCM step in our proposed synthesis was available 
to determine if it would be possible to generate lactam 184 using this approach. 
Over the last decade, there has been a large precedent in the literature towards 
generating nitrogen heterocycles in this way. 118 The advent of well-defined, 
functional group tolerant catalysts for olefin metathesis has meant reactions of this 
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4.3 RING CLOSING METATHESIS (RCM) 
The application of RCM in the synthesis of simple five, six and seven-membered 
oxygen and nitrogen heterocycles was first described by Grubbs and co-workers in 
1992.' 19,121  Since then the development of the metathesis reaction has been directly 
correlated to improvements in functional group compatability and the reactivity of 
catalysts. ' 2 ' 
The first generation of metathesis catalysts were developed by Schrock and 
co-workers. 122  These tetra-coordinated alkylidene species, such as molybdenum 
alkoxyimido alkylidene 190, are well established, commercially available metathesis 
catalysts which exhibit good functional group tolerance for a range of synthetic 
applications. 123  Despite their high activity, molybdenum-based complexes suffer the 
potential disadvantage of being air and moisture sensitive. To overcome this 
problem, more stable ruthenium-based carbene complexes, such as ruthenium 
benzylidene catalyst 191, have been developed by the Caltech group (Figure 4.2))24 
(CF 
(CF 












Figure 4.2 	Commonly used high activity RCM catalysts. 
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Commercially available Grubbs 1st  generation catalyst 191 offered comparably high 
RCM activity, similar to that of the molybdenum complex 190, with the added 
advantage of having excellent air and water stability. Since then, a variety of 
catalysts based on ruthenium complex 191 have been reported. 123 For example, 
ruthenium complexes containing N-heterocyclic carbene ligands, such as, Grubbs 2'' 
generation catalyst 192, offer significantly higher catalytic activity, increased thermal 
stability, resistance towards oxygen and moisture and excellent functional group 
compatability compared to catalyst 191.125  These improvements have meant that 
RCM is now routinely used by organic chemists to construct complex cyclic targets 
containing a wide variety of ring sizes. 126 
4.3.1 BASIC MECHANISM OF RCM 
The generally accepted mechanism of metathesis reactions consists of 
[2+2] cycloadditions/cycloreversions involving alkenes, metal carbenes and 
metallacyclobutane intermediates. It is thought that all individual steps of the 
catalytic cycle are reversible, resulting in an equilibrium mixture of olefins. In the 
case of RCM, the forward process is entropically driven because RCM converts one 
substrate molecule to two products. If one of the products is volatile the desired 
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Scheme 4.7 Basic catalytic cycle of RCM 
4.3.2 RCM OF N-ALLYL-N-ETHYL PENT-4-ENAMIDE 183 
Fu et al. describe the efficient catalytic RCM of dienes in unsaturated nitrogen 
heterocycles synthesis. 19 In an adaptation of their conditions, I attempted to 
synthesise seven-membered lactam 184 using 5 mol% 2 nd generation Grubbs catalyst 
192 dissolved in a solution of diene 183 in anhydrous DCM which had been 
degassed with N2 (Scheme 4.8). 
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catalyst 192 
5 mol % 
DCM, 24 hours, reflux 
183 	 184 
Scheme 4.8 Initial attempt at RCM on tertiary amide 183. 
After 24 hours, the solvent was removed and the resultant crude brown oil was 
analysed by ES-MS and 'H NMR to confirm the presence of the desired product 
184. However, highly-coloured dark brown ruthenium residues were also present in 
the crude product mixture. In an attempt to remove the metal catalyst, the crude 
product was purified by flash chromatography. After solvent evaporation, the 
product still contained trace amounts of catalyst. Several further attempts at flash 
chromatography failed to remove all of the ruthenium by-products from the desired 
product 184. 
4.3.3 REMOVAL OF RUTHENIUM BY-PRODUCTS 
One of the drawbacks in the use of RCM reactions is that it is extremely difficult to 
remove ruthenium by-products completely from the desired products by purification 
by silica gel column chromatography. This problem has been addressed by Grubbs 
and co-workers who have shown that ruthenium residues can be significantly 
reduced by the addition of water-soluble tris(hydroxymethyl) phosphine 193 during 
work-up, thus allowing metal residues to be extracted into aqueous media.' 27 More 
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194 or triphenyl phosphine oxide 195 to a RCM reaction mixture decomposed the 
catalyst, allowing its removal by flash chromatography (Figure 4.3). 
:1. 	•i: 
J P II 	Ph3P=O 
HO 	
/S\ 
193 	 194 	 195 
Figure 4.3 	Structures of reagents employed to assist in the removal of ruthenium 
by-products after RCM. 
Using these techniques, several unsuccessful attempts to remove the ruthenium 
residues from lactam 184 were carried out. In each case, dark coloured by-products 
were observed in the fractions collected following column purification. However, in 
the case of tris(hydroxymethyl) phosphine 193, a further catalyst filtration step 
through a pad of celite after column purification was performed to afford the desired 
product as a yellow oil in 61% yield. This was still contaminated by trace amounts 
of catalyst but it was decided to attempt hydrolysis of lactam 184 irrespective of the 
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4.4 BASE HYDROLYSIS OF LACTAM 184 
The unreactive nature of the tertiary amide functional group prompted me to attempt 
ring cleavage of lactam 184 using basic hydrolysis conditions (Scheme 4.9). 
(b) 	/ 
	 H 	 OH 
/\ 
(C) 
184 	 185 
KOH, H20, Dioxane, RT, 72 hours 
2M KOH, Dioxane:H 20 (1:1), reflux, 24 hours 
(C) tBuQK, H20, Et20, RT, ON 
Scheme 4.9 Attempted base hydrolysis of lactam 184. 
In general, the base hydrolysis of a tertiary amide requires fairly harsh conditions. 
Initial attempts at ring cleavage, using aqueous potassium hydroxide in dioxane at 
room temperature for 72 hours, was unsuccessful. This reaction was repeated under 
reflux for 24 hours, however, only starting material was recovered. 
In order to promote ring cleavage of lactam 184, the conditions reported by Gassman 
and co-workers 129  were tried. They demonstrated that base hydrolysis of tertiary 
amides at ambient temperature can be achieved by using a slurry of potassium tert-




Results and Discussion III 
tert-butoxide is a strong enough base to deprotonate the tetrahedral intermediate in 
the reaction to form the dianion species (Scheme 4.10). In this way, the nitrogen 










Scheme 4.10 Proposed mechanism of base hydrolysis. 
Unfortunately, several attempts to generate product 185 using these conditions were 
unsuccessful. In each instance, only staring material was recovered after work-up. 
To tackle this problem, it was proposed that an alternative route, involving 
hydrolysis of a more labile secondary amide functional group in the lactam ring, 
could be adopted to promote ring cleavage and generate the desired product. 
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4.5 ALTERNATIVE STRATEGY TOWARDS LAC TAM HYDROLYSIS 
4.5.1 RETROSYNTHETIC STRATEGY 
The synthesis outlined in Scheme 4.11 may offer a convenient route towards diene 
196 from commercially available starting materials. It was expected that RCM of 
diene 196 would generate lactam 197, which could then be more readily hydrolysed 
to afford alkene 198. 
Scheme 4.11 Retro synthetic route from commercially available starting materials. 
4.5.2 PREPARATION OF DIENE 196 
Initially, diene 196 was generated from allylamine 32 and 4-pentenoic acid 182 using 
standard peptide coupling conditions (Scheme 4.12). 
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Scheme 4.12 Synthesis of diene 196 using standard coupling reagents. 
Following work-up, the resultant yellow oil was purified by flash chromatography to 
afford the desired product as a colourless oil, in 94% isolated yield. However, a 
report by Loupy and co-workers 130  describes the solvent-free preparation of amides 
from acids and primary amines using microwave irradiation. This route benefits 
from shorter reaction times, cleaner reactions and higher yields compared to classical 
amide coupling conditions. In addition, the pyrolitic preparation of amides can be 
achieved in the absence of any coupling reagents or solvents (Scheme 4.13). An 
attempt to generate diene 196 was performed using these microwave conditions. 
RCO2H + RNH2 - 	 RCO2- NH3R' 	 RCONHR 
Scheme 4.13 Pyrolysis of salts obtained by mixture of amine and carboxylic acid. 
Equimolar amounts of allylamine 32 and 4-pentenoic acid 182 were placed in a 
microwave tube and irradiated for 30 minutes at 150°C (300 W, 250 psi) (Scheme 
4.14). The resultant yellow/brown oil was purified by bulb to bulb distillation to 
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faster and more convenient access towards diene 196 compared to the classical 
approach which was employed initially. 
0 
U), 150°C, 300W, 250 psi 








Scheme 4.14 Microwave irradiation amide coupling conditions. 
4.5.3 RCM OF DIENE 196 
On the assumption that ruthenium metathesis catalyst 192 would be well suited to the 
RCM of diene 196 due to its high tolerance of polar functional groups, RCM was 
carried out initially without protecting the secondary amide functionality present in 




0CM, 24 hours, reflux 
0 
196 	 197 
Scheme 4.15 Attempted RCM on unprotected diene 196. 
A number of attempts to ring close diene 196 were performed, however, lactam 197 
was not successfully isolated under these conditions. In each instance, multiple spots 
were observed by TLC analysis, indicating that a complex mixture of products, 
possibly generated by cross metathesis side reactions, were present in the crude 
reaction mixture. 
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In an attempt to reduce the likelihood of cross metathesis side-product formation I 
endeavoured to promote intra-molecular cyclisation of compound 196 by increasing 
the dilution of the reaction mixture. It is well known that low concentrations of ring 
closing substrates can minimise side-product formation during RCM reactions. The 
conditions that were employed to promote RCM of diene 196 are outlined in Table 
4.1. 
Concentration of Time Product 
Entry Catalyst 192 (mol %) diene 196 (mM) (hours) formed 
1 5 160 24 No 
2 5 50 24 No 
3 5 20 24 No 
4 5 10 24 No 
5 10 20 24 No 
Table 4.1 	Variety of conditions employed to promote RCM. 
It can be observed that in this case increasing the dilution of the reaction mixture did 
not promote desired product formation. In addition, no product was isolated after 
increasing the number of equivalents of catalyst 192 used to 10 mol% (Entry 5). 
Further stoichiometric increases of catalyst 192 were not attempted due to the 
difficulties that were previously encountered during the ruthenium removal step. 
4.5.4 N-Boc PROTECTION OF DIENE 196 
Evidence in the literature suggests that lactam formation can be inhibited if 
unprotected secondary amide groups are present in the RCM substrate. ' 3 ' To 
determine if protecting the secondary amide functionality present in diene 196 would 
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promote RCM product formation, conditions reported by Tarbell et al. were adopted 
that describe the preparation of N-Boc derivatives of lactams and amides (Scheme 
4.16). 132  It was envisaged that the Boc group would be a good choice of protection if 
the RCM step was successful. Previous studies 133  have suggested that N-Boc 
lactams can be regioselectively hydrolysed at the amide carbonyl using mild basic 
hydrolysis conditions. Under these conditions, it is thought that the amide carbonyl 
is more susceptible to nucleophilic attack than the carbamate carbonyl. In addition, 
Greico et al. propose that the tert-butyl group exerts a steric influence on the course 
of the hydrolysis reaction, forcing amide hydrolysis to occur regioselectively.' 33 
0 0 
QJLQAQ 
H 	 199 
DMAP, NEt3 , DCM 
0 RT, 8 hours Lel 
196 	 200 68% 
Scheme 4.16 Boc protection of diene 196. 
N-Boc diene 200 was prepared by the reaction of di-tert-butyl dicarbonate 199 (1.2 
equiv.) and diene 196 (1 equiv.) in the presence of catalytic amounts of DMAP and 
triethylamine, under an inert N2 atmosphere. After work-up, the resultant yellow oil 
was purified by column chromatography on silica gel to furnish the desired 
colourless oil in a satisfactory 68% yield. This reaction proceeded cleanly, however, 
'BuOH was generated as an unwanted side-product. Removal of tBUOH was 
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4.5.5 RCM OF N-Boc DIENE 200 
I was now in a position to establish if RCM of N-Boc diene 200 would generate the 
desired lactam product 201. It was postulated that the potential problems of cross 
metathesis side-product formation experienced in previous attempts at RCM 
reactions could be due to incomplete removal of ruthenium catalyst residues from the 
product mixture. However, a recent report by Cho and co-workers describes the 
sequential treatment of RCM products with silica gel, activated carbon (50 equiv. by 
weight relative to the crude products) and column chromatography on silica gel to 
efficiently remove dark brown ruthenium by-products from the reaction mixture. 134 
We decided to attempt RCM of N-Boc diene 200 using their modified purification 
procedure outlined in Scheme 4.17. This reaction was performed using various N-





5 mol % 	 0A N 
DCM, reflux, 24 hours 
silica gel, activated charcoal, 
column chromatography 	 201 
53% 
Scheme 4.17 RCM of N-Boc diene 200 using modified conditions. 
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Concentration of Time Product 
Entry Catalyst 192 (mol %) diene 200 (mM) (hours) isolated 
1 5 160 24 No 
2 5 80 24 No 
3 5 20 24 Dimer,31% 
4 5 4 24 Yes, 53% 
5 5 2 24 Yes, 52% 
Table 4.2 	Increasing dilutions of RCM reaction mixture. 
It was observed that at 160 mM and 80 mM concentrations of N-Boc diene 200, as 
shown in entries 1 and 2 respectively, none of the desired product was isolated. In 
both these cases, analysis by TLC indicated a complex, inseparable mixture of 
products was present in the crude reaction mixture. Flash chromatography was 
carried out to attempt separation of several close running spots but this proved 
unsuccessful. However, TLC analysis of the crude reaction mixture of entry 3 
looked much cleaner and more promising. Following work-up and column 
purification, a colourless crystalline solid was isolated in 31% yield. Analysis of the 
'H NMR and ' 3C NMR spectra of the product indicated that N-Boc diene 200 had 
dimerised under these RCM conditions to generate dimer 202. This result was 
confirmed by the X-ray crystal structure as depicted in Figure 4.4. 
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Figure 4.4 	X-ray crystal structure of dimer 202. 
It can be noted that under these conditions, the RCM reaction of N-Boc diene 200 
generated a C2 symmetrical 14-membered heterocycle product containing two 
opposing trans double bonds (C,3=C, 4 and C28=C29). Initially, it was postulated that 
the orthogonal intramolecular interactions between the amide carbonyls 
C24=025 C9=O,o could play an important role in forming and stabilising the dimer 
structure. Evidence in the literature suggests that non-covalent interactions of this 
type can be as effective as hydrogen bonds in stabilising the packing of small organic 
molecules and protein-protein complexes. 135,136  However, closer examination of the 
crystallographic data revealed that the C=O' "C=O dipolar electrostatic contacts were 
separated by a distance of about 5 A. This distance is likely to be too large to 
effectively stabilise the conformation of the dimer structure. In general, van der 
Waals contact distances between C=O' 'C=O interactions are commonly between 
2.25 to 4 A.' 37 
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In addition. both anuide carbonvi O\V1Cfl atoms (01 and 0,) have potentially 
stabilisine H-bondin interactions vitli the oleiThic protons attached to C and C 
respecti\ clv. It is also likely that the carbamate carbonyl oxygen atoms (07 and 018) 
may be involved in H-bonding interactions from the protons attached to C11 and C26 
respectively. This conformation also means that the bulkier Boc protecting groups 
minimize unfavourable steric interactions by protruding away from the centre of the 
ring (Figure 4.5). 
Figure 4.5 	Potential H-bonding stabilising interactions in dimer 202. 
The X-ray crystal structure of dimer 202 highlights potential H-bonding interactions 
between 0 7 I-I-C11 (2.700.4), 010 'H-C13 (2.726 A), 018 H-C26 (2.706.4) and 025 H-C28 
(2.696 A). 
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Further dilutions of the diene 200 RCM mixture to 4 mM and 2 mM (entries 4 and 5, 
Table 4.2) afforded the desired seven-membered cis-lactam 201 as a pale yellow oil 
in 53% and 48% isolated yields, respectively. This result meant the lactam 
hydrolysis step using conditions adapted from those reported by Greico and co-
workers could now be attempted. 133  Although the formation of the dimer 202 was 
unexpected, it was predicted that it would still be possible to hydrolyse this 
compound, using similar conditions, to furnish the trans-olefin product 204. 
4.5.6 HYDROLYSIS OF N-Boc LACTAM 201 AND DIMER 202 
At this stage, it was hoped that mild and efficient hydrolysis of the N-Boc lactam 201 
and dimer 202 would be more readily achieved compared to previous attempts at 
basic hydrolytic ring cleavage of lactam 184. Furthermore, as Boc groups are stable 
to basic reaction conditions, it was predicted that this method would leave the amino 
group in a protected form, permitting further modification of the carboxylic acid 
residue at a later stage. 
Our first attempt at ring cleavage was carried out by dissolving N-Boc lactam 201 in 
a 1.0 M solution of lithium hydroxide in THE The solution was stirred for 6 hours at 
room temperature, however, TLC analysis indicated that only starting material was 
present after this time. The reaction was left to stir overnight, after which, the THF 
was removed in vacuo and the basic aqueous residue was acidified with 2M HCI and 
extracted with ether. 'H NMR and ES-MS analysis of the crude product indicated 
that only starting material was present. This result could have been due to the lack of 
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solubility of N-Boc lactam 201 in either the reaction solution or in the work-up step. 
To tackle this problem, it was decided to repeat this reaction by dissolving N-Boc 
lactam 201 in a biphasic 2 M solution of lithium hydroxide in THF/H20 (1:1) 
(Scheme 4.18). The reaction was left to stir at room temperature overnight before 
the aqueous layer was separated and acidified to pH 2 with IM HC1. The crude 
product was extracted with EtOAc and purified using mass-directed chromatography 
(MeCN:H20 (95:5) with 0.1% TFA, 12 minute run) to afford the desired product as a 
pale yellow oil in 89 % yield. 'H and 21) COSY NMR confirmed that Z-alkene 203 
had been isolated. In addition, further evidence of successful hydrolysis was 
obtained from the JR spectrum of alkene 203, which showed bands at 1713 cm -1 and 
3400 cm', corresponding to the carbonyl and hydroxyl stretches in the free 
carboxylic acid respectively. These reaction conditions were employed to 
successfully hydrolyse dimer 202 to generate E-alkene 204 as a yellow oil in 74% 
yield. 
>°r-' - ° _~_o 	 4_~ 
201 	 202 
89% 	
2M LIOH in THF:H20 (1:1) 
RT 	 I 
0/N 
0 
>LOOH >L1 	 OH ON 
203 	 204 	0 
Scheme 4.18 Base hydrolysis of N-Boc lactam 201 and dimer 202. 
165 
Chapter 4 	 Results and Discussion III 
4.6 FURTHER Co1wouTiD GENERATION USING OPTIMISED 
CONDITIONS 
4.6.1 EXTENSION OF ALKYL SPACER 
In an effort to extend this strategy, an attempt to increase the length of the alkyl 
backbone in the olefin product was carried out. It was hoped that it would be 
possible to adopt the optimised conditions previously employed to generate olefins 
203 and 204, in order to efficiently synthesise olefin derivative 210. Using this 
approach, the nine-membered lactam intermediate 209 could be generated during 
RCM, however, it was unclear if either the trans or cis lactam would be 
preferentially formed during this reaction. Scheme 4.19 outlines the optimised route 
which was employed to generate analogue 210. 
Using this approach, microwave irradiation of equimolar amounts of allylamine 32 
and commercially available 6-heptenoic acid 205 furnished diene 206 in an excellent 
86% yield. Treatment of unprotected diene 206 with Grubbs 2nd  generation catalyst 
192 resulted in a complex, inseparable mixture of products and failed to give any of 
the desired nine-membered lactam product 207. Therefore, prior to ring closing, 
diene 206 was protected using excess Boc20 and catalytic DMAP to afford N-Boc 
diene 208 in 58% yield. Compound 208 was then subjected to the same RCM 
conditions to give the N-Boc lactam derivative 209 (4mM) as a colourless crystalline 
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outlined for diene 200 (Table 4.2). However, dimerisation of N-Boc diene 208 
(20 mM) was not observed. After olefin metathesis, 'H NMR indicated that the trans 
N-Boc lactam 209 was predominantly formed. Hydrolysis of N-Boc lactam 209 was 
achieved by treatment with 2M LiOH in THF/water (1:1). The crude product was 
purified by ZMD chromatography (MeCN:H20 (95:5) with 0.1% TFA, 12 minute 






HO 	 86% 
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208 	 207 
210 	 0 
Scheme 4.19 Reagents and conditions used in the synthesis of olefin 210. 
(a) w, 150 °C, 300W, 250 psi, 30 mins (b) Boc 2O, DMAP, NEt 3, DCM, RT, 8 hours 
5 mol % catalyst 192, refiux, DCM, 24 hours 




Results and Discussion III 
4.6.2 ATTEMPTED SHORTENING OF ALKYL SPACER 
The successful application of the synthetic methodology towards the synthesis of 
derivative 210 provided the impetus to determine if it would be possible to shorten 
the alkyl spacer in the olefin product using the optimised conditions. To achieve 
this, commercially available vinyl acetic acid 211 was selected in order to generate 
the desired amide diene product 212 (Scheme 4.20). 
(a) 	 H 
NH2 + HO 	 x 
0 







H 	 o 




Scheme 4.20 Attempted synthesis towards shorter olefin analogue 216. 
(a) Co. 150 °C, 300W, 250 psi, 30 mins (b) Boc 20, DMAP, NEt 3, DCM, RT, 8 hours 
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However, NMR analysis of the product distillate, following bulb to bulb purification, 
indicated that compound 212 had isomerised under microwave conditions to generate 
substituted diene 213 in 77% yield. Evidence in the literature suggested that the 
generation of conformationally strained five-membered lactam 215 would be 
difficult to achieve using the RCM approach. 138  However, it was decided to continue 
with the synthesis to determine if this would be the case. Boc protection of 
compound 213 proceeded without any difficulties to furnish substituted N-Boc diene 
214 in 84% yield. As expected, RCM of substituted N-Boc diene 214 did not afford 
the desired a, P unsaturated N-Boc lactam 215. A complex mixture of products was 
obtained after this step which could not be separated by column chromatography. 
For these reasons this approach was abandoned. 
4.6.3 FURTHER GENERATION OF ALTERNATIVE PRECURSORS 
Compound generation has begun with three additional substrates which will 
incorporate structural diversity along the alkyl backbone (Scheme 4.21, Table 4.3). 
In each case allylamine 32 was used, along with commercially available 3-methyl-4- 
pentenoic  acid 217, 2-methyl-4-pentenoic acid 218 (entries 1 and 2 respectively) and 
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Scheme 4.21 General procedure employed to incorporate structural diversity. 
(a) co, 150 °C, 300W, 250 psi, 30 mins (b) Boc 2O, DMAP, NEt 3, DCM, RT, 8 hours 
Entry 	 R (acid) Diene 	Yield N-Boc Yield (%) Diene (%) 
-CH2CH(CH3)CH=CH2 
1 220 	80 223 55 
217 
-CH(CH3)CH2CH=CH2 
2 221 	67 224 58 
218 
-CH(CH2CH=CH2)Ph 
222 	72 225 60 219 
Table 4.3 	Synthesis of additional precursors 
Unfortunately, time constraints have prevented any further development of this 
appraoch. However, RCM of these precursors should furnish the desired lactam 
intermediates which could be hydrolysed to afford the functionalised olefin products. 
Using this protocol, a number of structurally diverse olefin analogues can be 
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4.7 FUTURE WORK AND DIRECTIONS 
So far, using a combination of optimised microwave and olefin metathesis chemistry, 
a robust synthetic methodology towards a number of novel amino acid building 
blocks which can be used as an accessible starting point for further lead compound 
development has been developed (Figure 4.6). 










210 	 0 
Figure 4.6 	Novel amino acid building blocks. 
It can be envisioned that the application of RCM towards the development of novel 
AQP compounds using this methodology presents the opportunity to design and 
synthesise conformationally restricted amino acids and peptides. It can be predicted 
that it will be possible to selectively incorporate a range of hydrophobic and 
hydrophilic groups along the alkyl backbone using this approach to generate a 
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)5OH 
R= alkyl, aromatic, allyl 	n = 3-6 
Figure 4.7 	Generic structure of conformationally restricted amino acids. 
Previous approaches towards the design of this class of compound have been based 
on side chain modification, amide linkage modification and de novo synthesis of 
particular structural motifs.' 39" 4° These types of synthetic strategies have been 
frequently employed to restrict the conformational space in macrocyclic peptides. ' 4 ' 
However, the efficiency of ruthenium based ring closing reactions has provided 
interesting application possibilities for making backbone modified peptides. For 
example, it could be postulated that rigidified amino acid structures, similar to 
compounds 203, 204 and 210 could be engineered into cyclic amino acids and 








Figure 4.8 	Cyclic peptidic structure of cyclotheonamide A 226. 
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Current studies are in progress to extend our methodology towards the generation of 
other conformationally restricted amino acid analogues (Figure 4.9). If successful, it 
may be possible extend this approach towards a parallel synthesis route. 
4_0 	 OAN LOH 
227 	 228 
OJLN OH 
229 
Figure 4.9 	Proposed functionalised amino acid building blocks. 
Continuing crystallography research should provide a high resolution crystal 
structure of an AQP-ligand complex. It is expected that this work will establish 
potential binding site(s) in several AQPs and in turn, highlight important protein 
residues involved in ligand binding. Although this work is in the early stages of 
development, it may be possible to generate a range of AQP inhibitors, using our 
RCM approach, to provide more detailed quantitative SAR data for selective water 
channels throughout the AQP family. Ultimately, further biological evaluation of 
AQP lead compounds will determine possible structure-based design approaches 
towards lead compound optimisation. For example, it could be envisaged that 
further structural modification of lead compound dimethyl ethyl hexadecanyl 




Results and Discussion III 
selectively incorporate hydrophilic/hydrophobic functionality along the alkyl 
backbone as illustrated in Figure 4.10. 
selective incorporation of polar hydroxyl groups 




quartemerisation of nitrogen atom 
introduction of hydrophobic functionality 
Figure 4.10 Possible synthetic alterations based on dimethyl ethyl hexadecanyl 
ammonium bromide 152. 
Although the development of compounds that target modulation of AQP function is 
at an early stage it is hoped that further compound development and biological 
evaluation of these compounds will ultimately provide improved selective water 
inhibition for several AQP family members. 
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5 EXPERIMENTAL 
5.1 GENERAL TECHNIQUES 
5.1.1 INSTRUMENTATION 
'H and ' 3C NMR spectra were recorded on Brtiker AC250, DPX-360 or Varian 
Gemini-200 instruments. The following abbreviations are used: 5, chemical shift; d, 
doublet; dd, doublet of doublets; dt, doublet of triplets; J, coupling constant; m, 
multiplet; q, quartet; s, singlet; t, triplet. Chemical shifts are recorded in ppm and 
coupling constants (J) are stated in hertz (Hz). Residual protic solvent, CHC13 (H 
7.26, s) was used as the internal standard in 'H NMR spectra and ' 3C NMR shifts 
were referenced using CDC13 (öc 76.9, t) with broad band decoupling. High 
Resolution Mass Spectrometry Fast Atom bombardment (HRMS FAB) was 
performed using a Kratos MS50TC instrument and electrospray (ES-MS) nominal 
mass spectra were recorded using a Micromass Platform II instrument. Microwave 
reactions were carried out in a CEM Discover Microwave Synthesiser with Explorer 
Carousel. The reaction conditions were monitored using a pressure probe which was 
inserted through the septum of the reaction tube and black body irradiation measured 
to monitor the temperature of the sample. IR absorption spectra were recorded on a 
Jasco-FT/IR-4 10 spectrophotometer using standard techniques and Uma,  values are 
quoted in cm'. Melting points were obtained on Gallenkamp melting point 
apparatus and are uncorrected. CHN analysis was obtained for some crystalline 
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solids. Small samples were recrystallised three times then submitted for combustion 
analysis. 
5.1.2 CHROMATOGRAPHY 
Analytical TLC was performed on aluminium backed plates coated with silica gel 60 
F254 (Merck: layer thickness of 0.2 mm). Components were visualised using ultra-
violet fluorescence (254 run) and permanganate dips. Flash chromatography was 
carried out using silica gel 60H (Merck 9385, 0.04-0.063 mm, 230-400 mesh). 
Parallel chromatography was performed using a Waters® ZMD mass spectrometer 
with Waters® 600 HPLC using Mass Lynx v3.5 and Fraction Lynx software. The 
preparative HPLC column used was a Phenomenex Lunar C18 65 x  21.20 mm, 5 p. 
microns. For quaternary ammonium salt compounds, an X-Terra® Prep MS C 18 19 
x 50 mm, 5 ji microns column was used. 
5.1.3 SOLVENTS AND REAGENTS 
All chemicals were of synthetic, analytical or HPLC grade. All chemicals used are 
commercially available and were from Merck, Lancaster, Sigma-Aldrich or Fisher 
Scientific unless otherwise stated. All reagents and solvents were standard 
laboratory grade and were used as supplied unless otherwise stated. Anhydrous 
solvents were dried over molecular sieves stored under a nitrogen atmosphere. 
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5.2 EXPERIMENTAL PROCEDURES - RESULTS AND DISCUSSION I 
5.2.1 GLYCEROL-BASED ANALOGUES 
5.2.1.1 Synthesis of 1-Benzyloxy-3-diethylamino-propan-2-ol 23 
2 
OH 	1 -::2 
jO 	 4 
Route A 
To an ice cooled solution of zinc chloride in MeCN (1.0 M, 7.78 mL, 7.8 mmol) 
benzyl glycidyl ether 21(1.2 mL, 7.8 mmol) was added. The solution was left to stir 
for 5 minutes. Diethylamine 22 (0.82 mL, 7.8 mmol) was added dropwise to the 
reaction mixture which was left to stir for a further 24 hours. A white suspension 
had formed after this time. The reaction mixture was then poured into a solution 
containing EtOAc (100 mL) and saturated sodium bicarbonate (100 mL). The 
insoluble white solid which had formed was removed by filtration and washed with 
EtOAc (2 x  50 mL). The organic layers were then separated and the aqueous layer 
extracted with EtOAc (2 x  100 mL). The combined extracts were washed with water 
(2 x  100 mL), dried over anhydrous MgSO4 and concentrated in vacuo to yield a 
yellow/brown liquid (1.54 g). The crude product was purified by flash 
chromatography on silica gel, using 10% MeOH in EtOAc as the eluent, to afford the 
desired product as a colourless oil (222 mg, 12%). 
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Route B 
Anhydrous MeCN (10 mL) was added to a round bottom flask containing oven-dried 
zinc chloride (1.22 g, 8.95 mmol) and the solution was stirred for 15 mins. Benzyl 
glycidyl ether 21 (1.75 mL, 11.48 mmol) was added to the solution which was left to 
stir for several more minutes. Diethylamine 22 (57.4 mmol, 5.9 mL, 5 equiv.) was 
added dropwise with care as heat was evolved during addition. The reaction mixture 
was left to stir for 24 hours. The mixture was then concentrated in vacuo and 
transferred into a flask containing EtOAc (50 mL) and sodium bicarbonate (50 mL). 
The white solid which had formed during the work-up was filtered and washed with 
ethyl acetate (2 x 50 mL). The organic layer was separated and the remaining 
aqueous layer washed with EtOAc (2 x  50 mL). The organic layers were combined 
and washed with water (2 x  50 mL), dried over anhydrous MgSO4, filtered and 
concentrated under reduced pressure to yield the crude product as an oil (2.70 g). 
TLC analysis indicated the reaction had gone to completion with only trace amounts 
of starting material present. The crude product was purified by flash 
chromatography on silica gel, using EtOAc:MeOH (9:1) as the eluent, to yield the 
desired product as a colourless oil (2.52 g, 90%). bp 190-193°C @ 0.3 mbar; rf 
(EtOAc); 0.32; 811 (CDCI3, 250 MHz); 1.10 (6H, t, 3J = 7.0 Hz, 2 x  CH3), 2.51-2.78 
(6H, m, N(CH2)3), 3.56 (2H, d, 3J = 5.3 Hz, CHCH20), 3.90 (1H, quintet, 3J = 4.7 
Hz, CHOH), 4.66 (2H, s, OCH2Ar), 7.34-7.43 (5H, m, ArH); öc (CDC13, 63 MHz, 
DEPT); 11.8 (2 x  CH3), 46.9 (2 x  CH3CH2), 55.8 (NCH2), 66.4 (CHOH), 72.7 
(OCH2Ar), 73.3 (CHCH20), 127.4 (ArC3), 127.5 (ArC1/5), 128.2 (ArC2/C4), 138.1 





(ES-MS) [M+H] 238; found (HRMS FAB) [M+H] 238.18086 C14H23NO2 requires 
238. 18070. 
5.2.2 GLYCEROL-BASED ANALOGUE LIBRARY REHEARSAL 
5.2.2.1 Synthesis of Glycerol Analogues 27, 28 and 29 
The synthetic procedure towards glycerol analogues 27, 28 and 29 was followed as 












10 	 5 
1.75 g, 62%; bp 198-201°C @ 0.3 mbar; rf (EtOAc) 0.25; oH (CDC13, 250 MHz); 
1.62-1.68 (4H, m, H8/9), 2.24-2.62 (6H, m, H7/10, NCH2CH), 3.21-3.39 (2H, m, 
CHCH20), 3.79 (1H, quintet, 3J= 4.6 Hz, CHOH), 4.45 (2H, s, OCH 2Ar), 7.15-7.24 
(5H, m, ArH); öc  (CDCI3, 63 MHz, DEPT); 23.6 (C819), 54.3 (C7110), 58.8 
(NCH2CH), 68.1 (CHOH), 73.0 (OCH2Ar), 73.5 (CHCH20), 127.7 (ArC3), 127.8 
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(ArC1/5), 128.4 (ArC2/C4), 138.2 (ArC6); Umax (neat); 3430 (OH), 3090-2800 (br, 
CH), 1605 (Ar C=C); m/z; found (ES-MS) [M+H] 236; found (HRMS FAB) 
[M+H]236.16572 C 14H21NO2 requires 236.16505. 
5.2.2.1.2 	1-Benzyloxy-3-piperidin-1-yl-propan-2-ol 28 




QN O 4 
11 	 5 
2.65 g, 92%; bp 215-220 1C @ 0.3 mbar; rf (EtOAc) 0.25; oH (CDCI3, 250 MHz); 
1.59-1.76 (6H, m, H8/9/10), 2.49-2.57 (4H, m, 117/11), 2.70-2.76 (2H, m, 
NCH2CH), 3.33-3.42 (2H, m, CHCH20), 3.79 (1H, quintet, 3J = 4.6 Hz, CHOFI), 
4.47 (2H, s, OCH2Ar), 7.15-7.24 (5H, m, ArH); 0c  (CDCI3, 63 MHz, DEPT); 24.2 
(C9), 25.9 (C8/10), 54.7 (C7/11), 61.4 (NCH2CH), 66.0 (CHOH), 72.8 (OCH2Ar), 
73.4 (CHCHO), 127.6 (ArC3), 127.7 (ArC1/5), 128.4 (ArC2/C4), 138.2 (ArC6); 
Umax (neat); 3434 (OH), 3100-2800 (br, CH), 1605 (Ar C=C); m/z; found (ES-MS) 
[M+H]+ 250; found (HRMS FAB) [M+H] 250.18099 C 15H23NO2 requires 
250.18070. 
5.2.2.1.3 	1-Benzylamino-3-benzyloxy-propan-2-ol 29 




12 	 5 
2.18 g, 70%; bp 196-198°C @0.3 mbar; rf (EtOAc) 0.3; 8H (CDC13, 200 MHz); 2.02 





s, ArCH2N), 3.84-4.12 (1H, m, CHOH), 4.55 (2H, s, OCH2Ar), 7.52-7.65 (10H, m, 
ArH); ö (CDC13 , 63 MHz, DEPT); 52.1 (NCH 2CH), 54.3 (ArCH2N), 68.8 
(CHOH), 73.3 (OCH2Ar), 73.8 (CHCH20), 127.4-129.6 (ArC1-5, 8-12), 138.5 
(ArC6), 140.4 (ArC7); Umax (neat); 3445 (OH), 3302 (NH), 3100-2800 (br, CH), 
1604 (Ar C=C); m/z; found (ES-MS) [M+H] 272; found (HRMS FAB) [M+H] 





5.2.3 LIBRARY SYNTHESIS OF GLYCEROL ANALOGUES 23,29 AND 38-45 
5.2.3.1 Reagent Preparation 
Volume 
Molarity No. Moles 
Reagent Equivalents Dispensed Solvent (M) Dispensed (mmol) 
(mL) 
BGE 6.58 5 1 0.76 - 
ZnC12(s) 
0.62 3.1 0.625 5 MeCN 
in MeCN 
Amines 
22, 26, 2 5 - 5 - 
30-37 
Table 5.1 	Reagents used in library synthesis. 
Amines 
Diethylamine 22 	 Ethyl(isopropyl)amine 33 
Benzylamine 26 	 Cyclopropylamine 34 
Morpholine 30 	 2-Aminopyridine 35* 
Piperazine 31 * 	 tert-Butylamine 36 
Allylamine 32 	 N-Methylbenzylamine 37 






5.2.3.2 Library Synthesis Experimental Conditions 
Anhydrous MeCN (65 mL) was added to a flask containing ZnC12 (s) (5.62 g, 
40.6 mrnol) which had been dried overnight in a vacuum oven (20°C @ 1 
mbar). The solution was stirred under a nitrogen atmosphere for 15 mins 
prior to distribution by the Bodhan NeptuneTM-MB Automated Workstation. 
The NeptuneTM was used to dispense the ZnCl2 solution (5 mL) into 10 
reaction vessels (RVs) located in the MiniBlockTM 
A neat solution of benzyl glycidyl ether 21 (0.76 mL) was then dispensed to 
each RV. 
The MiniBlockTM was then shaken on the MiniBlockTM  High Capacity 
Shaking and Washing Station for 20 mins. 
The MiniBlockTM  was returned to the Bodhan NeptuneTM and amines 22, 26 
and 30-37 (25 mmol) were dispensed to RVs 1-10 respectively. 
The MiniBlockTM was shaken on the Shaking Station for 24 hours at room 
temperature. 
The MiniBlockTM was then drained under vacuum (water pump) and the 
filtrates collected into 20 ml, vials. Each product was then concentrated 
under reduced pressure using the Christ ALPHA-2-4 Freeze Dryer, BETA-
RVC Ceramic Vacuum Measurement system (170 mbar -> 100 mbar -> 50 





Each product was redissolved in EtOAc (2 mL) and transferred back to their 
respective RV in the MiniblockTM.  Aqueous sodium bicarbonate (2 mL) was 
manually dispensed to each RV. 
Each RV was filtered using the MiniBlockTM  vacuum manifold into wells 
1-10 of a 24 well microtitre plate. 
The microtitre plate was transferred to an Allex® liquid-liquid extraction 
robot. 
The organic phase was separated for each product and the aqueous phase was 
washed with EtOAc (2 x  4 mL). Each organic phase was washed with water 
(2 x  4 mL) and brine (2 x  1 mL). The organic phases were combined and 
concentrated under reduced pressure using the Christ (180 mbar @ 50°C for 
10 hours). 
Each sample was redissolved in EtOAc (2 mL) and transferred into pre-
weighed reagent vials before being concentrated under reduced pressure 
using the Christ (180 mbar @ 50°C for 10 hours). 
Each product (50 mg) was then dissolved in a solution of MeCN:H20 (50:50) 
with 0.1%TFA prior to running on the Waters® ZMD mass spectrometer (12 
min run, gradient H20/MeCN (95:5)—),(5:95), CV=25) for mass-directed 
purification of the samples. 
The fractions collected from the ZMD FractionLynx collector were 
transferred from test tubes to labelled 20 ml reagent vials and the H 20/MeCN 






5.2.3.2.1 	1-Ben2yloxy-3-morpholinopropan-2-ol 38 
8 	 2 
OH 	 1 
ON 	 0 
6 
10 	 5 
1.26 g, 51%; bp 215-218°C @ 0.3 mbar; rf (EtOAc) 0.26; 811  (CDCI3, 250 MHz); 
2.30-2.36 (4H, m, H7/10), 2.47-2.55 (2H, m, NCH2CH), 3.37-3.41 (2H, m, 
CHCH20), 3.55-3.62 (4H, m, H8/9), 3.84 (1H, quintet, 3J = 4.6 Hz, CHOH), 4.47 
(2H, s, OCH2Ar), 7.15-7.25 (5H, m, ArH); öc  (CDC13, 63 MHz, DEPT); 53.3 
(NCH2CH), 57.7 (C7/10), 65.6 (CHOH), 66.5 (C819), 72.1 (OCH2Ar), 73.1 
(CHCH20), 127.2 (ArC3), 127.3 (ArC1/5), 128.0 (ArC2/C4), 137.6 (ArC6); 'U max 
(neat); 3443 (OH), 3100-2800 (br, CH), 1605 (Ar C=C); m/z; found (ES-MS) 
[M+H] 252; found (HRMS FAB) [M+H] 252.15970 C 14H21NO3 requires 
252.15997. 
5.2.3.2.2 	1-Ben2yloxy-3-piperazin-1-yl-propan-2-ol 39 
8 	 2 
HN ' ' 	OH 	I 
O 4 
10 	 5 
0.13g, 11%; bp 238-242°C @ 0.3 mbar; rf (EtOAc) 0.20; 811  (CDC13, 250 MHz); 
2.28-2.33 (4H, m, H7/10), 2.42-2.48 (2H, m, NCH2CH), 2.73-2.77 (4H, m, H819), 
3.36-3.42 (2H, m, CHCH20), 3.84 (1H, quintet, 3J = 4.6 Hz, CHOH), 4.46 (2H, s, 
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OCH2Ar), 7.15-7.25 (5H, m, ArH); öc (CDC13, 63 MHz, DEPT); 46.1 (C819), 
47.1 (C7110), 54.6 (NCH2CH), 66.0 (CHOH), 72.7 (OCH2Ar), 73.5 (CHCH20), 
127.7 (ArC3), 127.8 (ArC1/5), 128.4 (ArC2/C4), 138.1 (ArC6); Umax (neat); 3443 
(OH), 3295 (NH), 3100-2800 (br, CH), 1604 (Ar C=C) cm -1 ; m/z; found (ES-MS) 
[M+Hf 251; found (1{RMS FAB) [M+H] 251.17590 C14H22N202 requires 
251. 17595. 






0.59 g, 53%; bp 205-208°C @ 0.3 mbar; rf (EtOAc) 0.25; oH (CDC13 , 250 MHz); 
2.46-2.60 (2H, m, NCH2CH), 2.71 (1H, s, NH), 3.12-3.15 (211, m, CH2=CHCH2), 
3.32-3.39 (2H, m, CHCH20), 3.76-3.82 (1H, m, CHOH), 4.44 (2H, s, OCH2Ar), 
5.00-5.10 (2H, m, CH2=CHCH2), 5.69-5.83 (1H, m, CH2CHCH2), 7.17-7.24 (5H, 
m, ArH); öc  (CDC13, 63 MHz, DEPT); 51.5 (CH2CHCH2), 52.3 (NCH 2CH), 68.4 
(CHOH), 72.7 (OCH2Ar), 73.5 (CHCH20), 116.2 (CH 2 CHCH2), 127.7 (ArC3), 
127.8 (ArC1/5), 128.5 (ArC2IC4), 136.6 (CH2=CHCH2), 138.1 (ArC6); U..,, (neat);  
3450 (OH), 3312 (NH), 3100-2800 (br, CH), 1643 (C=C), 1605 (Ar C=C); m/z; 











NO ] 4 
5 
0.86 g, 66%; bp 170-175°C @ 0.3 mbar; rf (EtOAc) 0.28; oH (CDCI3, 250 MHz); 
0.79-0.92 (9H, m, CH3CH2, (CH3)2CH), 2.24-2.41 (4H, m, CH3CH2, NCH2CH), 
2.83 (1H, septet, 3J = 6.6 Hz, (CH3)2CH)), 3.34-3.37 (2H, m, CHCH20), 3.60-3.65 
(1H, m, CHOH), 4.44 (2H, s, OCH2Ar), 7.11-7.24 (5H, m, ArH); ôc  (CDC13, 63 
MHz, DEPT); 14.6 (CH 3CH2), 20.4 ((CH3)2CH), 44.2 (CH3CH2), 50.4 (CH3)2CH), 
52.0 (NCH2CH), 66.6 (CHOH), 73.1 (OCH 2Ar), 73.6 (CHCH20), 127.7 (ArC3), 
127.8 (ArC1/5), 128.4 (ArC2/C4), 138.4 (ArC6); Umax (neat); 3440 (OH), 3100-2800 
(br, CH), 1605 (Ar C=C); m/z; found (ES-MS) [M+H] + 252; found (HRMS FAB) 
[M+H]+ 252.19624 C 15H25NO2 requires 252.19635. 




A '0 60 4 9 
5 
0.87 g, 74%; bp 226-231°C @ 0.3 mbar; rf (EtOAc) 0.25; oH  (CDCI3, 250 MHz); 
0.09-0.13 (2H, m, H81119), 0.36-0.41 (2H, m, 1181119), 0.78-0.87 (H7), 1.89 (1H, s, 
NH), 2.32-2.41 (2H, m, C3H5CH2N), 2.54-2.66 (2H, m, NCH2CH), 3.34-3.41 (2H, 
m, CHCH20), 3.77-3.81 (1H, m, CHOH), 4.47 (2H, s, OCH2Ar), 7.19-7.29 (5H, m, 
ArH); 8c  (CDC13, 63 MHz, DEPT); 3.8 (C8/9), 11.6 (C7), 52.2 (NCH 2CH), 55.3 





(ArC1/5), 128.8 (ArC2/C4), 138.4 (ArC6); 'Umax (neat); 3440 (OH), 3310 (NH), 
3100-2800 (br, CH), 1604 (Ar C=C); m/z; found (ES-MS) [M+H] 236; found 
(HRMS FAB) [M+H] + 236.16450 C14H21NO2 requires 236.16505. 
	
5.2.3.2.6 	1-Benzylamino-3-benzyloxy-propan-2-o1 29 
9 	 2 
10 	 8 	
OH .0 4 
12 	 5 
0.95 g, 70%; For characterisation refer to Section 5.2.2.1.3. 









0.24 g, 19%; bp 242-245 @ 0.3 mbar; rf (EtOAc) 0.21; oH (CDC13, 250 MHz); 2.01 
(1H, s, NH), 3.38-3.56 (4H, m, NCH2CH, CHCH20), 3.90-4.12 (1H, m, CHOH), 
4.44 (2H, s, OCH 2Ar), 6.51 (1H, t, 3J = 6.8 Hz, ArH10), 6.59 (1H, d, 3J = 9.0 Hz, 
ArH8), 7.23-7.35 (511, m, ArH1-5), 7.46 (1H, d, 3J= 5.5 Hz, ArH9), 7.81-7.89 (1H, 
m, ArH11); oc (CDC1, 63 MHz, DEPT); 54.5 (NCH2CH), 68.0 (CHOH), 73.8 
(OCH2Ar), 74.0 (CHCH20), 107.1 (ArC8), 114.2 (ArC10), 128.3-128.9 (ArC1-5), 





3197 (NH), 3100-2800 (br, CH), 1604 (Ar C=C); m/z; found (ES-MS) [M+H] 259; 
found (HRMS FAB) [M+H] 259.14411 C 15H 1 8N202 requires 259. 14465. 
	
5.2.3.2.8 	 1-Benzy1oxy-3-diethylamino-propan-2-ol 23 
2 
OH 	 1 
4 
1.01g, 85%; For characterisation refer to Section 5.2.1.1 
5.2.3.2.9 	 1-Benzyloxy-3-(tert-butylamino)-propan-2-oI 44 
2 
OH 
>  N ~"~01, 60 r 5 
4 
0.62 g, 52%; bp 185-188°C @ 0.3 mbar; rf (EtOAc) 0.23; oH (CDC13, 250 MHz); 
0.99 (9H, s, (CH3)3C), 2.44-2.60 (2H, m, NCH2CH), 3.34-3.41 (2H, m, CHCH20), 
3.65-3.72 (1H, m, CHOH), 4.44 (2H, s, OCH2Ar), 7.17-7.28 (5H, m, ArH); 
0c (CDC13, 63 MHz, DEPT); 27.2 ((CH 3)3C), 44.9 (NCH2CH), 54.0 ((CH3)3C), 69.3 
(CHOH), 72.8 (OCH2Ar), 73.5 (CHCH20), 127.6 (ArC3), 127.8 (ArC1/5), 128.4 
(ArC2/C4), 138.2 (ArC6); Umax (neat); 3425 (br, OH), 3302 (NH), 3100-2800 (br, 
CH), 1605 (Ar C=C); m/z; found (ES-MS) [M+H] 238; found (HRMS FAB) 
[M+H] 238.18058 C14H23NO2 requires 236.18070. 
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5.2.3.2.10 	1-(Benzyl(methyl)amino)-3-(benzyloxy)-propan-2-o1 45 
9 	 2 
10 	 8 	
OH 
12 	 5 
1.32 g, 92%; bp 245-250 @ 0.3 mbar; rf (EtOAc) 0.32; oH (CDC13 , 250 MHz); 2.24 
(3H, s, NCH3), 2.39-2.45 (2H, m, NCH2CH), 3.43-3.56 (2H, m, CHCH20), 3.75 
(2H, s, ArCH2N), 3.92-3.99 (1H, m, CHOH), 4.57 (2H, s, OCH2Ar), 7.25-7.37 (10H, 
m, ArH); 0c  (CDC13, 63 MHz, DEPT); 42.2 (NCH3), 59.9 (NCH2CH), 62.6 
(ArCH2N), 66.9 (CHOH), 72.7 (OCH2Ar), 73.6 (CHCH20), 127.0-129.1 (ArC1-5, 
8-12), 138.5 (ArC6), 140.2 (ArC7); bmax (neat); 3443 (OH), 3100-2800 (br, CH), 
1603 (Ar C=C); m/z; found (ES-MS) [M+H] 286; found (HRMS FAB) [M+H] +  
286.18044 C 1 8H23NO2 requires 286.18070. 
5.2.4 SOLID PHASE SYNTHESIS 
5.2.4.1 Synthesis of 3-(diethylamino)-propane-1,2-diol 51 
OH 
HO 
Glycidol 7 (137 p.L, 2.08 mmol) and pyridine (336 j.tL, 4.16 mmol) were dissolved in 
dry THF (10 mL). The reaction mixture was then added to a flask containing 
2-chiorotrityl chloride resin 48 (1.03 g, 1.2 mmol g) and heated at 60°C for 6 hours. 
After this time the resin was filtered and washed with DCM/MeOH/DIPEA (17:2:1) 
(3 x  2mL), DCM (3 x  2 mL), DMF (2 x  2 mL) and DCM (2 x  2 mL). 
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A solution of LiC104 in anhydrous MeCN (300 tL, 0.31 mmol) was added to a flask 
containing epoxide resin 49 (130 mg, 0.14 mmol) and dry MeCN (2 mL). 
Diethylamine 22 (62 tL, 0.60 mmol) was then added dropwise and the reaction 
mixture was heated at 85°C for 24 hours. Resin 50 was then filtered and washed 
with dioxane:H20 (1:1) (3 x  3 mL), dioxane (1 x  3mL), propan-2-ol (3 X  3m1), 
DMF (3 x  3 mL), propan-2-ol (3 x  3 mL) and DCM (6 x  3 mL). 
Resin 50 was then treated with 5% TFA in DCM (4 mL) and stirred at room 
temperature for 3 hours. The resin 50 was washed with DMF (6 x  3 mL) and DCM 
(6 x  3 mL). The solvent was removed under reduced pressure to yield a yellow oil 
(10 mg) and the product placed on a high vacuum line for 30 mins. ES-MS 
confirmed the presence of the molecular ion product @ 148 m/z. 10 mg; bp 112-
115°C @4  mbar 
[lit.  142 106°C @ 4mbar] 8H(CDC13, 250 MHz); 1.00 (6H, t, 3J= 7.1 
Hz, 2 x  CR3), 2.42-2.64 (6H, m, 3 x  NCH2), 3.44-3.51 (1H, m, CHOH), 3.66-3.79 
(2H, m, CR20H); öc (CDCI3, 63 MHz, DEPT); 11.6 (2 x  CH3), 47.1 (2 x  CH3CH2), 
55.7 (NCH), 65.0 (CHOH), 67.2 (CH20H); m/z; found (ES-MS) [M+H] 148. 
5.2.5 MICROWAVE SYNTHESIS OF GLYCEROL ANALOGUES 23,29 AND 3845 
5.2.5.1 General Procedure for Microwave Synthesis 
Benzy] glycidyl ether 21 (152 jtL, 1 mmol) was dispensed into a microwave tube and 
dissolved in absolute ethanol (2.5 mL). Each amine 22-26 and 30-37 (1.5 mmol) was 





Carousel. Each sample was heated at 140°C with stirring for 4 mins (80 watts, 50 
psi). A period of 5 mins was allowed for sample cooling. Each sample was 
concentrated in vacuo and purification was performed, if necessary, by using 
Kugelrohr bulb to bulb distillation apparatus to yield the desired products 23, 29 and 
38-45. For characterisation refer to Section 5.2.3. 
Amines 
Diethylamine 22 Morpholine 30 Cyclopropylamine 34 
Pyrrolidine 24 Piperazine 31 2-Aminopyridine 35 
Piperidine 25 Allylamine 32 tert-Butylamine 36 
Benzylamine 26 	Ethyl(isopropyl)amine 33 	N-Methylbenzylamine 37 
5.2.5.2 Product Yields 

















5.2.6 MICROWAVE SYNTHESIS OF GLYCEROL ANALOGUES 55 AND 57-68 
5.2.6.1 Attempted Ring Opening of Epichiorohydrin 52 with Diethylamine 22 
Using Microwave Irradiation 
To a microwave tube containing epichlorohydrin 52 (78 jtL, 1 mmol) dissolved in 
absolute ethanol (2.5 mL) was added diethylamine 22 (155 pL, 1.5 mmol) dropwise. 
A stirrer bar was added and the reaction placed in the CEM Discover microwave for 
4 mins @ 140°C (80 watts, 50 psi). The solution changed from colourless to 
yellow/orange. The crude product was allowed to cool and was then concentrated in 
vacuo to yield a yellow/orange oil. The crude product was placed under high 
vacuum for 1 hour after which time yellow/brown solid had formed. The product 
was then recrystallised from ethanol (3 mL). The product was then cooled in ice and 
left in the fridge overnight. No crystals had formed after this time. The solvent was 
removed under reduced pressure to yield a yellow/orange oil (105 mg). ES-MS 
indicated that the desired product was not present, however, crude side-product 1,3 
bis-(diethylamino)propan-2-ol 55 was isolated and purified by flash chromatography, 
using 100% EtOAc as the eluent, to afford a clear yellow oil (150 mg, 75%). 
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5.2.6.1.1 	 1,3 bis-(diethylamino)propan-2-ol 55 
01-1 
150 mg, 75%; 611 (CDCI3, 250 MHz); 1.22 (12H, t, 3J = 7.2 Hz, 4 x  CH3), 2.79 (411, 
d, 3J= 8.4 Hz, 2 x  NCH2), 2.98 (8H, q, 3J= 6.5 Hz, 4 x  CH3CH2), 4.29 (1H, quintet, 
= 4.0 Hz) CHOH); öc (CDC13, 63 MHz, DEPT); 9.9 (4 x  CH3), 47.6 
(4 x  CH3CH2), 56.7 (2 x  Nd 2), 63.1 (CHOH); umax (neat); 3435 (OH), 3100-2800 
(br, CH); m/z; found (ES-MS) [M+H]' 203; found (HRMS FAB) {M+Hf 
203.21212 C11H26N20 requires 203.21234. 
5.2.6.2 	General Procedure for the Microwave Synthesis of Glycerol 
Analogues 57-68 
To a microwave tube containing epichlorohydrin 52 (78 j.tL, 1 mmol) dissolved in 
absolute ethanol (2.5 mL) were added amines 22-26 and 30-37 (0.9 mmol). A stirrer 
bar was added and the reaction placed in the CEM Discover microwave for 1 minute 
@ 20°C (80 wafts, 50 psi). The crude product was allowed to cool and concentrated 
in vacuo (keeping water bath temperature <20°C) to yield the desired products 57-
64. Purification was achieved by placing the product under high vacuum for 1 hour 






5.26.2.1 	 1-chloro-3-diethylamino-propan-2-ol 57 
OH 
CI 
112 mg, 68%; 6H(CDC13, 250 MHz); 1.03 (6H, t, 3J= 7.2 Hz, 2 x  CH3), 2.40-2.68 
(6H, m, 3 x  NCH2), 3.50-3.61 (2H, m, CH20), 3.80 (1H, quintet, 3J = 5.1 Hz, 
CHOH); oc (CDC1, 63 MHz, DEPT);. 11.8 (2 x  CH3), 47.1 (CH20), 56.2 
(3 x  NCH2), 66.8 (CHOH); v..,, (neat); 3410 (OH), 3100-2800 (br, CH); m/z; found 
(ES-MS) [M+H] 166; found (HRMS FAB) [M+H] 166.09204 C 7H16NOC1 
requires 166.09211. 
5.2.6.2.2 	 1-chloro-3-(pyrrolidin-1-yI)-propan-2-oI 58 
2 
1 	
OH ON c' 
106 mg, 65%; 88 (CDC13, 250 MHz); 1.73-1.78 (4H, m, H2/3), 2.42-2.50 (4H, m, 
H1/4), 2.63-2.74 (2H, m, NCH2), 3.51-3.60 (2H, m, CH20), 3.88 (1H, quintet, 
= 5.1 Hz, CHOH); öc (CDCI3, 63 MHz, DEPT); 23.5 (C2/3), 47.2 (CH20), 54.5 
(C1/4), 56.2 (NCH2), 68.2 (CHOH); Umax (neat); 3418 (OH), 3100-2800 (br, CH); 
m/z; found (ES-MS) [M+H] 164; found (HRMS FAB) [M+H] 164.05937 
C7H 14NOC1 requires 164.06562. 
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128 mg, 72%; oH (CDCI3, 250 MHz); 1.43-1.47 (2H, m, H3), 1.52-1.61 (4H, m, 
H2/4), 2.31-2.46 (411, m, H1/5), 2.53-2.57 (2H, m, NCH2), 3.50-3.61 (2H, m, 
CH20), 3.91 (IH, quintet, 3J = 5.1 Hz, CHOH); 0c (CDC13, 63 MHz, DEPT); 24.0 
(C3), 25.9 (C214), 47.2 (CH20), 54.6 (C1/5), 61.5 (NCH2), 66.3 (CHOH); ,flax 
(neat); 3430 (011), 3100-2800 (br, CH); m/z; found (ES-MS) [M+H] 178; found 
(HRMS FAB) [M+Hj 178.09204 C 8H 1 6NOC1 requires 178.09214. 




126 mg, 70%; oH (CDC13, 250 MHz); 2.40-2.47 (4H, m, 111/4), 2.57-2.65 (2H, m, 
NCH2), 3.51-3.60 (2H, m, CH20), 3.67-3.71 (4H, m, H2/3), 3.92 (1H, quintet, 
3J= 5.1 Hz, CHOH); oc(CDCI3, 63 MHz, DEPT); 46.9 (CH20), 53.6 (C1/5), 61.3 
(NCH2), 66.3 (CHOH), 66.7 (C2/3); 1)max (neat); 3434 (OH), 3100-2800 (br, CH); 
m/z; found (ES-MS) [M+H]+  180; found (HRMS FAB) [M+H] 180.07932 
C7H 14NO2C1 requires 180.07913. 
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109 mg, 61%; oH (CDC13, 250 MHz); 2.39-2.48 (4H, m, H1/4), 2.55-2.62 (2H, m, 
NCH2), 2.86-2.92 (4H, m, H2/3), 3.51-3.69 (2H, m, CH20), 3.92 (1H, quintet, 
3J = 5.1 Hz, CHOH); ôc  (CDC13, 63 MHz, DEPT); 45.5 (C213), 46.4 (CH20), 47.0 
(C1/4), 61.4 (NCH2), 66.5 (CHOH); Umax (neat); 3432 (OH), 3315 (NH), 3100-2800 
(br, CH); m/z; found (ES-MS) [M+H] 179; found (HRMS FAB) [M+H] 
179.08711 C7H 15N20C1 requires 179.08705. 
5.2.6.2.6 	 1-chloro-3-(ethyl(isopropyl)amino)-propan-2-oI 62 
OH 
CI 
22 mg, 12 %; O (CDC13 , 250 MHz); 0.82-0.95 (9H, m, CH3CH2, (CH3)2CH), 2.20-
2.38 (4H, m, CH3CH2, NCH2CH), 2.79 (1H, septet, 3J= 6.6 Hz, (CH3)2CH)), 3.51-
3.60 (2H, m, CH20), 3.89 (1H, quintet, 3J = 5.2 Hz, CHOH); 8c  (CDCI 3 , 63 MHz, 
DEPT); 15.1 (CH3CH2), 21.1 ((CH3)2CH), 44.2 (CH3CH2), 46.5 (CH20), 50.4 
(CH3)2CH), 51.7 (NCH2CH), 66.3 (CHOH); Umax (neat); 3440 (OH), 3100-2800 (br, 
CH); m/z; found (ES-MS) [M+H] +  180; found (HRMS FAB) [M+Hj 180.11503 
C8H 1 8NOCI requires 180.11560. 
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5.2.6.2.7 	1-(Benzj'I(methyl)amino)-3-chloro-propan-2-ol 63 
2 
3 — 	 OH 
4 
5 
162 mg, 76%; 811 (CDC13, 250 MHz); 2.21 (3H, s, NCH3), 2.43-2.57 (2H, m, 
NCII2CH), 2.65-2.83 (2H, m, NCH2CH), 3.50-3.62 (2H, m, CH2CI), 3.78 (2H, s, 
ArCH2N), 3.92 (1H, quintet, 3J = 5.1 Hz, CHOH), 7.19-7.33 (5H, m, ArH); ôc 
(CDC1 3 , 63 MHz, DEPT); 42.1 (NCH3), 47.0 (CH 2C1), 58.2 (NCH2CH), 62.4 
(ArCH2N), 67.1 (CHOH), 127.5 (ArC3), 128.3 (ArC1/5), 128.7 (ArC2/C4), 137.9 
(ArC6); 1)max (neat); 3441 (OH), 3100-2800 (br, CH), 1605 (Ar C=C); m/z; found 
(ES-MS) [M+H] 214; found (HRMS FAB) [M+HfF  212.08390 C111115N0C1 
requires 212.08422. 
5.2.6.2.8 	 1-(allylamino)-3-chloropropan-2-o1 64 
OH 
82 mg, 55%; oH (CDC13, 250 MHz); 2.56 (1H, s, NH), 2.65-2.83 (2H, m, NCH2CH), 
2.86-2.92 (2H, m, H2/3), 3.28 (211, m, CH2=CHCH 2), 3.50-3.62 (2H, m, CH2C1), 
3.90 (1H, quintet, 3J = 5.1 Hz, CHOH), 5.10-5.23 (211, m, CH2CHCH2), 5.82-5.95 
(1H, m, CH2=CHCH2); 6c(CDC13, 63 MHz, DEPT); 47.3 (CH20), 51.2 (NCH 2CH), 
5 2. 0 (CH2=CHCH2), 69.3 (CHOH), 116.5 (CH2=CH), 13 6. 0 (CH2CH); Umax (neat); 
3440 (OH), 3315 (NH), 3100-2800 (br, CH), 1645 (C=C); m/z; found (ES-MS) 






5.3 EXPERIMENTAL PROCEDURES - RESULTS AND DISCUSSION II 
5.3.1 UV ACTIVATED REACTIONS TOWARDS THIOETHER ANALOGUES 108-113 
5.3.1.1 General Procedure for UV Photochemical Coupling 
Nitrogen gas was bubbled through a solution of anhydrous MeOH (50 mL) for 30 
minutes in a 2-necked water-cooled photochemical reactor. Allyl triethyl ammonium 
bromide 88 (2 g, 9 mmol) was added and stirred for 5 minutes until fully dissolved. 
After this time, thiols 101-107 (45 mmol, 5 equiv.) were carefully added with stirring 
to the reaction mixture over a period of a few minutes. The water-cooled mixture 
was then irradiated with UV light (254nm) for 8 hours with stirring under a nitrogen 
atmosphere. The reaction mixtures were concentrated under reduced pressure to 
afford the resultant crude oils. Each crude product (50 mg) was purified using ZMD 
mass-directed purification (H20:MeCN (95:5) with 0.1 % TFA, 30 minute run) to 




N-(2-mercaptoethyl) acetamide 103 
Benzyl mercaptan 104 
Dithioerythritol 105 






5.3.1.1.1 	3-(hexylthio)- N,N,N-triethylpropanyl ammonium bromide 108 
Br 
2.12 g, 58%; öH(MeOD, 250 MHz); 1.11 (3H, t, 3J = 7.2 Hz, Cl3), 1.47-1.56 (15H, 
m, 3 X  CH3CH2N, (CH2)3CH3)), 1.71-1.93 (2H, m, SCH2CH2), 2.08-2.20 (2H, m, 
NCH2CH2), 2.81 (4H, dt, 3J = 7.1 Hz, CH2SCH2), 3.49-3.58 (8H, m, 4 x  NCH2); 
öc (MeOD, 63 MHz, DEPT); 5.8 (3 x  CH3CH2N), 12.5 (CH3), 20.8 (CH2CH2CH3), 
21.7 (NCH2CH2), 28.3 SCH2(CH2)3), 30.7 (CH2S), 31.2 (SCH2), 52.1 
(3 x  CH3CH2N), 55.1 (NCH2CH2); m/z; found (ES-MS) [M-Brf 260; found 
(HRMS FAB) [M-Br] 260.24051 C ISH34NS requires 260.24062. 
5.3.1.1.2 3-(2-aminoethylthio)-N,N,N-triethylpropany1 ammonium bromide 109 
Br 
I+ s NH2 
463 mg, 15 %; ö (MeOD, 250 MHz); 1.46 (9H, t, 3J = 7.1 Hz, 3 x  CH3CH2N), 
2.05-2.18 (411, m, NCH2CH2, CH2S), 2.81 (2H, t, 3J = 6.9 Hz, SCH2), 3.43-3.51 
(I OH, m, 4 x  NCH2, CH2NH2); öc (MeOD, 63 MHz, DEPT); 5.8 (3 x  CH3CH2N), 
21.7 (NCH2CH2), 30.8 (CH2S), 31.2 (Sd2), 35.6 (CH2NH2), 52.4 
(3 x  CH3CH2N), 55.3 (NCH2CH2); m/z; found (ES-MS) [M-Br] + 219; found 
(HRMS FAB) [M-Br]219.18933 C II H27NS requires 219.18971. 
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2.39 g, 65%; ÔH(MCOD,  250 MHz); 1.12 (911, t, 3J= 7.2 Hz, 3 x  CH3CH2N), 2.11 
(311, s, COCH3), 2.12-2.25 (4H, m, NCH2CH2, CH2S), 2.83-2.98 (2H, m, SCH2), 
3.49-3.58 (10H, m, 4 x  NCH2, CH2NH); ö (MeOD, 63 MHz, DEPT); 5.9 
(3 x  CH3CH2N), 20.5 (COCH3), 20.9 (NCH2CH2), 27.6 (CH2S), 30.1 (SCH2), 41.6 
(CH2NHCO), 52.1 (3 x  CH3CH2N), 54.9 (NCH2CH2), 172.3 (C=O); m/z; found 
(ES-MS) [M-Br] + 261; found (HRMS FAB) [M-Br] 1 261.19946 C13H29N20S 
requires 261.19951. 
5.3.1.1.4 	3-(benzylthio)-N,N,N-triethylpropany1 ammonium bromide 111 




2.02 g, 54 %; 811 (MeOD, 250 MHz); 1.12 (9H, t, 3J= 7.2 Hz, 3 x  CH3CH2), 1.64- 
1.76 (2H, m, NCH2CH2), 2.40 (2H, t, 3J = 6.6 Hz, CH2CH2S), 3.10 (6H, q, 
= 7.1 Hz, 3 x  CH3CH2), 3.17-3.22 (2H, m, NCH2CH2), 3.65 (211, s, ArCH2), 
7.11-7.25 (511, m, ArH); tic (MeOD, 63 MHz, DEPT); 5.8 (3 x  CH3CH2N), 20.8 
(NCH2CH2), 27.6 (CH2S), 46.0 (ArCH 2), 52.1 (3 x  CH3CH2N4 ), 54.9 (NCH2CH2), 





[M-Br] 266; found (HRMS FAB) [M-Br] 266.19377 C I 6H28NS requires 
266.19370. 
5.3.1.1.5 	3-(2,3-dihydroxy-4-mercaptobutylthio)-N,N,N-triethylpropany1 
ammonium bromide 112 
Br 	 OH 
SH 
OH 
2.17 g, 52%; oH (MeOD, 250 MHz); 1.52 (9H, t, 3J= 7.2 Hz, 3 x  CH3CH2), 2.05-
2.24 (4H, m, NCH2CH2, CH2SCH2), 2.67-2.93 (4H, m, CH2SCH2, CH2SH) 3.38-
3.44 (8H, m, 4 x  NCH2, ), 3.61-3.76 (2H, m, 2 x  CHOH); 0c  (MeOD, 63 MHz, 
DEPT); 5.8 (3 x  CH3CH2N), 20.9 (NCH2CH2), 27.3 (CH2S), 28.2 (SCH2), 35.3 
(CH2SH), 52.0 (3 x  CH3CH2N), 54.8 (NCH 2CH2), 73.3 (CHOH), 73.8 (CHOH); 
m/z; found (ES-MS) [M-Br] 1 296; found (HRMS FAB) [M-Br] 296.17148 
C13H30NO2S2 requires 296.17125. 
5.3.1.1.6 	3-(2mercaptopropylthio)-N,N,N-triethylpropanyl ammonium 
bromide 113 
Br 
2.15 g, 61 %; OH(MeOD, 250 MHz); 1.55 (9H, t, 3J= 7.2 Hz, 3 x  CH3CH2), 2.07- 
2.28 (4H, m, N4 CH2CH2, CH2CH2SH), 2.93 (4H, dt, 3J = 7.1 Hz, CH2SCH2), 3.05 
(2H, t, 	= 7.0 Hz, CH2SH), 3.53-3.56 (2H, m, NCH2CH2), 3.59 (6H, q, 
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= 7.2 Hz, 3 x  CH3CH2); öc (MeOD, 63 MHz, DEPT); 5.8 (3 x  CH3CH2N), 20.7 
(NCH2CH2), 27.7 (CH2 SH), 29.3 (CH2SCH2), 30.5 (CH2SCH2), 35.8 (CH2CH2SH), 
52.0 (3 x  CH3CH2N), 55.0 (NCH2CH2); m/z; found (ES-MS) [M-Br] 250; found 
(HRMS FAB) [MBrI[F  250.16581 C 1 2H28NS2 requires 250.16577. 
5.3.2 SYNTHESIS OF THIOETHER ANALOGUE 118 
5.3.2.1 	Synthesis of Allyl-N-ethyl-N,N-dimethyl ammonium bromide 117 
Br 
Dimethylethylamine 115 (542 j.tL, 5 mmol) was dissolved in DMF (5 mL) and allyl 
bromide 116 (476 j.tL) was added. The slightly yellow reaction mixture was stirred 
at room temperature for 2 h, then left to stir overnight. After this time the crude 
reaction mixture was concentrated in vacuo to afford a yellow oil (1.03g) which was 
then cooled over ice to furnish the solidified product. The crude product was 
recrystallised from diethyl ether to yield a white crystalline solid (0.84g, 86%). mp 
160-162°C; 6H(CDCI3, 250 MHz); 1.34 (3H, t, 3J= 7.2 Hz, CH3CH2), 3.23 (6H, s,2 
x NCH3), 3.60 (2H, q, 3j= 7.3 Hz, CH3CH2), 4.25 (2H, d, 3J = 7.0 Hz, 
CH2CHCH2), 5.62-5.81 (2H, m, CH2CHCH2), 5.87-5.98 (1H, m, CH2CH=CH2); 
m/z; found (ES-MS) [M-Br] 114. 
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5.3.2.1.1 N-ethy1-3(hexylthio)-N,N, dimethylpropan-1-ammonium bromide 118 
Br 
For UV activated photochemical procedure refer to Section 5.3.1.1. 
2.65 g, 65%; oH (MeOD, 250 MHz); 0.89 (3H, t, 3J = 6.9 Hz, CH3CH2CH2), 1.27-
1.38 (9H, m, CH3CH2N, (CH2)3CH3)), 1.54 (2H, quintet, 3J = 7.1 Hz, SCH2CH2), 
2.01 (211, quintet, 3J = 6.8 Hz, NCH2CH2), 2.57 (4H, dt, 3J = 6.8 Hz, CH2SCH2), 
3.05 (6H, s, 2 x  NCH3), 3.34-3.41 (4H, m 2 x  NCH2); Oc  (MeOD, 63 MHz, 
DEPT); 6.4 (CH3CH2N), 12.5 (CH3CH2CH2), 21.6 (CH2CH2CH3), 21.7 
(NCH2CH2), 28.3 SCH2(CH2)3), 30.7 (CH2S), 30.9 (SCH2), 48.9(2 x  CH3N), 58.8 
(CH3CH2N 4 ), 61.7 (NCH2CH2); m/z; found (ES-MS) [M-Br] 232; found (HRMS 
FAB) [M-Br] 232.20942 C13H30NS requires 232.20935. 
5.3.3 SYNTHESIS OF TEA-BASED CARBON ANALOGUES 122-124 
5.3.3.1 General Synthetic Procedure Towards Carbon Analogues 122-124 
Amines 115, 119 and 120 (2.7 mmol) were placed in separate RVs in the 
MiniblockTM and dissolved in anhydrous DCM (10 mL). 1-Bromodecane (3.0 
mmol) was added to each RV and the resultant solutions were left to shake at room 
temperature overnight using the MiniBlockTM  High Capacity Shaking and Washing 
Station. After this time, each reaction mixture was transferred to a reagent vial 
(20 mL) and placed in the Christ -RVC vacuum centrifuge and concentrated in 
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vacuo to yield the desired crude solids. 	Purification was achieved by 
recrystallisation of the crude products from anhydrous diethyl ether. 
Amines 
Dimethyl ethylamine 115 
Triethylamine 119 
Diethyl methylamine 120 
5.3.3.1.1 	N,N,N-triethyl decanyl ammonium bromide 122 
Br 
597 mg, 75%; mp 101-104°C [lit. 141  106-107°C (EtOAc)]; 811 (MeOD, 250 MHz); 
0.95 (3H, t, 3J = 6.9 Hz, CH2CH2CH3), 1.30-1.44 (23H, m, 3 x  CH3CH2N, 
(CH2) 7CH3), 1.70-1.76 (2H, m, NCH2CH2), 3.18-3.24 (2H, m, NCH2CH2), 3.38 
(611, q, = 7.3 Hz, 3 x  CH3CH2N); Oc  (MeOD, 63 MHz, DEPT); 5.8 
(3 x  CH3CH2N4 ), 12.5 (CH2CH2CH3), 20.8 (NCH2CH2), 21.8 (CH2CH2CH3), 25.8 
(N+CH2CH2CH2), 28.3-28.5 ((CH 2)4CH2CH2CH3), 31.1 (CH2CH2CH3), 51.9 
(3 x  CH3CH2N), 56.2 (NCH2CH2); m/z; found (ES-MS) [M-Br] 242; found 






5.3.3.1.2 	NN-diethyl-N-m ethyl decanyl ammonium bromide 123 
Br 
-+ 
743 mg, 84%; mp 98-100°C; oH (MeOD, 250 MHz); 0.90 (3H, t, 3J = 7.1 Hz, 
CH2CH2CH3), 1.30-1.42 (20H, m, 2 x  CH3CH2N, (CH2)7CH3), 1.70-1.81 (2H, m, 
NCH2CH2), 3.00 (3H, s, CH3N'), 3.24-3.31 (2H, m, NCH 2CH2), 3.56 (4H, q, 
= 7.3 Hz, 2 x  CH3CH2N'); Oc  (MeOD, 63 MHz, DEPT); 6.2 (2 x  CH3CH2N), 
12.5 (CH2CH2CH3), 21.2 (NCH2CH2), 21.8 (CH2CH2CH3), 25.6 (NCH2CH2CH2), 
28.3-28.7 ((CH2)4CH2CH2CH3), 31.1 (CH 2CH2CH3), 45.8 (NCH3), 55.5 
(2 x  CH3CH2N), 59.9 (NCH2CH2); m/z; found (ES-MS) [M-Br] 228; found 
(HRMS FAB) [M-Br] 228.26879 C 15H34N requires 228.26858. 
5.3.3.1.3 	N-ethyl-NN-dimethyl decanyl ammonium bromide 124 
Br 
759 mg, 94%; mp 125-127°C; 0H  (CDCI3, 250 MHz); 0.86 (3H, t, 3J = 7.2 Hz, 
CH2CH2CH3), 1.41-1.53 (17H, m, CH3CH2N, (CH 2)7CH3), 1.56-1.72 (2H, m, 
NCH2CLI2), 3.38 (6H, s, 2 x  NCH3), 3.42-3.49 (2H, m, NCH2CH2), 3.63 (2H, q, 
= 7.3 Hz, CH3CH2N); oc (CDC13, 63 MHz, DEPT); 8.4 (CH3CH2N), 13.9 
(CH2CH2CH3), 22.5 (CH 2CH2CH3), 22.6 (NCH2CH2), 26.1 (NCH2CH2CH2), 29.2 
((CH2)4CH2CH2CH3), 31.6 (CH 2CH2CH3), 50.6 (2 x  NCH3), 59.1 (CH3CH2N), 
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63.3 (NCH2CH2); m/z; found (ES-MS) [M-Br] 214; found (HRMS FAB) [M-Br] 
214.25326 C 14H32N requires 214.25348. 
5.3.4 SYNTHESIS OF TERMINALLY FUNCTIONALISM CARBON ANALOGUES 129-
137 
5.3.4.1 General Procedure Towards the N-Alkylation of Tertiary Amines 115, 
120 and 128 
Amines 115, 120 and 128 (2 mmol) were dispensed into the MiniBlockTM  apparatus 
and dissolved in anhydrous DMF (2 mL). DIPEA (364 jtL, 2 mmol, 1 equiv.) was 
added to RVs containing trimethylamine hydrochloride 128. The MiniBlockTM  was 
shaken for 5 minutes. Subsequently, functionalised bromoalkanes 125-127 (2.2 
mmol) were carefully added to the respective RVs and the MiniBlockTM  was left to 
shake at room temperature for 24 hours. Each crude mixture was then transferred to 
a reagent vial (20 mL) and concentrated in vacuo using the Christ 13-RVC vacuum 
centrifuge. Crude products 131, 132 and 134-136 (50 mg) were dissolved in 
MeCN:H20 (50:50)(2 mL) and purified using ZMD mass directed purification (12 
min run, gradient H20IMeCN (95:5)—+(5:95) with 0.1% 10 mM (NH4)2CO3). Crude 
products 129, 130, 133 and 137 were recrystallised from anhydrous diethyl ether. 
Amines 
	 Bromoalkanes 
Dimethyl ethylamine 115 
	
11 -bromoundecanol 125 
Diethyl methylamine 120 
	
11-bromo-1-undecene 126 
Trimethylamine hydrochloride 128 
	
11 -bromoundecanoic acid 127 
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5.3.4.1.1 N-Ethyl-11-hydroxy-NN-dimethyl undecanyl ammonium bromide 129 
Br 
556 mg, 86%; mp 188-190°C; oH (CDCI3, 250 MHz); 0.86-1.27 (17H, m, CH3CH2, 
7 x  CH), 1.34-1.42 (211, m, CH2CH20H), 1.49-1.57 (2H, m, NCH2CH2), 1.78 (1H, 
s, OH), 3.36 (611, s, 2 x  NCH3), 3.45-3.52 (2H, m, CH20H), 3.59-3.73 (4H, m, 
CH2NCH2); 0c  (CDC13, 63 MHz, DEPT); 8.4 (CH3CH2), 22.6 (NCH2CH2), 25.5 
(CH2CH2CH20H), 29.0 (6 x  CH2), 32.6 (CH2CH20H), 50.6 (2 x  NCH3), 59.5 
(CH3CH2), 617 (CH20H), 63.1 (NCH2CH2); Umax (KBr); 3387 (OH), 3100-2800 
(br, CH); m/z; found (ES-MS 4) [M-Brf 244; found (HRMS FAB) [M-Br] +  
244.26401 H3NO requires 244.2 6404. 
5.3.4.1.2 	N,N,N-triethyl-11-hydroxy undecanyl ammonium bromide 130 
Br 
521 mg, 74%; mp 98-100°C; (CDCI 3, 250 MHz); 1.14-1.24 (23H, m, 3 X  CH3CH2, 
7 x  CH2), 1.32-1.40 (2H, m, CH2CH20H), 1.52-1.65 (211, m, NCH2CH2), 2.10 (1H, 
s, OH), 3.45-3.5 1 (2H, m, CH20H), 3.34-3.65 (8H, m, 4 x  NCH2); 0c  (CDC13, 63 
MHz, DEPT); 7.9 (3 x  CH3CH2), 21.8 (NCH2CH2), 25.5 (CH2CH2CH20H), 28.8 (6 
x CH2), 32.5 (CH2CH20H), 53.3 (3 x  CH3CH2), 59.6 (NCH2CH2), 62.4 (CH20H); 
Umax (KBr); 3376 (OH), 3100-2800 (br, CU); m/z; found (ES-MS) [M-Br] + 272; 
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found (HRMS FAB) [M-Br] + 272.29558 C 17H38NO requires 272.29534; CHN; C 
57.94, H 10.87, N 3.97, found C 58.01, H 10.80, N 3.22. 
5.3.4.1.3 	11-hydroxy-N,N,N-trimethyl undecanyl ammonium bromide 131 
Br 
184 mg, 30%; mp 128-131°C; öH(MeOD,  360 MHz); 1.23-1.35 (14H, m, 7 x  CH2), 
1.40-1.51 (2H, m, CH2CH20H), 1.66-1.78 (2H, m, NCH 2CH2), 3.07 (9H, s, 
3 x  NCH3), 3.26-3.30 (2H, m, NCH2), 3.46-3.51 (2H, m, CH20H); öc(MeOD, 90 
MHz, DEPT); 22.0 (NCH2CH2), 25.4 (CH2CH2CH20H), 28.3-28.8 (6 X  CH2), 31.8 
(CH2CH20H), 54.0 (3 x  NCH3), 61.0 (N4 CH2CH2), 65.9 (CH20H); Umax (KBr); 
3365 (OH), 3100-2800 (br, CH); m/z; found (ES-MS) [M-Br] 230; found (HRMS 
FAB) [M-Br] + 230.24791 C 14H32NO requires 230.24839. 
5.3.4.1.4 	N-ethyl-NN-dimethyl undec-10-enyl ammonium bromide 132 
Br 
440 mg, 72%; mp 95-97°C; 811 (CDC13, 250 MHz); 1.17-1.39 (15H, m, CH3CH2, 
6 x  CH2), 1.60-1.64 (2H, m, NCH2CH2), 1.85-1.95 (2H, m, CH2CH=CH2), 3.26 
(6H, s, 2 x  NCH3), 3.36-3.44 (4H, m, CH2NCH2), 4.79-4.92 (2H, m, CH=CH2), 
5.64-5.76 (1H, m, CH=CH2); ac  (CDC13, 63 MHz, DEPT); 8.3 (CH3CH2), 22.4 
(NCH2CH2), 28.4-28.7 (6 x  CH2), 33.4 (CH2CH=CH2), 50.3 (2 x  NCH3), 59.0 
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(CH3CH2), 63.1 (NCH2CH2), 113.8 (CH=CH2), 138.7 (CH=CH2); m/z; found (ES-
MS) [M-Br] 226; found (HRMS FAB) [M-Br] 226.25361 C 15H32N requires 
226.25348. 
	
5.3.4.1.5 	N,N,N-triethyl undec-10-enyl ammonium bromide 133 
Br 
457 mg, 69%; mp 98-100°C; oH (CDC13, 250 MHz); 1.17-1.40 (21H, m, 
3 x  CH3CH, 6 x  Cl2), 1.59-1.69 (2H, m, NCH2CH2), 1.84-1.96 (2H, m, 
CH2CH=CH2), 3.14-3.21 (2H, m, NCH2CH2), 3.41 (611, q, 3j= 7.2 Hz, 
3 x  CH3CH), 4.80-4.93 (2H, m, CHCH 2), 5.65-5.76 (1H, m, CH=CH2); 0c 
(CDC13, 63 MHz, DEPT); 7.8 (3 x  CH3CH2), 21.7 (NCH2CH2), 28.8 (6 x  CH2), 
33.4 (CH2CH=CH2), 53.2 (3 x  CH3CH2), 57.1 (NCH 2CH2), 113.8 (CH=CH2), 
138.7 (CH=CH2); m/z; found (ES-MS) [M-Br] 254; found (HRMS FAB) [M-Br] 
254.28408 C 17H36N requires 254.28478. 
5.3.4.1.6 	N,N,N-trimethyl undec-10-enyl ammonium bromide 134 
Br 
282 mg, 46%; mp 75-78°C; 6H  (MeOD, 250 MHz); 0.94-1.12 (12H, m, 6 x  CH2), 
1.66-1.78 (2H, m, NCH2CH2), 1.89-1.95 (2H, m, CH2CH=CH2), 2.70-2.85 (2H, m, 
NCH2), 2.99 (9H, s, NCH3), 4.44-4.54 (2H, m, CH=CH2), 5.30-5.41 (1H, m, 
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CH=CH2); öc (MeOD, 63 MHz, DEPT); 22.0 (NCH 2CH2), 28.1-28.6. (6 x  CH2), 
31.8 (CH2CH=CH2), 53.9(3 x  NCH3), 65.8 (NCH2CH2), 112.9 (CH=CH2), 138.2 
(CH=C112) m/z; found (ES-MS) [M-Br] 212; found (HRMS FAB) [M-Br] + 
212.23789 C14H30N requires 212.23783. 
	
5.3.4.1.7 	10-carboxy-N-ethyl-N,N-dimethyl decanyl ammonium bromide 135 
0 
N 	 OH 
230mg, 34%; mp 167-169°C; 8H  (CDC13, 250 MHz); 1.23-1.40 (15H, m, 
3 x  CH3CH, 6 x  CH2), 1.52-1.58 (4H, m, NCH2CH2, CH2CH2COOH), 2.28 (2H, t, 
3J= 7.3 Hz, CH2COOH), 3.12-3.18 (4H, m, 2 x  NCH2), 3.32 (6H, s, 2 X  NCH3), 
10.76 (1H, s, COOH); öc (CDC13, 63 MHz, DEPT); 9.5 (CH 3CH2), 22.4 
(NCH2CH2), 25.5 (CH2CH2COOH), 28.3-28.7 (6 x  CH2), 42.1 (CH2COOH), 52.7 
(2 x NCH3), 59.0 (CH3CH2), 63.1 (NCH2CH2), 178.2 (COOH); Umax (KBr); 3428 
(OH), 3100-2800 (br, CH), 1731 (C=O); m/z; found (ES-MS) [M-Brj 258; found 
(HRMS FAB) [M-Br]258.24349 C 15H32NO2 1 requires 258.24330. 
5.3.4.1.8 	10-carboxy- N,N,N-triethyl decanyl ammonium bromide 136 
Br 	 0 
~OH 
123 mg, 17%; mp 185-188°C; 611 (CDC13, 250 MHz); 1.19-1.43 (21H, m, 
3 x  CH3CH2, 6 x CH2), 1.54-1.60 (4H, m, NCH 2CH2, CH2CH2COOH), 2.28 (2H, t, 
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= 7.2 Hz, CH2COOH), 3.08-3.19 (8H, m, 4 x  NCH2), 10.76 (1H, s, COOH); ôc 
(CDCI3 , 63 MHz, DEPT); 8.5 (3 x  CH3CH2), 21.7 (NCH2CH2), 25.6 
(CH2CH2COOH) 28.6-28.9 (6 x  Cl2), 42.1 (CH2COOH), 53.2 (3 x  CH3CH2), 57.4 
(NCH2CH2), 178.1 (COOH); Umax (KBr); 3421 (OH), 3100-2800 (br, CH), 1732 
(C=O); m/z; found (ES-MS) [M-Br] 286; found (HRMS FAB) [M-Br] + 286.27408 
C 17H36NO2 requires 286.27460. 
5.3.4.1.9 	1 O-carboxy-N,N,N-trimethyl decanyl ammonium bromide 137 
0 
298 mg, 61%; mp 142-145°C; oH (MeOD, 250 MHz); 1.30-1.52 (12H, m, 6 X  CH2), 
1.54-1.78 (4H, m, NCH2CH2, CH 2CH2COOH), 2.25 (2H, t, 3J = 7.2 Hz, 
CH2COOH), 3.13 (9H, s, 3 x  NCH3), 3.38-3.53 (2H, m, NCH2); Oc  (MeOD, 63 
MHz, DEPT); 22.0 (NCH2CH2), 24.1 (CH2CH2COOH) 28.0-28.6 (6 x  Cl2), 42.0 
(CH2COOH), 53.9 (3 x  NCH3), 65.9 (NCH2CH2), 175.6 (COOH); imax (KBr); 
3432 (OH), 3100-2800 (br, CH), 1723 (C=O); m/z; found (ES-MS) [M-Br] + 244; 





5.3.4 PARALLEL LIBRARY SYNTHESIS OF CARBON ANALOGUES 147-166 
5.3.5.1 General Parallel Synthetic Procedure Towards Carbon 
Analogues 147-166 
Amines 115, 119 and 120 (5 mmol) were dispensed into the MiniBlockTM  apparatus 
and dissolved in anhydrous DCM (5 mL). The MiniBlockTM was shaken for 20 
minutes to ensure complete dissolution of starting reagents. Subsequently, 
bromoalkanes 138-147, 167 and 168 (5.1 mmol) were carefully added to the 
respective RVs and the MiniBlockTM  was left to shake at room temperature for 24 
hours. Each crude mixture was then transferred to a reagent vial (20 mL) and 
concentrated in vacuo using the Christ 13-RVC vacuum centrifuge. Each crude 
product was then recrystallised from anhydrous diethyl ether to afford the desired 
salt. 
Amines 
Dimethyl ethylamine 115 
Triethylamine 119 




1 -bromooctane 140 
1 -bromododecane 141 
1 -bromotetradecane 142 
1 -bromooctadecane 144 
1 -bromoeicosane 145 
1 -bromodoco sane 146 
1 -bromopentadecane 167 
1 -bromoheptadecane 168 
1 -bromohexadecane 143 
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5.3.5.1.1 N-ethyl-NN-dimethyl butyl ammonium bromide 147 
Br 
903 mg, 86%; mp 109-111°C; oH (MeOD, 250 MHz); 1.10 (3H, t, 3J = 7.2 Hz, 
CH2CH2CH3), 1.40-1.56 (5H, m, CH3CH2N, CH2CH2CH3), 1.76-1.86 (211, m, 
NCH2CH2), 3.15 (6H, s, 2 x  NCH3), 3.39 (2H, t, 3J = 8.9 Hz, NCH2CH2), 3.50 
(2H, q, 3J = 7.3 Hz, CH3CH2N); 0c  (MeOD, 63 MHz, DEPT); 6.6 (CH3CH2N'), 
12.0 (CH2CH2CH3), 18.8 (CH2CH2CH3), 23.5 (NCH2CH2), 48.8 (2 x  NCH3), 58.8 
(CH3CH2N 4 ), 62.8 (NCH2CH2); m/z; found (ES-MS) [M-Br] + 130; found (HRMS 
FAB) [M-Br]+ 130.15963 C8H2oNrequires 130.15957. 
5.3.5.1.2 N-ethyl-NN-dimethyl hexyl ammonium bromide 148 
Br 
1.11 g, 93%; mp 113-115°C; O (CDC1, 360 MHz); 0.84 (3H, t, 3J = 7.1 Hz, 
CH2CH2CH3), 1.26-1.41 (9H, m, CH3CH2N, (CH2)3CH3), 1.63-1.71 (2H, m, 
NCH2CII2), 3.33 (6H, s, 2 x  NCH3), 3.44-3.49 (211, m, NCH2CH2), 3.61 (2H, q, 
= 7.2 Hz, CH3CH2N1 ); oc (CDC1, 90 MHz, DEPT); 6.6 (CH3CH2N), 12.0 
(CH2CH2CH3), 18.8 (CH2CH2CH3), 23.5 (NCH2CH2), 48.8 (2 x  NCH3), 58.8 
(CH3CH2N4 ), 62.8 (NCH 2CH2); m/z; found (ES-MS) [M-Br] 158; found (fiRMS 
FAB) [M-Br] 158.19033 C10H24N requires 158.19045. 
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5.3.5.1.3 	N-ethyl-NN-dimethyl octyl ammonium bromide 149 
Br 
1.18 g, 89%; mp 119-121°C; oH (MeOD, 250 MHz); 1.00 (3H, t, 3J = 6.9 Hz, 
CH2CH2CH3), 1.41-1.53 (13H, m, CH3CH2N, (CH2)5CH3), 1.78-1.91 (2H, rn, 
NCH2CH2), 3.15 (611, s, 2 x  NCH3), 3.35-3.42 (2H, m, NCH2CH2), 3.50 (2H, q, 
= 7.2 Hz, CH3CH2N); 0c  (MeOD, 63 MHz, DEPT); 6.5 (CH3CH2N), 12.5 
(CH2CH2CH3), 21.6 (CH2CH2CH3), 21.8 (NCH2CH2), 25.5 (NCH2CH2CH2), 28.3 
((CH2)2CH2CH2CH3), 31.0 (CH 2CH2CH3), 48.8 (2 x  NCH3), 58.8 (CH3CH2N), 
63.0 (NCH2CH2); m/z; found (ES-MS) [M-Br] 186; found (HRMS FAB) [M-Br] +  
186.22 150 C 12H28N requires 186.22218. 
5.3.5.1.4 	N-ethyl-NN-dimethyl dodecanyl ammonium bromide 150 
Br 
1.44 g, 98%; mp 151-154°C; 0H  (CDC13, 250 MHz); 0.86 (3H, t, 3J = 6.9 Hz, 
CH2CH2CH3), 1.25-1.48 (21H, m, CH3CH2N, (CH2)9CH3), 1.65-1.73 (2H, rn, 
NCH2CH2), 3.36 (6H, s, 2 x NCH3), 3.42-3.48 (2H, m, NCH2CH2), 3.64 (211, q, 
= 7.3 Hz, CH3CH2N); oc (CDC13, 63 MHz, DEPT); 8.4 (CH3CH2N), 14.0 
(CH2CH2CH3), 22.5 (CH2CH2CH3), 22.6 (NCH2CH2), 26.1 (NCH2CH2CH2), 28.7-
29.2 ((CH2)5CH2CH2CH3), 31.7 (CH 2CH2CH3), 50.6 (2 x NCH3), 59.1 
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(CH3CH2N), 63.3 (NCH2CH2); m/z; found (ES-MS) [M-Br] 242; found (HRMS 
FAB) [M-Br] 214.25326 C 1 6H36N requires 214.25348. 
5.3.5.1.5 	N-ethyl-NN-dimethyl tetradecanyl ammonium bromide 151 
Br 
1.68 g, 96%; rap 188-191°C; oH (CDC13, 250 MHz); 0.86 (311, t, 3J = 7.0 Hz, 
CH2CH2CH3), 1.16-1.47 (25H, m, CH3CH2N, (CH2)11CH3), 1.73-1.89 (2H, m, 
NCH2CH2), 3.38 (6H, s, 2 x  NCH3), 3.43-3.47 (2H, m, NCH2CH2), 3.70 (2H, q, 
= 7.3 Hz, CH3CH2N); oc  (CDC1, 63 MHz, DEPT); 8.4 (CH 3CH2N), 14.0 
(CH2CH2CH3), 22.4 (CH2CH2CH3), 22.5 (NCH2CH2), 26.2 (NCH2CH2CH2), 28.6-
29.5 ((CH2)8CH2CH2CH3), 31.7 (CH2CH2CH3), 50.6 (2 x  NCH3), 59.0 
(CH3CH2N), 63.3 (NCH 2CH2); m/z; found (ES-MS) [M-Br] 270; found (HRMS 
FAB) [M-Br] 270.31612 C 1 8H40N requires 270.31608. 
5.3.5.1.6 	N-ethyl-NN-dimethyl hexadecanyl ammonium bromide 152 
Br 
1.74 g, 92%; mp 187-189°C [lit. 	188-191 0C]; 011 (CDCI3, 250 MHz); 0.78 (3H, t, 
3J = 7.0 Hz, CH2CH2CH3), 1.16-1.34 (29H, m, CH3CH2N, (CH 2)13CH3), 1.73-1.81 
(211, m, NCH2CH2), 3.29 (611, s, 2 x  NCH3), 3.40-3.47 (2H, m, NCH 2CH2), 3.63 
(2H, q, = 7.3 Hz, CH3CH2N); oc (CDC1, 63 MHz, DEPT); 8.4 (CH3CH2N 4), 
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13.8 (CH2CH2CH3), 22.4 (CH2CH2CH3), 22.5 (NCH2CH2), 26.0 (NCH2CH2CH2), 
28.9-29.4 ((CH2)10CH2CH2CH3), 31.6 (CH 2CH2CH3), 50.4 (2 x  NCH3), 59.1 
(CH3 CH2N), 63.2 (NCH2CH2); m/z; found 298 (ES-MS) [M-Br] 298. 
	
5.3.5.1.7 	N-ethyl-NN-dimethyl octadecanyl ammonium bromide 153 
Br 
1.76 g, 87%; mp 201-203°C; oH (CDCI3, 250 MHz); 0.87 (3H, t, 3J = 7.0 Hz, 
CH2CH2CH3), 1.24-1.39 (31H, m, CH3CH2N, (CH2) 15CH3), 1.73-1.81 (211, m, 
NCH2CH2), 3.38 (6H, s, 2 x  NCH3), 3.46-3.56 (2H, m, NCH2CH2), 3.70 (2H, q, 
= 7.3 Hz, CH3CH2N); oc (CDC1, 63 MHz, DEPT); 8.4 (CH3CH2N), 14.0 
(CH2CH2CH3), 22.5 (CH2CH2CH3), 22.6 (NCH2CH2), 26.2 (NCH2CH2CH2), 28.7-
29.3 ((CH2) 12CH2CH2CH3), 31.8 (CH2CH2CH3), 50.6 (2 x  NCH3), 59.0 
(CH3CH2N), 63.3 (NCH2CH2); m/z; found (ES-MS) [M-Br] 326; found (HRMS 
FAB) [MBr]F  326.3 7863 C221443N requires 326.37868; CHN; expected C 65.00, H 
11.90,N3.45, found  65.5 1, H 11.20,N3.25. 
5.3.5.1.8 	N-ethyl-NN-dimethyl eicosanyl ammonium bromide 154 
Br 
2.00 g, 92%; mp 194-196°C; 0H  (CDCI3 , 250 MHz); 0.86 (3H, t, 3J = 7.0 Hz, 
CH2CH2CH3), 1.25-1.48 (35H, m, CH3CH2N, (CH2)16CH3), 1.67-1.79 (2H, m, 
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NCH2CH2), 3.38 (6H, s, 2 x  NCH3), 3.42-3.49 (2H, m, NCH2CH 2), 3.69 (2H, q, 
= 7.1 Hz, CH 3CH2N); öc (CDC1 3 , 63 MHz, DEPT); 8.4 (CH3CH2N), 13.5 
(CH2CH2CH3), 22.1 (CH2CH2CH3), 22.3(NCH2CH2), 26.3 (NCH 2CH2CH2), 28.9-
29.5 ((CH2)14CH2CH2CH3), 31.3 (CH2CH2CH3), 50.6 (2 x  NCH3), 59.0 
(CH3CH2N), 63.3 (NCH2CH2); m/z; found (ES-MS) [M-Br] 354; found (HRMS 
FAB) [M-Br] 354.41021 C24H52N requires 354.40998. 
5.3.5.1.9 N-ethyl-NN-dimethyl docosanyl ammonium bromide 155 
Br 
1.94 g, 84%; mp 208-210°C; 8 11 (CDCI3 , 250 MHz); 0.87 (3H, t, 3J = 6.7 Hz, 
CH2CH2CH3), 1.25-1.49 (39H, m, CH3CH2N, (CH2) 1 8CH3), 1.72-1.87 (2H, m, 
NCH2CH2), 3.39 (6H, s, 2 x  NCH3), 3.43-3.51 (2H, m, NCH2CH2), 3.71 (2H, q, 
31 = 7.3 Hz, CH3CH2N); öc (CDC13, 63 MHz, DEPT); 8.4 (CH3CH2N), 14.0 
(CH2CH2CH3), 22.4 (CH2CH2CH3), 22.5 (NCH2CH2), 26.2 (NCH2CH2CH2), 28.9-
29.5 ((CH2) 1 6CH2CH2CH3), 31.8 (CH 2CH2CH3), 50.6 (2 x  NCH3), 59.0 
(CH3CH2N), 63.3 (NCH2CH2); m/z; found (ES-MS) [M-Br] 382; found (I{RMS 
FAB) [M-Br] 1 382.44091 C26H56N requires 382.44 128. 
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5.3.5.1.10 	N,N,N-triethyl octyl ammonium bromide 156 
Br 
1.20 g, 82%; mp 102-104°C [lit.  141 107-108°C]; oH (MeOD, 250 MHz); 0.94 (3H, t, 
= 6.9 Hz, CH2CH2CH3), 1.27-1.41 (19H, m, 3 x  CH3CH2N, (CH2)5CH3), 1.67-
1.74 (2H, m, NCH2CH2), 3.18-3.24 (2H, m, NCH2CH2), 3.35 (6H, q, 3J= 7.3 Hz, 
3 x  CHCH2N); 0c  (MeOD, 63 MHz, DEPT); 5.9 (3 x  CH3CH2N), 12.5 
(CH2CH2CH3), 20.8 (NCH2CH2), 21.8 (CH2CH2CH3), 25.5 (NCH2CH2CH2), 28.3 
((CH2)2CH2CH 2CH3), 31.0 (CH2CH2CH3), 51.8 (3 x  CH3CH2N), 56.2 
(NCH2CH2); m/z; found (ES-MS) [M-Br] 214; found (HRMS FAB) [M-Br] 
214.25335 C14H32N requires 214.25348. 
5.3.5.1.11 	N,N,N-triethyl dodecanyl ammonium bromide 157 
Br 
1.47 g, 84%; mp 92-95°C [lit. 14' 84°C]; OH(MeOD,  250 MHz); 0.89 (3H, t, 3J = 7.0 
Hz, CH2CH2CH3), 1.26-1.38 (27H, m, 3 x  CH3CH2N, (CH2)9CH3), 1.69-1.78 (2H, 
M, NCH2CH2), 3.15-3.28 (2H, m, NCH2CH2), 3.31 (611, q, = 7.3 Hz, 3 x 
CH3CH2N); oc  (CDC13, 63 MHz, DEPT); 7.9 (3 x  CH3CH2N), 13.8 
(CH2CH2CH3), 21.8 (NCH 2CH2), 22.4 (CH2CH2CH3), 26.2 (NCH2CH2CH2), 27.9-
29.3 ((CH2)6CH2CH2CH3), 31.6 (CH2CH2CH3), 53.0 (3 x  CH3CH2N'), 57.2 
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(NCH2CH2); m/z; found (ES-MS) [M-Br] 270; found (HRMS FAB) [M-Br] 
270.31617 C 18H40N requires 270.31608. 
5.3.5.1.12 	N,N,N-tri ethyl tetradecanyl ammonium bromide 158 
") Br 
1.66 g, 88%; mp 118-122°C; oH (MeOD, 250 MHz); 0.89 (3H, t, 3J = 6.9 Hz, 
CH2CH2CH3), 1.24-1.38 (31H, m, 3 x  CH3CH2N, (CH0 11CH3), 1.69-1.82 (2H, m, 
NCH2CH2), 3.14-3.21 (2H, m, NCH2CH2), 3.31 (6H, q, = 7.3 Hz, 
3 x  CH3CH2N); 0c  (CDCI3, 63 MHz, DEPT); 8.0 (3 x  CH3CH2N), 13.9 
(CH2CH2CH3), 21.9 (NCH2CH2), 22.5 (CH 2CH2CH3), 26.3 (NCH2CH2CH2), 27.9-
29.5 ((CH2)8CH2CH2CH3), 31.7 (CH2CH2CH3), 53.2 (3 x  CH3CH2N4 ), 57.3 
(NCH2CH2); m/z; found (ES-MS) [M-Br] 298; found (HRMS FAB) [M-Br] 
298.34754 C20HN requires 298.34761. 
5.3.5.1.13 	N,N,N-triethyl hexadecanyl ammonium bromide 159 
Br 
1.64 g, 81%; mp 138-142°C [lit. 146  145-155 0C]; OH(MeOD,  250 MHz); 0.90 (3H, t, 
3J= 6.9 Hz, CH2CH2CH3), 1.24-1.42 (35H, m, 3 x  CH3CH2N, (CH2) 13CH3), 1.71-
1.81 (211, m, NCH2CH2), 3.14-3.21 (2H, m, NCH2CH2), 3.32 (6H, q, 3J= 7.3 Hz, 





(CH2CH2CH3), 20.8 (NCH2CH2), 21.8 (CH2CH2CH3), 25.8 (NCH2CH2CH2), 28.6-
28.9 ((CH2) 1 0CH2CH2CH3), 31.2 (CH2CH2CH3), 51.8 (3 x  CH3CH2N'), 56.4 
(NCH2CH2); m/z; found (ES-MS) [M-Br] 326; found (HRMS FAB) [M-Br] +  
326.37685 C22H48N requires 326.37868. 
5.3.5.1.14 	NN-diethyl-N-methyl hex-yl ammonium bromide 160 
Br 
-+ 
1.13 g, 90%; mp 60-62°C; oH (CDC13, 250 MHz); 0.80 (3H, t, 3J = 6.9 Hz, 
CH2CH2CH3), 1.19-1.42 (12H, m, 2 x  CH3CH2N, (CH2)3CH3), 1.58-1.65 (2H, m, 
NCH2C1I2), 3.19 (3H, s, CH3N), 3.24-3.31 (2H, m, NCH 2CH2), 3.54 (2H, q, 
3J = 7.3 Hz, CH3CH2N), 3.71 (2H, q, 3J = 7.3 Hz, CH3CH2N); 8c(CDC13, 63 MHz, 
DEPT); 8.2 (2 x  CH3CH2N 4), 13.7 (CH2CH2CH3), 22.2 (NCH2CH2, CH2CH2CH3), 
25.9 (NCH2CH2CH2), 31.1 (CH2CH2CH3), 46.3 (NCH3), 55.7 (CH3CH2N), 56.4 
(CH3CH2N), 60.4 (NCH2CH2); m/z; found (ES-MS) [M-Br] 172; found (HRMS 






5.3.5.1.15 	NN-diethyl-N-m ethyl octyl ammonium bromide 161 
Br 
-+ 
1.25 g, 89%; mp 62-64°C; 811 (MeOD, 250 MHz); 0.90 (3H, t, 3J = 7.1 Hz, 
CH2CH2CII3), 1.28-1.41 (16H, m, 2 x  CH3CH2N, (CH 2)5CH3), 1.68-1.78 (2H, m, 
NCH2CH2), 2.98 (311, s, CH3N'), 3.21-3.27 (2H, m, NCH2CH2), 3.36 (2H, q, 
= 7.3 Hz, CH3CH2N), 3.54 (2H, q, = 7.3 Hz, CH 3CH2N); öc (MeOD, 63 
MHz, DEPT); 6.2 (2 x  CH3CH2N), 12.5 (CH2CH2CH3), 21.2 (NCH2CH2), 21.8 
(CH2CH2CH3), 25.6 (NCH2CH2CH2), 28.3 ((CH2)2CH2CH2CH3), 31.1 
(CH2CH2CH3), 45.8 (NCH3), 55.4 (CH3CH2N), 55.6 (CH3CH2N), 59.9 
(NCH2CH2); m/z; found (ES-MS 4) [M-Br] 200; found (HRMS FAB) [M-Br] 
200.23786 C 13H30N requires 200.23799. 
5.3.5.1.16 	N, N-diethyl-N-m ethyl dodecanyl ammonium bromide 162 
Br 
-+ 
1.41 g, 84%; mp 68-70°C; oH (MeOD, 250 MHz); 0.90 (3H, t, 3J = 6.9 Hz, 
CH2CH2CH3), 1.30-1.42 (24H, m, 2 x  CH3CH2N, (CH2)9CH3), 1.69-1.81 (2H, m, 
NCH2CH2), 3.00 (3H, s, CH3N), 3.22-3.27 (2H, m, NCH2CH2), 3.37 (2H, q, 
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= 7.3 Hz, CH3CH2N), 3.55 (2H, q, 3J = 7.3 Hz, CH3CH2N); ôc (MeOD, 63 
MHz, DEPT); 6.2 (2 x  CH3CH2N), 12.5 (CH2CH2CH3), 21.2 (NCH2CH2), 21.8 
(CH2CH2CH3), 25.6 (NCH2CH2CH2), 28.3-28.7 ((CH2)6CH2CH 2CH3), 31.2 
(CH2CH2CH3), 45.8 (NCH3 ), 55.4 (CH3 CH2N1), 55.6 (CH3CH2N), 59.8 
(NCH2CH2); m/z; found (ES-MS) [M-Br] + 256; found (HRMS FAB) [M-Br] 
256.30060 C1 7H38N requires 256.30063. 
5.3.5.1.17 	NN-diethyl-N-m ethyl tetradecanyl ammonium bromide 163 
Br 
-+ 
1.60 g, 88%; mp 65-68°C; oH (MeOD, 250 MHz); 0.90 (3H, t, 3J = 7.1 Hz, 
CH2CH2CH3), 1.29-1.42 (28H, m, 2 x  CH3CH2N, (CH2) 11CH3), 1.70-1.78 (2H, m, 
NCH2CH2), 2.99 (3H, s, CH3N), 3.22-3.28 (2H, m, NCH2CH2), 3.37 (2H, q, 
3J= 7.3 Hz, CH30H2N), 3.55 (2H, q, 3J= 7.3 Hz, CH3CH2N); 8c(CDC13, 63 MHz, 
DEPT); 8.2 (2 x  CH3CH2N4), 13.9 (CH2CH2CH3), 21.7 (NCH2CH2), 21.9 
(CH2CH2CH3), 25.6 (NCH2CH2CH2), 27.9-28.9 ((CH2)8CH2CH2CH3), 31.2 
(CH2CH2CH3), 46.3 (CH 3N), 55.6 (CH3 CH2N), 56.3 (CH3CH2N), 60.3 
(NCH2CH2); ,n/z; found (ES-MS) [M-Br] 284; found (HRMS FAB) [M-Br] 





5.3.5.1.18 	NN-diethyl-N-m ethyl hexadecanyl ammonium bromide 164 
Br 
-+ 
1.67 g, 85%; mp 69-73°C [lit.' 70-72 1C]; oH (MeOD, 250 MHz); 0.90 (3H, t, 
= 7.1 Hz, CH2CH2CH3), 1.30-1.44 (32H, m, 2 x  CH3CH2N, (CH2) 1 3CH3), 1.70-
1.78 (2H, m, NCH2CH2), 3.01 (3H, s, CH3N), 3.22-3.28 (2H, m, NCH2CH2), 
3.37 (2H, q, = 7.3 Hz, CH3CH2N), 3.56 (2H, q, = 7.3 Hz, CH3CH2N); dc 
(MeOD, 63 MHz, DEPT); 6.2 (2 x  CH3CH2N), 12.5 (CH2CH2CH3), 21.2 
(NCH2CH2), 21.8 (CH2CH2CH3), 25.6 (NCH2CH2CH2), 27.3-28.8 
((CH2) 10CH2CH2CH3), 31.2 (CH2CH2CH3), 46.1 (NCH3), 55.4 (CH3CH2N), 55.6 
(CH3CH2N), 59.8 (NCH2CH2); m/z; found (ES-MS 4) [M-Br] 4 312; found (HRMS 
FAB) [M-Br]312.36310 C21 H46N requires 312.36303. 
5.3.5.1.19 	N-ethyl-NN-dimethyl pentadecanyl ammonium bromide 165 
Br 
1.71 g, 94%; mp 176-179°C; O (CDC13, 360 MHz); 0.86 (3H, t, 3J = 7.0 Hz, 
CH2CH2CH3), 1.23-1.41 (27H, m, CH 3CH2N, (CH2)12CH3), 1.65-1.74 (2H, m, 
NCH2CH2), 3.37 (6H, s, 2 x  NCH3), 3.45-3.5 1 (211, m, NCH2CH2), 3.70 (211, q, 
= 7.3 Hz, CH3CH2N'); 0c  (CDC13, 63 MHz, DEPT); 8.4 (CH3CH2N), 13.9 
(CH2CH2CH3), 22.4 (CH2CH2CH3), 22.5 (NCH2CH2), 26.0 (NCH2CH2CH2), 28.9- 





(CH3CH2N), 63.1 (NCH2CH2); m/z; found (ES-MS) [M-Br] 284; found (HRMS 
FAB) [M-Br] 284.33176 C 1 9H42N requires 284.33173. 
5.3.5.1.20 	N-ethyl-NN-dimethyl heptadecanyl ammonium bromide 166 
Br 
1.74 g, 89%; mp 198-201°C; oH (CDCI3, 250 MHz); 0.81 (3H, t, 3J = 7.0 Hz, 
CH2CH2CH3), 1.19-1.43 (31H, m, CH3CH2N, (CH2)14CH3), 1.61-1.67 (2H, m, 
NCH2CH2), 3.32 (6H, s, 2 x  NCH3), 3.43-3.47 (2H, m, NCH2CH2), 3.65 (2H, q, 
= 7.3 Hz, CH3CH2N4); 0c  (CDC13 , 63 MHz, DEPT); 8.3 (CH 3CH2N), 13.8 
(CH2CH2CH3), 22.4 (CH2CH2CH3), 22.5 (NCH2CH2), 26.0 (NCH2CH2CH2), 28.5-
29.4 ((CH2)11CH2CH2CH3), 31.6 (CH2CH2CH3), 50.4 (2 x  NCH3), 59.0 
(CH3CH2N), 63.1 (NCH2CH2); m/z; found (ES-MS) [M-Br] 312; found (HRMS 
FAB) [M-Br]312.36314 C21 H46N requires 312.36303. 
5.3.6 SYNTHESIS OF FUNCTIONALISM ALKYL TAIL DERIVATIVES 
5.3.6.1 	Synthesis of (E)-1-bromo-3,7,1 1,1 5-tetramethylhexadec-2-ene 172 
2 8 13 18 
1 
To phytol 171 (2.97 g, 10 mmol) was carefully added phosphorous tribromide (950 
p1, 5 mmol) over a period of 15 mins. The mixture was stirred at 0°C for 15 mins, 
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warmed to room temperature and stirred for a further 2 hours. The reaction mixture 
was then refluxed at 100°C for 1.5 hours. After this time the solution was cooled to 
0°C, quenched with ice (12.5 g), diluted with brine (1 x  25 mL) and the crude 
product extracted with diethyl ether (1 x  25 mL). The organic layer was then 
separated, washed with brine (1 x  15 mL) and dried over anhydrous Na2SO4. After 
filtration, the filtrate was concentrated under reduced pressure to yield a viscous 
yellow/orange oil (2.10 g). The crude oil was then distilled using bulb to bulb 
distillation apparatus to afford an orange oil (972 mg, 54%). bp 147-150°C @ 0.04 
mmHg; 8H  (CDC13, 250 MHz); 0.85 (12H, t, 3J = 6.5 Hz, (CH3)2CH(CH2)3CH-
(CH3)(CH2)3CH(CH3)), 1.08-2.41 (24H, m, (CH3)2CH(CH2)3CH(CH3)(CH2)3CH-
(CH3)(CH2)3C(C113)), 3.98 (2H, d, 3J = 6.7 Hz, CHCH2Br), 5.32-5.45 (1H, m, 
CHCH2Br); öc (CDC1 3 , 63 MHz, DEPT); 16.3 (C18), 19.6 (C8/13), 22.5 (C1/2), 
24.4-25.0 (C5/10/15), 27.9 (C3), 31.6 (C20), 32.7 (C7/12), 37.3 (C6/9/11/14), 39.3 
(C16), 39.8 (C4), 123 (09), 140.0 (C17); m/z; found (ES-MS) [M+H]+ 360. 
5.3.6.2 	Synthesis of (E)-N-ethyl-N,N-3,7,1 1,15-hexamethylhexadec-2-enyl 
ammonium bromide 173 




-.--.'  24 	 19 17 16 	14 	11 	9 	6 	4 	
1 
22 
Dimethylethylamine 116 (250 j.tL, 2.3 mmol) was dissolved in anhydrous DCM (10 
mL) and a solution of compound 173 (830 mg, 2.3 mmol) in anhydrous DCM (5 mL) 
was added. The resultant solution turned slightly yellow in colour and was left to stir 
226 
Chapter 5 	 Experimental 
overnight. After this time the mixture was concentrated in vacuo to yield an off 
white solid. The crude solid was dissolved in water (5 mL) to afford a milky white 
solution which was washed with diethyl ether (3 x  5 mL). The aqueous layer was 
separated and freeze-dried overnight to yield a slightly wet yellow solid (1.39 g). 
The product was placed in a vacuum oven (30'C, 0.1 mbar) overnight and then 
recrystallised from diethyl ether to furnish the desired product a gummy yellow solid 
(699 mg, 70 %). oH (CDCI3 , 250MHz); 0.85 (12H, t, 3J = 6.5 Hz, 
(CH3)2CH(CH2)3CH(CH3)(CH2) 3CH(CH3)), 1.08-2.41 (28H, m, (CH 3 )2CH(CH2)3 -
CH(CH3)(CH2)3CH(CH3)(CH2)3C(CH3), CH3CH 2N), 3.41 (6H, s, 2 x  NCH3), 
3.45-3.73 (4H, m, NCH2CH, CH3CH2N), 5.32-5.50 (1H, m, NCH2CH); 
öc (CDC13, 63 MHz, DEPT); 8.6 (C24), 16.3 (C18), 19.6 (C8/13), 22.5 (C112), 
24.4-25.0 (C5/10/15), 27.9 (C3), 31.6 (C20), 32.7 (C7/12), 37.3 (C6/9/11/14), 39.3 
(C16), 39.8 (C4), 51.3 (C21/22), 59.3 (C23), 123 (C19), 140.0 (C17); m/z; found 
(ES-MS) [M-Br]+ 352; found (HRMS FAB) [M-Br] 352.39449 C24H 50N requires 
352.39455. 
5.3.6.3 	Synthesis of (Z)-N-ethyl-N-methylhexadec-11-en-1-amine 178 
2 	4 	6 	8 	10 	12 	14 	15 	17 	19 
I 5 	7 	9 	11 	13 	 16 	18 
3 
To a stirring solution of N-methylethylamine hydrochloride 175 (500 mg, 8.46 
mmol) in deionised water (20 mL) was carefully added NaOH (346 mg, 8.46 mmol). 
After 5 minutes, DCM (20 mL) was added and the organic layer was separated. To 
this layer, cis- li-hexadecanal 174 (1.34 g, 5.64 mmol) was added dropwise over 10 
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minutes and the reaction mixture left to stir for a further 2 hours. Borohydride resin 
176 (3.81 mmol g', 2.0 g, 8.39 mmol) was added and the mixture was left to stir for 
another 24 hours. After this time, anhydride resin 177 (6.6 mmol g', 909 mg, 4.61 
mmol) was added and the reaction left to stir for a further 24 hours. The reaction 
mixture was filtered and the resin washed with DCM (5 x  10 mL). The filtrate was 
then concentrated under reduced pressure to yield a pale green oil (915 mg). The 
crude product was then purified by bulb to bulb distillation to afford a colourless oil 
(850 mg, 72%). bp 96-98°C @ 0.1 mbar; oH (CDCI3, 250 MHz); 0.90 (6H, dt, 
= 7.2 Hz, CH3CH2N, CH 2CH2CH3), 1.28-1.36 (1811, rn, (CH2) 7, (CH2)2CH3), 
1.51-1.64 (2H, m, NCH2CH2), 1.99-2.03 (4H, m, CH2CH=CHCH2), 2.18 (3H, s, 
CH3N), 2.29-2.33 (4H, m, CH3CH2NCH2), 5.35 (2H, d, 3J 1 = 9.1 Hz, 
CH2CH=CHCH2); 0c  (CDC13, 63 MHz, DEPT); 8.5 (Cl), 13.8 (C19), 22.2 (C18), 
25.6 (C6), 26.8 (C13/16), 27.1 (C5), 29.2-29.6 (C7-11), 31.9 (C17), 32.7 (C12), 
47.0 (C3), 62.9 (C2/4), 129.8 (C14115); m/z; found (ES-MS) [M+H] 282. 
5.3.6.4 	Synthesis of (Z)-N-ethyl-N,N-dimethylhexadec-1 1-enyl 
ammonium iodide 179 
2 20 
	
6 	8 	10 	12 	14 	15 	17 	19 
I 5 	7 	9 	11 	13 	 16 	18 
3 
Amine 178 (150 mg, 0.53 mmol) was dissolved in anhydrous diethyl ether (1 mL) 
and cooled to 0°C over ice. Excess iodomethane (62 pL, 1 mmol) was added 
carefully and the reaction mixture stirred and left to warm to room temperature for 
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30 mins. After this time a further equivalent of iodomethane was added (62 j.tL, 1 
mmol) and the reaction left to stir for a further 2.5 hours. The crude mixture was 
then concentrated in vacuo to yield a colourless oil. A minimum amount of diethyl 
ether was added to the flask and the mixture was placed in the fridge overnight. The 
white precipitate which had formed was filtered and recrystallised from anhydrous 
diethyl ether to furnish the desired product 179 as a waxy white solid (160 mg, 71%). 
oH (CDCI 3 , 250 MHz); 0.87 (3H, t, 3J= 7.1 Hz, CH2CH2CH3), 1.25-1.38 (21H, m, 
(CH2)7, (CH2)2CH3, CH3CH2N), 1.54-1.67 (2H, m, NCH2CH2), 1.99-2.03 (4H, m, 
CH2CH=CHCII2), 3.35 (6H, s, 2 x  CH3N), 2.29-2.33 (4H, m, CH3CH2NCH2), 
5.37 (2H, d, 3fcis = 8.9 Hz, CH2CH=CHCH2); 0c  (CDC13, 63 MHz, DEPT); 8.3 (Cl), 
13.8 (C19), 22.4 (C18), 25.9 (C6), 27.1 (C13/16), 27.3 (C5), 29.2-29.6 (C7-11), 
31.8 (07), 32.7 (02), 51.0 (C31C20), 62.9 (C214), 129.8 (C14115); m/z; found 
(ES-MS) [M-Br] +  296; found (HRMS FAB) [M-Br] 296.33081 C 20H42N requires 
296.33087. 
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5.4 EXPERIMENTAL PROCEDURES - RESULTS AND DIscussIoN III 
5.4.1 SYNTHETIC ROUTE TOWARDS PROPOSED BUILDING BLOCK 185 
5.4.1.1 	Attempted preparation of N-ethylallylamine 181 
H 
Ethylamine hydrochloride 185 (1 g, 12.26 mmol) was dissolved in anhydrous DMF 
(45 mL). Cesium carbonate (4 g, 12.26 mmol) was added to the flask and the 
mixture was stirred for 30 mins at room temperature. Excess ally! bromide 116 (1.3 
mL, 15 mmol) was added dropwise and the reaction mixture stirred for a further 5 
hours. The reaction mixture was filtered and the white residue which had formed 
was washed with ethyl acetate (2 x  20 mL). The filtrate was concentrated in vacuo 
and taken up in 1M NaOH (20 mL) and extracted three times with EtOAc (3 x  50 
mL). The organic layers were combined and washed with water (2 x  30 mL), brine 
(1 x  30 mL) and then dried over anhydrous Na2SO 4. The crude product was 
concentrated under reduced pressure to yield a yellow/orange oil (0.67 g): ES-MS 
analysis indicated recovery of over-alkylated tertiary amine derivative 186 only. 
m/z; found (ES-MS) [M+H] + 126. 
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5.4.1.2 	Synthesis of N-ethylallylamine 181 
H 
Bromoethane 187 (2.24 mL, 0.03 mol) was added dropwise to a neat solution of 
allylamine 32 (13 mL, 0.173 mol) with stirring. The reaction mixture was then 
refluxed for 48 hours. The excess amine 32 was removed by bulb to bulb distillation 
and the residual orange precipitate which was recovered was treated with 5M KOH 
(10 mL). The crude product was then extracted with diethyl ether (2 x  20 mL) and 
dried over anhydrous MgSO 4. The solvent was then removed under reduced pressure 
and the resultant orange oil purified on silica by flash chromatography, eluting with 
EtOAc:EtOH (9:1) to yield a pale orange oil (0.950 g, 37%). oH (CDC13, 250 MHz); 
1.11 (311, t, 3J= 7.1 Hz, C113CH2), 2.66 (2H, q, 3J= 7.2 Hz, CH3CH2), 3.25 (2H, dt, 
= 6.1 Hz, CH2CH=CH2), 5.06-5.21 (2H, m, CH=CH2), 5.86-5.97 (1H, m, 
CHCH2); m/z; found (ES-MS) [M+H] 86. 
5.4.1.3 	Conversion of pentenoic acid 182 to acid chloride derivative 189 
CA~~ 
4-pentenoic acid 182 (2.6 mL, 25 mmol) was placed in a 3-neck 250 ml, flask 
containing anhydrous DCM (50 mL) and 3 drops of DMF. Under a nitrogen 
atmosphere, the mixture was cooled in ice to 0°C and oxalyl chloride 188 (2.25 mL, 
25.8 mmol) was added dropwise via a dropping funnel over 15 mins with stirring. 
Initially the reaction mixture fizzed vigorously however over time this subsided. The 
reaction mixture was stirred for 3 hours whilst warming to room temperature. After 
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this period the crude product was concentrated under reduced pressure to yield a 
yellow oil (2.93 g). Purification of the crude product was achieved by bulb to bulb 
distillation to yield desired product 189 as a pale yellow oil (1.95 g, 67%). bp 84-
86°C @ 0.3 mbar; oH (MeOD, 250 MHz); 2.33-2.42 (4H, m, CH2CH2CH=CH2), 
4.96-5.09 (2H, m, CH2CH2CH=CH2), 5.78-5.89 (1H, m, CH2CH2CH=CH2); Umax 
(neat); 3100-2800 (br, CH), 1799 (C=O acid chloride). 
5.4.1.4 	Conversion of pentenoic acid 182 to acid fluoride derivative 191 
4-pentenoic acid 182 (1.02 mL, 9.98 mmol) was dissolved in dry DCM (20 mL) and 
DAST 190 (1.58 mL, 11.98 mmol) was added. The resultant solution was stirred for 
2.5 hours and washed with ice water (2 x  10 mL). The aqueous layers were 
separated and the organic layer dried over anhydrous MgSO4. After filtration, the 
crude product was concentrated in vacuo to yield a yellow/brown oil (1.12 g). 
Purification by bulb to bulb distillation afforded a pale yellow oil (559 mg, 55%). bp 
88-90°C @ 0.3 mbar; OH (MeOD, 250 MHz); 2.29-2.44 (4H, m, CH2CH2CHCH2), 
4.90-5.05 (2H, m, CH2CH2CH=CH2), 5.78-5.92 (111, m, CH2CH2CH=CH2); umax 
(neat); 3100-2800 (br, CH), 1844 (C=O acid fluoride). 
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5.4.1.5 	Synthesis of N-allyl-N-ethyl pent4-enamide 183 
4 
2 	 5 	7 
9 
10 
N-ethylallylamine 181 (250 mg, 2.9 mmol) was dissolved in anhydrous DCM (20 
mL) and Na2CO 3 (636 mg, 6 mmol) was added. The mixture was left to stir for 5 
mins and cooled to 0°C before a solution of acid chloride 189 (367 mg, 3.1 mmol) in 
dry DCM (20 mL) was carefully added dropwise to the flask. The reaction was 
allowed to warm to room temperature and stirred for a further 2 hours. Water (20 
mL) was added and the organic layer was separated and washed with brine (2 x  20 
mL) and dried over anhydrous MgSO 4. The crude product was then concentrated in 
vacuo and purified by bulb to bulb distillation to furnish the desired product as a 
yellow oil (380 mg, 78%). bp 186-188°C @0.3 mbar; 8H(CDC13, 250 MHz); 1.11 
(3H, t, 3J = 7.3 Hz, CH2CH3), 2.35-2.41 (4H, m, CH2CH2CHCH2), 3.26 (2H, q, 
3J= 7.0 Hz, CH3CH2), 3.94 (2H, dt, 3J= 5.6 Hz, NCH2CH=CH2), 4.98-5.19 (4H, m, 
2 x  CHCH2), 5.71-5.97 (2H, m, 2 x  CH=CH2); öc (CDCI3, 63 MHz, DEPT); 12.8 
(dO), 29.2 (C6), 32.2 (C5), 40.7 (C9), 49.5 (C3), 116.3 (C8), 116.6 (Cl), 133.1 
(C2), 137.5 (C7), 172.1 (C4); Umax (neat); 3100-2800 (br, CH), 1643 (amide C=O); 
m/z; found (ES-MS) [M+H] 168. 
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5.4.1.6 	Synthesis of (Z) 1-ethyl-3, 4-dihydro-2H-azepin-2(711)-one 184 
03 3 
To a stirring solution of diene 183 (493 mg, 2.95 mmol) in degassed anhydrous 
DCM (50 mL) was carefully added Grubbs 2nd  generation catalyst 192 (127 mg, 0.15 
mmol). The solution turned from yellow to dark brown and the reaction mixture was 
heated under reflux for 24 hours. After this time the mixture was allowed to cool to 
room temperature and the solvent removed under reduced pressure. A crude black 
oil (405 mg) was obtained which was then purified by flash chromatography on silica 
gel using EtOAc:MeOH (9:1) as the eluent. It was observed that the ruthenium 
catalyst was still present after purification. The product was then redissolved in 
diethyl ether (30 mL) and passed through a pad of celite to afford a yellow/brown oil 
(357 mg, 87%). Traces of the ruthenium catalyst were still observed after this step. 
rf (EtOAc:MeOH 9:1); 0.57; 811 (CDCI3, 250 MHz); 1.08 (311, t, 3J = 7.2 Hz, 
CH3CH2), 2.35-2.74 (4H, m, H4/5), 3.35 (2H, q, 3J = 7.1 Hz, CH3CH2), 3.84 (2H, dt, 
= 5.7 Hz, Hi), 5.72-5.76 (211, m, H2/3); öc (CDC1 3 , 63 MHz, DEPT) 14.1 
(C113CH2), 25.5 (C4), 34.1 (C5), 43.3 (CH3CH2), 60.8 (Cl), 124.9 (C2), 131.9 (C3), 
172.5 (C=O lactam); umax (neat); 3100-2800 (br, CH), 1642 (C=O lactam); m/z; 
found (ES-MS) [M+H] 140. 
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5.4.1.7 	Attempted Removal of Ruthenium By-products after RCM 
Route A 
Lactam 184 was dissolved in anhydrous DCM (50 mL) and DMSO 194 (142 1.LL, 2 
mmol, 50 equiv. to catalyst) was added. The resultant solution was left to stir 
overnight. After this time, the solvent was removed in vacuo to afford a black crude 
oil. Purification by column chromatography on silica gel was carried out using 
EtOAc:MeOH (9:1) as the eluent. ES-MS results confirmed the presence of desired 
product however dark brown ruthenium by-products were still observed in all the 
fractions that were collected during purification. 
Route B 
To a solution of lactam 184 (100 mg, 0.72 mmol) in anhydrous DCM (500 pi)  was 
added a solution of trishydroxymethyl phosphine 193 (445 mg, 3.59 mmol) and 
triethylamine (726 j.tL, 7.2 mmol) in anhydrous DCM (1.5 mL). The reaction 
mixture was stirred for 10 minutes and water (2 mL) was then added. The biphasic 
solution was stirred vigorously for 15 minutes after which the aqueous layer was 
separated and the organic layer dried over anhydrous MgSO4. After filtration the 
DCM was removed in vacuo to yield a yellow/brown oil (86 mg, 77%). ES-MS 
confirmed presence of desired product however residual traces of triethylamine and 
ruthenium catalyst were also observed. The crude oil was then placed under high 
vacuum overnight, redissolved in diethyl ether (10 mL) and filtered through a pad of 
celite. The product was concentrated under reduced pressure to afford a yellow oil 
(68 mg, 61%) which contained minimal amounts of ruthenium by-products. 
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5.4.1.8 	Attempted Base Hydrolysis of Lactam 184 
NOH 
Route A 
To a solution containing lactam 184 (100 mg, 0.72 mmol) in dioxane (600 j.tL) was 
added potassium hydroxide (45 mg, 0.79 mmol) in water (45 .tL). This reaction 
mixture was stirred at room temperature and the course of the reaction followed by 
TLC. After 3 hours, TLC indicated only starting material was present. The reaction 
mixture was left for a further 72 hours. After this time, ES-MS' of the crude 
reaction mixture indicated that only starting material was present. 
Route B 
Lactam 184 (300 mg, 2.16 mmol) was dissolved in a mixture of dioxane/water (1:1) 
(18 mL). Aqueous 2M KOH (9 mL) was added to the reaction mixture which was 
then heated under reflux for 24 hours. After this time, the mixture was acidified to 
pH 3 by dropwise addition of 2M HC1. The crude material was extracted three times 
with EtOAc (3 x  15 mL), dried over anhydrous MgSO4 and concentrated in vacuo to 
yield a yellow oil. ES-MS' indicated that only starting material was recovered. 
Route C 
A slurry of potassium tert-butoxide (403 mg, 3.3 mmol), water (20 tL) and lactam 
184 (72 mg, 0.55 mmol) in diethyl ether (10 mL) was stirred vigorously at room 
temperature for 1 hour. The course of the reaction was monitored by TLC however 
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no formation of product was observed. The reaction was left to stir overnight. After 
this time, ice was carefully added to the slurry until two layers were formed. The 
crude material was then extracted twice with diethyl ether (2 x  10 mL) and dried 
over anhydrous MgSO4. Following filtration, the solvent was removed under 
reduced pressure to yield a yellow oil (68 mg). ES-MS' indicated that only starting 
material was recovered at this point. 
5.4.2 ALTERNATIVE SYNTHETIC STRATEGY TOWARDS LACTAM HYDROLYSIS 
5.4.2.1 	 Synthesis of N-alIyl pent-4-enamide 196 
0 
1 3 )L"~' ~6 8 
5 	7 
Route A 
To a solution of allylamine 32 (1.66 mL, 22 mmol) and 4-pentenoic acid 182 (2.24 
mL, 22 mmol) in anhydrous DCM (50 mL) was added HOBt (4.46 g, 0.033 mol), 
EDCI (5.40 g, 0.028 mmol) and DIPEA (8.44 mL, 0.048 mmol). The resulting 
solution was stirred at room temperature overnight and quenched by the addition of 
2M NaCl (30 mL) and the layers separated. The aqueous phase was extracted with 
DCM (2 x  30 mL) and the combined extracts dried over anhydrous MgSO4. The 
resultant solution was concentrated in vacuo to yield a slightly yellow oil (6.25 g). 
The crude product was then purified by flash column chromatography on silica 
eluting with EtOAc:Hex (1:1) to yield the desired colourless oil (2. 89 g, 94%). rf 
(EtOAc:Hexane 1:1); 0.40; oH (CDC13, 250 MHz); 2.20-2.34 (4H, m, 
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(CH2)2CH=CH2), 3.57 (2H, dt, 3J = 5.7 Hz, NCH2), 4.68-4.90 (4H, m, 
2 x  CH=CH2), 5.27 (1H, s, NH), 5.46-5.57 (2H, m, 2 x  CH=CH2); öc (CDCI3 , 63 
MHz, DEPT); 29.5 (C6), 35.6 (CS), 41.7 (C3), 115.5 (C8), 116.2 (Cl), 134.7 (C2), 
136.9 (C7), 172.1 (C4); u..,, (neat); 3293 (NH), 3100-2800 (br, CH), 1643 (amide I), 
1548 (amide II); m/z; found (ES-MS) [M+H] 140; found (HRMS FAB) [M+H] 
140.10720 C8H13N0 requires 140.10754. 
Route B 
Allylamine 32 (1.10 mL, 14.60 mmol) was dissolved in 4-pentenoic acid 182 
(1.49 mL, 14.60 mmol) and stirred in the microwave synthesiser at 150°C (300W, 
250 psi) for 30 minutes on constant irradiation. After cooling, the crude mixture was 
concentrated in vacuo and redissolved in EtOAc (20 mL). Brine (1 x  15 mL) was 
added and the organic layer separated and washed with 2M HC1 (1 x  15 mL), 
aqueous NaHCO3 0 x 15 mL) and dried over anhydrous Na2SO 4 The crude product 
was concentrated in vacuo to give a pale yellow oil. The crude material was purified 
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5.4.2.2 	Synthesis of tert-butyl allyl (pent-4-enoyl) carbamate 200 
0 
2 	 9 	5 	7 
0 0 * 
N-allyl pent-4-enamide 196 (1 g, 7.18 mmol) was dissolved in anhydrous DCM (20 
mL) along with di-tert butyl dicarbonate 199 (3.13 g, 14.36 mmol), triethylamine 
(240 p1, 1.8 mmol) and DMAP (220 mg, 1.8 mmol). The reaction mixture turned 
from yellow to deep red in colour. The reaction was stirred under reflux for 8 hours 
and concentrated in vacuo to yield a viscous orange oil. Water (20 mL) was added 
and the crude product extracted twice with EtOAc (2 x  30 mL). The organic layer 
was separated and washed twice with aqueous NaHCO3 (2 x  15 mL). The aqueous 
layer was then acidified to pH 1 with 2M HC1 and washed twice more with EtOAc (2 
x 30 mL). The combined organic layers were dried over anhydrous MgSO4 before 
being concentrated in vacuo to yield a pale orange oil (965 mg). The crude material 
was purified by column chromatography on silica gel eluting with ethyl acetate: 
hexane (1:1) to yield the desired product 200 as a colourless oil (680 mg, 68%). rf 
(EtOAc:Hexane 1:1); 0.69; oH (CDC13 , 250 MHz); 1.50 (9H, s, C(CH3)3), 2.43 (2H, 
q, 3j= 6.5 Hz, CH2CH2CH=CH2), 2.96 (2H, t, 3J = 7.2 Hz, CH2CH2CHCH2), 4.28 
(2H, dt, 3J = 5.6 Hz, NCH2), 4.95-5.15 (4H, m, 2 x  CH=CH2), 5.73-5.86 (2H, m, 
2 X  CHCH2); 0c  (CDC13, 63 MHz, DEPT); 27.9 (C(CH3)3), 29.0 (C6), 37.4 (C5), 
46.3 (0), 82.9 (C(CH3)3), 115.0 (C8), 116.3 (Cl), 133.3 (C2), 137.3 (C7), 152.9 
(C9), 174.9 (C4); 1)max (neat); 3100-2800 (br, CH), 1736 (C=0 carbamate), 1698 
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(amide I), 1542 (amide II); m/z; found (HRMS FAB) [M+H] 240.16035 C13H21NO3 
requires 240.15997. 
5.4.2.3 	Synthesis of (Z) tert-butyl 2-oxo-3,4-dihydro-2H-azepine-1(7H)- 
carboxylate 201 using Modified Purification Conditions 
0 Q6 
N-Boc-N-allyl pent-4-enamide 200 (100 mg, 2.09 mmol) was dissolved in degassed, 
anhydrous DCM (180 mL). 2nd  Generation Grubbs catalyst 192 (34 mg, 5 mol %) 
was added and the resultant solution refluxed under N2 for 24 hours. After this time, 
the resultant dark brown solution was adsorbed on silica gel (340 mg, 10 equiv by 
weight relative to catalyst) and loaded onto a pad of silica gel. The crude product 
was eluted with hexane:EtOAc (6:1--+1:1) (6 x  30 mL). The filtrate was then stirred 
with activated charcoal (8.85 g, 50 equiv. by weight relative to crude product) 
overnight. The charcoal solution was filtered through a pad of celite using 
hexane:EtOAc (1:1) as the eluent, the filtrate was concentrated in vacuo and purified 
using column chromatography on silica gel (hexane:EtOAc (1:1)) to yield the desired 
product 201 a pale yellow oil (47 mg, 53%). rf (EtOAc:Hexane 1:1); 0.60; oH 
(CDC13, 250 MHz); 1.52 (911, s, C(CH3)3), 2.39-2.87 (4H, m, H5/6), 4.33 (2H, dt, 
= 5.6 Hz, H2), 5.78 (2H, d, 3J 1 = 7.9 Hz, H3/4); 0c  (CDCI3, 63 MHz, DEPT) 
26.1 (0), 28.4 (C(CH3)3), 36.5 (C6), 42.4 (C2), 83.4 (C(CH3)3), 124.8 (C3), 132.1 
(C4), 152.6 (C=O carbamate), 174.6 (C=O lactam); Umax (neat); 3100-2800 (br, CH), 
240 
Chapter 5 	 Experimental 
1770 (C=O carbamate), 1720 (C=O lactam); m/z; found (1{RMS FAB) [M+H] 
212.12878 C 11 H1 7NO3 requires 212.12867. 







N-Boc-N-allyl pent-4-enamide 200 (500 mg, 2.09 mmol) was dissolved in degassed, 
anhydrous DCM (180 mL). 2nd  Generation Grubbs catalyst 192 (89 mg, 5 mol %) 
was added and the resultant dark brown solution was refluxed under N2 for 24 hours. 
After this time, the dark brown solution was adsorbed on silica gel (0.9 g, 10 equiv 
by weight relative to catalyst) and passed through a pad of silica gel using 
hexane:EtOAc as the eluent (6:1 --+1:1) (6 x  30 mL). The filtrate was then stirred 
with activated charcoal (16 g, 50 equiv. by weight relative to the crude product). 
After this time, the solution was filtered through a pad of celite using hexane:EtOAc 
(1:1) as the eluent and the filtrate concentrated in vacuo and purified using column 
chromatography on silica gel (hexane:EtOAc (1:1)) to yield an off-white crystalline 
solid (136 mg, 31%). rf (EtOAc:Hexane 1:1); 0.63; 811  (CDC13, 250 MHz); 1.52 
(18H, s, 6 x  CH3), 2.27-2.35 (4H, m, H5/13), 2.81-2.89 (4H, m, H6/14), 4.10-4.22 
(4H, m, H2/10), 5.30-5.47 (4H, m, H3/4, H11/12); oc (CDC13, 63 MHz, DEPT); 
27.3, 27.4 (C5/13), 27.9 (2 x  C(CH3)3), 37.1, 37.3 (C6/14), 454, 45.7 (C2/10), 82.9, 
82.7 (2 x  C(CH3)3), 125.7, 127.7 (C3IC11), 129.1, 131.2 (C4/12), 153.0, 153.2 
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(C9116), 174.1, 174.3 (C7/15); Umax (KBr); 1729 (C=O carbamate), 1698 (C=O 
lactam); m/z; found (HRMS FAB) [M+H] 423.24904 C22H3 4N206 requires 
423.24904. 





Compound 201 (20 mg, 0.42 mmol) was dissolved in a solution of 1M LiOH in 
TI{F/H20 (1:1) 0  mL). The solution was stirred overnight at 25 °C. The reaction 
mixture was diluted with H20 (1 mL) and EtOAc (2 mL) was added. The organic 
layer was separated and the aqueous layer was acidified to pH 2 by the dropwise 
addition of 1M HC1. The crude product was then extracted twice with EtOAc (2 x  2 
mL), dried over anhydrous magnesium sulphate and concentrated in vacuo to yield a 
yellow oil (24 mg, 89%). rf (EtOAc:Hexane 1:1); 0.27; ö (CDC13, 360 MHz); 1.43 
(9H, s, 3 X  CH3), 2.41-2.44 (4H, m, CH=CHCH2CH2), 3.70-3.81 (2H, m, NCH2), 
4.60 (1 H, s, NH), 5.7 (2H, d, 3J 1 = 5.9 Hz, CH=CH); öc (CDC13, 90 MHz, DEPT); 
22.4 (C6), 27.8 (C(CH3)3), 33.6 (C7), 37.3 (C3), 79.3 (C(CH 3)3), 127.5 (CS), 130.2 
(C4), 155.9 (Cl), 177.9 (C8); )max  (nujol); 3344 (NH), 3100-2800 (br, CH), 1714 
(C=O acid), 1685 (C=O carbamate), 1519 (C=C); m/z; found (ES-MS) [M-H] 228; 





5.4.2.6 	Synthesis of (E)-6-(tert-butoxylcarbonyl) hex4-enoic acid 204 
Y 2 	 OH 
Compound 202 (20 mg, 0.05 mmol) was dissolved in a solution of 1M LiOH in 
THF/H20 (1:1) (1 mL). The solution was stirred overnight at 25 °C. The reaction 
mixture was diluted with H20 (1 mL) and EtOAc (2 mL) was added. The organic 
layer was separated and the aqueous layer was acidified to pH 2 by dropwise 
addition of 1M HCI. The crude product was then extracted twice with EtOAc 
(2 x  2 mL), dried over anhydrous MgSO4 and concentrated in vacuo to yield a 
yellow oil (16 mg, 74%). rf(EtOAc:Hexane 1:1); 0.27; 811  (CDC13 , 360 MHz); 1.44 
(9H, s, 3 x  CH3), 2.31-2.46 (4H, m, CHCH 2CH2), 3.60-3.69 (2H, m, NCH2), 4.55 
(1H, 5, NH), 5.54 (2H, d, 3Jtrans = 15.4 Hz, CH=CH); oc  (CDCl, 90 MHz, DEPT); 
27.0 (C6), 28.3 (C(CH3)3), 33.3 (C7), 42.2 (C3), 79.3 (C(CH 3)3), 127.7 (CS), 130.0 
(C4), 155.6 (Cl), 178.4 (C=O acid); umax (nujol); 3344 (NH), 3100-2800 (br, CH), 
1713 (C=O acid), 1685 (amide I), 1519 (amide II); m/z; found (ES-MS) EM-H] 228; 





5.4.3 SYNTHETIC ROUTE TOWARDS EXTENDING ALKYL SPACER 
5.4.3.1 	 N-aIlyl hept-6-enamide 206 
0 
2 	H 	5 	7 	9 
For the experimental conditions refer to Section 5.4.2.1, Route B. 6-heptenoic acid 
205 was used instead of 4-pentenoic acid 182. 
2.11 g, 86%; bp 145-147°C @0.35 mbar; 811 (CDCI3 , 250 MHz); 1.24-1.44 (2H, m, 
CH2CH2CHCH2)), 1.60-1.68 (2H, m, NHCOCH2CH2), 2.01-2.07 (2H, m, 
CH2CH2CHCH2 ), 2.14 (2H, t, 3J = 7.5 Hz, NHCOCH2CH2), 3.87 (2H, dt, 
= 5.7 Hz, NCH2), 4.91- 5.20 (4H, m, 2 x  CH=CH2), 5.65 (111, s, NH), 5.76-6.06 
(211, m, 2 x  CH=CH2); oc (CDCl, 63 MHz, DEPT); 25.1 (C6), 28.4 (C7), 33.3 
(C8), 36.4 (C5), 41.7 (C3), 114.5 (dO), 116.7 (Cl), 134.2 (C2), 138.3 (C9), 172.7 
(C4); Umax  (neat); 3290 (NH), 3100-2800 (br, CH), 1643 (amide I), 1549 (amide II); 
m/z; found (ES-MS) [M+Na] 190; found (HRMS FAB) [M+H] 168.13886 





5.4.3.2 	 tert-butyl allyl (hept-6-enoyl) carbamate 208 
2 
10 
For the experimental conditions refer to Section 5.4.2.2. 
925 mg, 58%; bp 160-165°C @0.35 mbar; rf(EtOAc:Hexane 1:1); 0.67; 6H(CDCI3, 
250MHz); 1.37 (211, m, CH 2CH2CH=CH2)), 1.52 (9H, s, C(CH3)3), 1.63-1.69 (2H, 
m, NHCOCH2CH2), 2.03-2.12 (211, m, CH2CH2CH=CH2 ), 2.86 (211, t, 3J = 7.2 
Hz, NHCOCH2CH2), 4.27 (2H, dt, 3J = 5.6 Hz, NCH2), 4.92-5.16 (411, m, 2 X 
CHCH2), 5.74-5.82 (211, m, 2 x  CH=CH2); ac (CDCI3, 63 MHz, DEPT); 24.5 (C6), 
27.9 (C(CH3)3), 28.3 (C7), 33.5 (C8), 38.0 (CS), 46.3 (C3), 82.7 (C(CH3)3), 114.4 
(dO), 116.2 (Cl), 133.4 (C2),138.6 (C9), 152.9 (Cli), 175.5(C4); umax (neat) 1733 
(C=O carbamate), 1645 (amide I), 1543 (amide II); m/z; found (HRMS FAB) 
[M+H]F268.19097 C15H25NO3 requires 268.19127. 
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For the experimental conditions refer to Section 5.4.2.4. 
mp 155-158°C; rf (EtOAc:Hexane 1:1); 0.72; 8H(nth3/8411)  (CDC13, 250 MHz); 1.23- 
1.35 (2H, m, H5), 1.55 (9H, s, C(CH3)3), 2.00 (2H, q, 3J= 7.0 Hz, H4), 2.76 (2H, t, 
= 7.1 Hz, H7), 4.14 (2H, dt, 3J = 5.8 Hz, Hi), 5.29-5.58 (2H, m, H2/3); ac 
(CDC13, 63 MHz, DEPT); 24.5 (C6), 28.0 (C(CH 3 )3), 28.2 (C5), 32.1 (C4), 38.0 
(C7), 45.9 (Cl), 82.7 (C(CH3) 3), 124.5 (C2), 134.1 (C3), 153.3 (C=O carbamate), 
175.1 (C0 amide); imax (KBr); 3100-2800 (br, CH), 1729 (C=O carbamate), 1691 
(amide I), 1556 (amide II); m/z; found (HRMS FAB) [M+H]+ 240.16008 C 13H21 NO3 
requires 240.15997; CHN; C 65.25, H 8.84, N 5.85, found C 64.69, H 8.82, N 5.61. 
5.4.3.4 	(E)-8-(tert-butoxycarbonyl) oct-6-enoic acid 210 
2 	 OH 
0 
For the experimental conditions refer to Section 5.4.2.5. 
(16 mg, 74%). rf (EtOAc:Hexane 1:1); 0.27; 611 (CDC13, 360 MHz); 1.44 (911, s, 
3 x  CH3), 2.31-2.46 (4H, m, CHCH2CH2), 3.60-3.69 (2H, m, NCH2), 4.55 (1H, s, 







(C6), 28.3 (C(CH3)3), 33.3 (C7), 42.2 (C3), 79.3 (C(CH3)3), 127.7 (C5), 130.0 (C4), 
155.6 (Cl), 178.4 (C=O acid); Umax (nujol); 3344 (NH), 3100-2800 (br, CH), 1713 
(C0 acid), 1685 (amide I), 1519 (amide II); m/z; found (ES-MS) EM-H] 228; 
found (HRMS FAB) [M+H] + 230.13912 C11H19N04 requires 230.13923. 
5.4.4 SYNTHETIC ROUTE TOWARDS SHORTENING ALKYL SPACER 
5.4.4.1 	(E)-N-allyl but-2-enamide 213 
0 
2 	H 
For the experimental conditions refer to Section 5.4.2.1, Route B. Vinyl acetic acid 
211 was used instead of 4-pentenoic acid 182. 
1.40 g, 77%; bp 98-102°C @ 0.35 mbar; oH (CDC13, 250 MHz); 1.84 (3H, d, 
= 6.9 Hz, CH3), 3.92 (2H, dt, 3J = 5.7 Hz, NCR2), 5.08-5.21 (2H, m, CH2=CH), 
5.77 (1H, d, = 15.3 Hz, CH=CHCH3), 6.74-6.94 (111, m, CHCHCH3), 8.85 
(1H, s, NH); 6c(CDC13, 250 MHz); 15.2 (C7), 41.7 (C3), 116.2 (Cl), 124.8 (CS), 
134.1 (C2), 139.9 (C6), 165.7 (C4); Umax (neat); 3285 (NH), 3100-2800 (br, CH), 
1632 (amide I), 1547 (amide II); m/z; found (ES-MS) [M+Na] 148; found (HRMS 






5.4.4.2 	(E)-tert-butyl allyl (but-2-enoyl) carbamate 214 
0 
1 3 )~~6 
2 	18 	5 	7 
For the experimental conditions refer to Section 5.4.2.2. 
1.49 g, 84%; bp 135-138°C @ 0.35 mbar; rf (EtOAc:Hexane 1:1); 0.67; 811 (CDC13, 
250 MHz); 1.52 (9H, s, C(CH3)3), 1.90 (31-1, d, 3J = 6.6 Hz, CH3), 4.29 (2H, dt, 
3J= 5.6 Hz, NCH2), 5.08-5.17 (2H, m, CH2=CH), 5.76-5.87 (1H, m, CH2=CH), 6.80 
(1H, d, 3Jtrans = 15.1 Hz, CH=CHCH3), 6.89-7.01 (1H, m, CH=CHCH3); öc (CDCI3, 
63 MHz, DEPT); 18.1 (C7), 27.9 (C(CH3)3), 46.6 (C3), 82.9 (C(CH3)3), 116.2 (Cl), 
125.5 (0), 133.4 (C2), 142.8 (C6), 153.1 (C8) 168.2 (C4); 1)max (neat); 3100-2800 
(br, CH), 1731 (C=O carbamate), 1682 (amide I), 1542 (amide II); m/z; found 
(HRMS FAB) [M+H]+  226.14447 C 1 2H19NO3 requires 226.14432. 
5.4.5 FURTHER PRECURSOR GENERATION 
5.4.5.1 	General Procedure for the Synthesis of Dienes 221-223 
Allylamine 32 (1.10 mL, 14.60 mmol) was dissolved in acids 217-219 (14.60 mmol) 
and stirred in the microwave synthesiser at 150°C (300W, 250 psi) for 30 minutes on 
constant irradiation. After cooling, each crude mixture was concentrated in vacuo 





layer separated and washed with 2M HC1 (1 x  15 mL), aqueous NaHCO3 (1 X  15 
mL) and dried over anhydrous Na 2SO4. Each crude product was concentrated in 
vacuo and purified by bulb to bulb distillation to yield the desired products 221-223. 
Acids 
3-methyl pent-4-enoic acid 217 
2-methyl pent-4-enoic acid 218 
2-phenyl pent-4-enoic acid 219* 
* The synthetic procedure for acid 219 is described in Section 5.4.5.1.3.1. 
5.4.5.1.1 	 N-aIIyl-3-methylpent-4-enamide 220 
7 
2 	 5 	8 
1.80 g, 80%; bp 152-155°C @ 0.35 mbar; 80 (CDC13, 250 MHz); 1.06 (3H, d, 
= 6.8 Hz, CH3), 2.09-2.28 (2H, m, NHCOCH2CH), 2.67-2.72 (1H, m, (CH3)CH), 
3.88 (211, dt, 3J= 5.7 Hz, NCH2), 4.95-5.21 (4H, m, 2 x  CH=CH2), 5.71-5.90 (2H, 
m, 2 x  CHCH2); oc (CDC13, 63 MHz, DEPT); 19.5 (C7), 34.6 (C6), 41.7 (C3), 
43.6 (0), 113.4 (C9), 116.2 (Cl), 134.1 (C2), 142.6 (C8), 171.6 (C4); vmax (neat); 
3291 (NH), 3100-2800 (br, CH), 1644 (amide I), 1550 (amide II); m/z; found (ES-
MS) [M+K] 192; found (HRMS FAB) [M+H] 154.12327 C9H15N0 requires 
154. 123 19. 
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1.51 g, 67%; bp 142-145°C @ 0.35 mbar; oH (CDC13, 250 MHz); 1.15 (3H, d, 
= 6.7 Hz, CH3), 2.13-2.37 (3H, m, CH(CH3)CH2), 3.87 (2H, dt, 3J = 5.7 Hz, 
NCH2), 4.99-5.19 (4H, m, 2 x  CH=CH2), 5.72-5.87 (3H, m, 2 x  CH=CH2, Nil); Oc 
(CDC13 , 63 MHz, DEPT); 17.3 (C6), 37.5 (C7), 41.1 (C5), 41.6 (C3), 116.1 (C9), 
116.7 (Cl), 134.2 (C2), 135.7 (C8), 175.5 (C4); Umax (neat); 3291 (NH), 3100-2800 
(br, CH), 1644 (amide I), 1549 (amide II); m/z; found (ES-MS) [M+H] 154; found 
(HRMS FAB) [M+H] 154.12303 C9H 15N0 requires 154.123 19. 




2.27 g, 72%; bp 189-192°C; OH  (CDC13, 250 MHz); 2.39-2.44 (1H, m, 
CHCHAHBCH=CH2), 2.79-2.90 (1H, m, CHCHAHBCH=CH2), 3.30 (1H, t, 3J = 7.6 
Hz, ArCHCOOH), 3.70 (2H, dt, 3J = 5.8 Hz, NCH2), 4.82-4.96 (4H, m, 
2 x  CHCH2), 5.38 (1H, s, NH), 5.53-5.61 (2H, m, CHCH2), 7.14-7.22 (5H, m, 
ArH); Oc  (CDC13, 63 MHz, DEPT); 37.2 (CHCH2CH=CH2), 41.8 (NCR 2), 53.1 
(ArCHCOOH), 115.9 (NCH2CHCH2), 116.7 (CH2CHCH2), 127.3 (C3), 127.9 
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(C2/4), 128.7 (C115), 133.9 (C6), 136.6 (NCH2CH=CH2), 136.9 (CH2CH=CH2), 
172.6 (C=O amide); 1)max (neat); 3298 (NH), 3100-2800 (br, CH), 1643 (amide I), 
1545 (amide II); m/z; found (ES-MS) [M+H] + 216; found (HRMS FAB) [M+H] +  
216.13840 C141117N0 requires 216.13884. 





BuLi (31.3 mL, 50 mmol, 1.6 M in hexanes) was added dropwise to a flame dried 
250 mL 3-necked flask containing diisopropylamine (7.05 mL, 50 mmol) in 
anhydrous THF (20 mL) cooled to 0°C and left to stir for 30 mins. After this time a 
solution containing phenyl acetic acid (2.72 g, 20 mmol) in anhydrous THF (10 mL) 
was added to the flask over 10 mins to give a suspension which was stirred for 1 hour 
and allowed to warm to room temperature under N 2 . The mixture was then cooled to 
0°C and allyl bromide (4.33 mL, 50 mmol) was added over 15 mins. The reaction 
was stirred for a further 16 h at room temperature. The reaction mixture was then 
quenched with saturated aqueous ammonium chloride (1 x  30 ML) and acidified with 
2M H2SO4 (1 x 30 mL). The aqueous layer was extracted with diethyl ether (1 x  50 
mL) and washed with 20% K2CO3 solution (1 x  30 mL). The aqueous layer was then 
acidified with 6M 142SO4 and re-extracted with diethyl ether (1 x  30 mL). The 
organic layers were combined, dried over anhydrous MgSO4 and the crude product 
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was concentrated in vacuo to yield a viscous yellow/orange oil (2.79g). The crude 
product was then purified using flash chromatography on silica using EtOAc:hexane 
(1:1) as the eluent to yield a pale yellow oil (2.42g, 69%). rf (EtOAc:Hexane 1:1); 
0.62; oH (CDC13, 250 MHz); 2.37-2.43 (1H, m, CHCHAHBCH=CH2), 2.64-2.73 (1H, 
m, CHCHAHBCH=CH2), 3.53 (1H, t, 3J= 7.2 Hz, ArCHCOOH), 4.86-5.00 (2H, m, 
CH=CH2), 5.54-5.65 (1H, m, CH=CH2), 7.13-7.21 (5H, m, ArH), 10.02 (1H, OH); 
0c (CDC13, 63 MHz, DEPT); 36.9 (CH2CH=CH2), 51.2 (ArCHCOOH), 117.2 
(CH2CH=CH2), 127.5 (C3), 127.9 (C214), 128.6 (C115), 134.7 (C6), 136.8 
(CH2CH=CH2), 179.5 (COOH); Umax (neat); 3100-2800 (br, CH), 1736 (C=O acid); 
m/z; found (ES-MS) [M-H] 175. 
5.4.5.5 	General Procedure for the Boc protection of Dienes 220-222 
Dienes 220-222 (7.18 mmol) were dissolved in anhydrous DCM (20 mL) along with 
di-tert butyl dicarbonate 199 (3.13 g, 14.36 mmol), triethylamine (240 tL, 1.8 mmol) 
and DMAP (220 mg, 1.8 mmol). Each reaction was stirred under reflux for 8 hours 
and concentrated in vacuo to yield the desired crude oil. Water (20 mL) was added 
and the crude product extracted twice with EtOAc (2 x 30 mL). The organic layer 
was separated and washed twice with aqueous NaHCO3 (2 x  15 mL). The aqueous 
layer was then acidified to pH 1 with 2M HC1 and washed twice more with EtOAc 
(2 x 30 mL). The combined organic layers were dried over anhydrous MgSO 4 before 
being concentrated in vacuo and purified by column chromatography on silica gel 
eluting with EtOAc: Hexane (1:1) to yield desired products 223-225. 
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998 mg, 55%; rf (EtOAc:Hexane 1:1); 0.58; 811 (CDC13, 250 MHz); 1.11 (3H, d, 
3J= 6.5 Hz, CHCH3), 1.50 (9H, s, C(CH3)3), 2.85-2.93 (3H, m, CH2CH(CH3)), 4.27 
(2H, dt, 3J = 5.6 Hz, NCH2), 4.90-5.15 (4H, m, 2 x  CHCH2), 5.73-5.84 (2H, m, 
2 x  CH=CH2); ac (CDC13, 63 MHz, DEPT); 19.5 (C7), 27.8 (C(CH3)3), 34.4 (C6), 
43.5 (C3), 45.9 (C5), 82.9 (C(CH 3)3), 114.0 (C9), 116.2 (Cl), 134.1 (C2), 138.1 
(C8), 152.9 (ClO), 174.6 (C4); bmax (neat); 3100-2800 (br, CH), 1738 (C0 
carbamate), 1697 (amide I); m/z; found (HRMS FAB) [M+H] + 254.17559 
C14H23NO3 requires 254.17562. 
5.4.5.5.2 	tert-butyl ally! (2-methyl-pen-4-enoyl) carbamate 
0 
Nr 
2 	 8 
0 	O6 
----k 
1.05 g, 58%; rf (EtOAc:Hexane 1:1); 0.58; 811 (CDCI3, 250 MHz); 1.16 (3H, d, 
3J= 6.8 Hz, CHCH3), 1.51 (9H, s, C(CH3)3), 2.14-2.45 (2H, m, CH(CH3)CH2), 3.66 
(1H, m, CH(CH3)), 4.25 (2H, dt, 3J = 5.6 Hz, NCH2), 5.00-5.15 (4H, m, 
2 X  CHCH2), 5.69-5.84 (2H, m, 2 x  CH=CH2); öc (CDC13, 63 MHz, DEPT); 17.3 
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(C6), 27.9 (C(CH 3)3), 38.3 (C7), 39.6 (C5), 46.7 (C3), 82.8 (C(CH3)3), 116.2 (C9), 
116.5 (C 1), 133.5 (C2), 135.9 (C8), 152.9 (C 1 0), 179.1 (C4); v..,, (neat); 3100-2800 
(br, CH), 1734 (C=O carbamate), 1699 (amide I); m/z; found (HRMS FAB) [M+H] 
254.17588 C14H23NO3 requires 254.17562. 





 ~~Oj 1 5 
1.37 g, 60%; rf (EtOAc:Hexane 1:1); 0.69; oH (CDCI3, 250 MHz); 1.53 (9H, s, 
C(CH3)3), 2.41-2.48 (1H, m, CHCHAHBCHCH2), 2.80-2.87 (1H, m, 
CHCHAHBCH=CH2), 3.32 (1H, t, 3J = 7.6 Hz, ArCHCOOH), 4.23 (2H, dt, 
= 5.8 Hz, NCH2), 4.83 -4.96 (411, m, 2 x  CH=CH2), 5.58-5.72 (2H, m, CH=CH2), 
7.10-7.19 (5H, m, ArH); 0c  (CDCI 3 , 63 MHz, DEPT); 28.4 (C(CH3)3), 37.2 
(CHCH2CH=CH2), 41.8 (NCH2), 53.1 (ArCHCOOH), 83.2 (C(CH3)3), 115.9 
(NCH2CH=CH2), 116.7 (CH2CH=CH2), 127.3 (C3), 127.9 (C2/4), 128.7 (Cl/5), 
133.9 (C6), 135.6 (NCH 2CH=CH2), 136.9 (CH2CH=CH2), 153.4 (C=0 carbamate), 
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Selected bond lengths 
{ ] 






0(l)-C(2) 1.210(4) C(13)-H(133) 1.002 
C(2)-C(3) 1.506(5) 0(1 6)-C(1 7) 1.216(4) 
C(2)-N(23) 1.408(4) C(1 7)-C(1 8) 1.504(5) 
C(3)-C(4) 1.525(5) C(1 8)-C(1 9) 1.518(5) 
C(3)-H(3 1) 1.000 C(1 8)-H(1 81) 1.000 
C(3)-H(32) 1.000 C(1 8)-H(1 82) 1.001 
C(4)-C(5) 1.490(5) C(19)-C(20) 1.473(5) 
C(4)-H(41) 1.000 C(19)-H(191) 1.001 
C(4)-H(42) 0.998 C(19)-H(192) 1.003 
C(5)-C(6) 1.304(5) C(20)-C(2 1) 1.319(5) 
C(5)-H(51) 1.004 C(20)-H(201) 1.003 
C(6)-C(7) 1.499(5) C(2 1 )-C(22) 1.497(5) 
C(6)-H(61) 0.999 C(21)-H(211) 1.000 
C(7)-N(8) 1.471(5) C(22)-N(23) 1.471(5) 
C(7)-H(71) 1.000 C(22)-H(221) 0.999 
C(7)-H(72) 1.001 C(22)-H(222) 1.002 
N(8)-C(9) 1.415(5) N(23)-C(24) 1.399(4) 
N(8)-C(17) 1.401(5) C(24)-0(25) 1.323(4) 
C(9)-0(10) 1.307(4) C(24)-0(30) 1.207(5) 
C(9)-0(15) 1.206(5) 0(25)-C(26) 1.482(4) 
0(1 0)-C(1 1) 1.485(4) C(26)-C(27) 1.504(7) 
C(1 1)-C(12) 1.499(6) C(26)-C(28) 1.480(8) 
C(1 1)-C(13) 1.494(7) C(26)-C(29) 1.519(6) 
C(1 1)-C(14) 1.490(6) C(27)-H(271) 0.999 
C(12)-H(121) 0.999 C(27)-H(272) 0.998 
C(12)-H(122) 1.006 C(27)-H(273) 1.007 
C(12)-H(123) 0.994 C(28)-H(28 1) 0.999 
C(1 3)-H(1 31) 1.000 C(28)-H(282) 1.002 
C(13)-H(132) 1.001 C(28)-H(283) 1.001 
Appendix 
C(29)-H(291) 0.997 C(5)-C(4)-H(41) 108.433 
C(29)-H(292) 0.999 C(3)-C(4)-H(42) 108.712 
C(29)-H(293) 1.003 C(5)-C(4)-H(42) 108.740 
C(14)-H(141) 1.000 H(41)-C(4)-H(42) 109.636 
C(14)-H(142) 0.998 C(4)-C(5)-C(6) 127.1(4) 
C(14)-H(143) 1.001 C(4)-C(5)-H(5 1) 116.426 
C(6)-C(5)-H(51) 116.508 
0(1)-C(2)-C(3) 121.2(3) C(5)-C(6)-C(7) 127.3(4) 
0(l)-C(2)-N(23) 118.4(3) C(5)-C(6)-H(61) 116.208 
C(3)-C(2)-N(23) 120.4(3) C(7)-C(6)-H(61) 116.508 
C(2)-C(3)-C(4) 110.8(3) C(6)-C(7)-N(8) 113.0(3) 
C(2)-C(3)-H(3 1) 109.207 C(6)-C(7)-H(71) 108.647 
C(4)-C(3)-H(3 1) 109.063 N(8)-C(7)-H(71) 108.685 
C(2)-C(3)-H(32) 109.254 C(6)-C(7)-H(72) 108.567 
C(4)-C(3)-H(32) 108.927 N(8)-C(7)-H(72) 108.585 
H(3 1)-C(3)-H(32) 109.545 H(7 I)-C(7)-H(72) 109.356 
C(3)-C(4)-C(5) 112.6(3) C(7)-N(8)-C(9) 119.9(3) 
C(3)-C(4)-H(41) 108.665 C(7)-N(8)-C(1 7) 116.9(3) 
C(9)-N(8)-C(1 7) 123.2(3) C(1 9)-C(1 8)-H(1 81) 109.080 
N(8)-C(9)-0(10) 109.4(3) C(1 7)-C(1 8)-H( 182) 108.966 
N(8)-C(9)-0(15) 123.8(4) C(1 9)-C(1 8)-H(1 82) 108.876 
0(10)-C(9)-0(15) 126.8(4) H(181)-C(18)-H(182) 109.393 
C(9)-O(1 0)-C(1 1) 121.0(3) C(1 8)-C(1 9)-C(20) 113.0(3) 
0(10)-C(11)-C(12) 110.9(3) C(18)-C(19)-H(191) 108.593 
0(10)-C(1 1)-C(1 3) 101.8(4) C(20)-C(19)-H(191) 108.882 
C(12)-C(1 1)-C(1 3) 110.2(4) C(18)-C(19)-H(192) 108.548 
0(10)-C(1 1)-C(14) 107.8(4) C(20)-C(19)-H(192) 108.595 
C(12)-C(1 1)-C(14) 113.6(5) H(191)-C(19)-H(192) 109.151 
C(13)-C(11)-C(14) 111.9(4) C(19)-C(20)-C(21) 126.2(4) 
C(11)-C(12)-H(121) 109.516 C(19)-C(20)-H(201) 116.770 
C(11)-C(12)-H(122) 109.029 C(21)-C(20)-H(201) 117.021 
H(121)-C(12)-H(122) 109.062 C(20)-C(2 l)-C(22) 127.3(4) 
C(1 1)-C(12)-H(123) 109.743 C(20)-C(21)-H(21 1) 116.439 
H(121)-C(12)-H(123) 110.027 C(22)-C(21)-H(21 1) 116.277 
H(122)-C(12)-H(123) 109.443 C(2 1 )-C(22)-N(23) 113.0(3) 
C(11)-C(13)-H(131) 109.710 C(21)-C(22)-H(221) 108.698 
C(1 1)-C(1 3)-H(1 32) 109.546 N(23)-C(22)-H(22 1) 108.737 
H(131)-C(13)-H(132) 109.380 C(21)-C(22)-H(222) 108.513 
C(1 1)-C(1 3)-H(1 33) 109.628 N(23)-C(22)-H(222) 108.551 
H(131)-C(13)-H(133) 109.346 H(22 1)-C(22)-H(222) 109.336 
H(132)-C(13)-H(133) 109.216 C(22)-N(23)-C(2) 115.9(3) 
N(8)-C(17)-0(16) 118.0(4) C(22)-N(23)-C(24) 120.2(3) 
N(8)-C( 1 7)-C( 18) 120.4(3) C(2)-N(23)-C(24) 123.9(3) 
0(1 6)-C(1 7)-C(1 8) 121.5(4) N(23)-C(24)-0(25) 108.8(3) 
C(17)-C(18)-C(19) 111.5(3) N(23)-C(24)-0(30) 124.5(4) 





























C(1 1)-C(14)-H(142) 109.553 
H(141)-C(14)-H(142) 109.612 
C(1 1)-C(14)-H(143) 109.294 
H(141)-C(14)-H(143) 109.409 
H(142)-C(14)-H(143) 109.594 
III 
